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Laboratory results serve at least two major goals: 1) Diagnosis or exclusion of 
disease and 2) monitoring changes in the clinical condition of a patient (1-4). 
Diagnosing or exclusion of disease benefits from the availability of population-
based reference intervals (5-8).  For monitoring of patients however, population-
based reference intervals have no or limited utility, because the variability between 
serial measurements that is considered normal in an individual, is generally much 
smaller than the population-based reference interval (8).  Take serum creatinine 
as an example: a change in creatinine from 65 to 105 µmol/L does not exceed the 
population-based reference interval on either side, but nevertheless represents a 
highly significant change within an individual. This phenomenon applies to most 
parameters that can be measured in laboratory medicine, and illustrates why 
population-based reference values have limited value when monitoring patients 
over time (8-10).
Population-based reference values
A population-based reference interval typically includes 95% of test results obtained 
from a healthy population (11, 12).  As such, it represents the spectrum of values for 
a given parameter that is considered “normal”, and population-based reference 
values (or “normal values”) are probably the most commonly applied interpretative 
aid in diagnosis and case finding in clinical practice (8, 13).  By definition, 5% of 
healthy subjects will have results outside the population-based reference interval. 
This percentage rapidly increases with each additional laboratory test being 
conducted. Awareness of this limitation of reference intervals is useful, as it may 
trigger unnecessary further investigation and over-testing (14-16). 
Since population-based reference values are based on the normal variation 
between subjects, they are generally not suited to interpret changes in serial 
measurements within an individual for the purpose of patient monitoring over 
time (8, 17).  As demonstrated in the creatinine example above, normal biomarker 
variation within an individual is usually much lower than normal variation between 
individuals. Each individual has its own “homeostatic set point” for a biomarker 
(6, 8).  Day-to-day or hour-to-hour biomarker concentrations fluctuate randomly 
around this homeostatic set point within individuals (18-21).  This is called within-
subject biological variation. Some biomarkers exhibit relatively large variability 
around their homeostatic set point e.g. triglycerides, whereas for other biomarkers 
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the range permitted by normal homeostasis of the body is very small (e.g. 
sodium). Homeostatic set points differ between individuals, and may span the 
full population-based reference range (8). An individual’s homeostatic set point 
can increase or decrease, e.g due to aging or a chronic disease, but the variability 
around the homeostatic set point is believed to be relatively stable, and similar 
across individuals (8, 22-24). 
When conducting serial measurements in a person who has a homeostatic set 
point close to the lower bound of the reference range, a slightly lower second 
measurement may turn a result from ‘normal’ to ‘abnormal’ (according to 
reference range values), although the result may have hardly changed from the 
previous value (25-27).  On the other hand, a significant (and clinically relevant) 
rise in this individual may give a result that does not yet cross the upper bound 
and remains within the reference interval. Such change however may well require 
further investigation. Thus, when using population-based reference values for 
monitoring purposes, normal fluctuation in parameters may erroneously be 
flagged as abnormal, while significant changes may not be flagged and remain 
unnoticed.
Monitoring test results over time.
The much less known counterpart of population-based reference values, developed 
for the interpretation of serial measurements, is the “reference change value” or 
“critical difference” (25, 28).  For a change between serial measurements to become 
significant, the difference between the two measurements must exceed the total 
inherent variation (29).  The reference change value is the minimal difference 
between serial measurements that can be considered a statistically significant 
change. Quantitative test results vary over time, even without a change in the 
patient’s clinical status, due to three sources of inherent variation: 1) pre-analytical 
variability (e.g. delays in centrifugation, temperature changes prior to analysis, 
delay in tube transport to the lab), 2) analytical variability (random error) in the 
measurement itself, and 3) biological variability (6-8, 30). 
Pre-analytical variation, such a sample collection and sample handling, can be 
well standardized by training and adherence to standard operating procedures, 
and is considered negligible compared to the other two sources of variation (31). 
Analytical variation is intrinsic to the measurement technique. Each laboratory 
measurement is associated with random error of which the magnitude depends 
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on the methodology and analyzer used (32).  Analytical variation is considered 
acceptable when it is ≤50% of the biological variation, and in laboratory medicine 
this ratio is an important quality criterion for the desired precision of an assay (10, 
33).  Finally, biological variation refers to random fluctuation around an individuals’ 
homeostatic set point due to fasting status, hydration status, recent exercise, 
cyclical rhythms etcetera. All three parameters together contribute to day-to-day 
variability in test results and influence the probability that a change between serial 
laboratory measurements is “real” or “random fluctuation” (10, 17, 34). 
The reference change value (RCV) can be easily calculated: within-subject biological 
variation (CVI) is relatively constant, and has been studied and published for a 
number of laboratory parameters. The analytical variation (CVA) for each parameter 
is available on request from clinical laboratories.
In this formula Z represents the number of standard deviations and corresponds 
to the desired probability (8). Any probability can be chosen here, but often used 
Z-scores are 1.96 en 2.58. With these values one calculates the percentage rise or 
fall required to reach significance, while accepting the chance of a false positive 
change of 5% (p≤0.05) and 1% (p≤0.01), respectively (35).
Using Reference Change values in medical decision making
Although reference change values are a well-established concept in laboratory 
medicine, its use is hardly implemented in clinical practice (36). One reason may 
be that many medical decisions are not taken at fixed probability levels (e.g. p<0.05 
or p<0.01). Often, changes between serial measurements do not reach significance 
from a statistical perspective, but are still sufficiently large to influence a clinical 
decision. Hence, the classical RCV-formula that only indicates high (and fixed) 
probability level is less convenient in daily practice. A more informative outcome 
would be to derive the probability of change between any two serial measurements. 
This can be easily achieved through a simple rearrangement of the RCV formula 
that makes the Z-score (and hence the probability) the unknown:
Z-score = 
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This rearrangement allows the calculation of the probability as a percentage 
between 0% and 100% between any two serial measurements (8). 
Outline of this thesis
Population-based reference intervals, based on between-subject biological 
variations are generally unsuitable for monitoring of serial lab results. Availability 
of data on within-subject biological variation, which is a pre-requisite for the 
calculation of a reference change value is incomplete, limiting evidence-based 
interpretation of serial laboratory measurements in clinical practice. In addition, 
the classical concept of the reference change values is primarily a laboratory 
tool, which is not user-friendly in clinical practice. Bridging the gap between the 
theoretical RCV concept in laboratory medicine and its translation to a user-friendly 
medical application would help clinicians discriminate between real changes and 
random fluctuation when interpreting serial laboratory results. This thesis aims to 
1) extend the availability of within-subject biological variation data, and 2) translate 
raw biological variation data to an educational/medical software device, based on 
the rearranged RCV formula as described above.
To translate the scientific concept of biological variation to clinical practice, a 
medical smartphone app was developed: Labtracker. In chapter 2, the background 
and underlying calculation algorithm of the app are described.
Chapter 3 reports the within-day and hour-to-hour biological variation of 21 
hematological parameters. In subsequent chapters, the biological variation data 
and RCV’s were compared in healthy subjects versus various chronic diseases, for a 
broad set of laboratory parameters, including general clinical chemistry parameters 
(chapter 4), parameters of renal function (chapter 5), troponin I (chapter 6), and 
various novel cardiac markers (hsTnI, hsTnT and ST2) in subjects with aortic valve 
stenosis (chapter 7)
Chapter 8 reports data of a validation study with Labtracker: concordance rates of 
Labtracker-based calculations were compared with intuitive assessments by medical 
students, clinical fellows and experienced clinicians. The final chapter, chapter 
9, provides a general discussion of the work presented in this thesis, as well as 
directions for future research.
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Abstract
When following patients over time, it may be difficult to distinguish ‘real changes’ 
in consecutive blood parameters from so-called ‘natural fluctuations’. Consider a 
patient whose cholesterol level decreased from 6.6 mmol/L to 6.1 mmol/L in six 
months after receiving lifestyle advice. How likely is it that this is a ‘real change’ 
and that the advice is working?
Physicians mostly rely on their intuition and clinical experience when interpreting 
changes in consecutive laboratory results. For inexperienced physicians, the lack 
of an easy reference for the interpretation of consecutive laboratory results can 
be challenging. However, it is possible to objectify the interpretation of these 
results. We have developed a medical smartphone app that does so. It produces the 
probability that a change over time in a specific laboratory parameter is ‘real’, given 
the time between measurements. It provides more objective input for physicians 
treating patients such as the one above.
It is a well-known phenomenon: a lab test result that is just slightly too high or too 
low and when the test is repeated a few months later, the value has dropped or 
risen. How much attention should you pay to such a change? Is it a ‘real’ change 
or merely a physiological occurrence? Two cases are presented below.
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Case 1
Patient A, a 55-year-old man, visits his general practitioner (GP) for a health check 
at his own initiative. His blood cholesterol concentration is 6.6 mmol/L (reference 
value: 5.0-6.4). The GP determines the patient’s cardiovascular risk profile and 
decides not to prescribe any cholesterol medication for the time being. The GP 
does provide lifestyle advice. The patient returns after six months. During this 
second consultation, the cholesterol concentration is determined once again. It 
is now 6.1 mmol/L.
What are the chances that this patient’s cholesterol level has ‘really’ dropped and, 
therefore, is not a reflection of a change in the cholesterol concentration in the 
blood due to physiological fluctuations?
1A Unlikely (< 50% chance)
1B Dubious (50-80% chance)
1C Likely (< 80-95% chance)
1D Very likely (> 95% chance)
Case 2
Patient B, a 35-year-old woman, visits the general practice because of fatigue since 
six months. The GP checks her thyroid function and arrives at the following results 
(reference values between brackets): TSH: 6.4 mU/l (0.4-4.3); free thyroxine (FT4): 
14.2 pmol/l (9-24). The GP diagnoses ‘subclinical hypothyroidism’, but explains to 
the patient that fatigue is usually not a symptom. After 3 months, the GP checks 
the thyroid function again. The TSH concentration is now 7.5 mU/l.
To what extent is it likely that the TSH concentration in this patient has ‘really’ 
changed and so is not a reflection of a change in the TSH level due to physiological 
fluctuations?
2A Unlikely (< 50% probability)
2B Dubious (50-80% probability)
2C Likely (< 80-95% probability)
2D Very likely (> 95% probability)
Answer to case 1: answer 1B is correct
Answer to case 2: answer 2A is correct
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Awareness of day-to-day variability within an individual is particularly important 
when monitoring disease progression or response to treatment. Importantly, 
reference values have limited value in the setting of monitoring as they are based 
on variation between individuals, whereas the interpretation of consecutive 
measurements requires information on the day-to-day variation within an 
individual.
Changes in a patient’s consecutive laboratory results may be due to clinical 
improvement or deterioration, but they can also be caused by natural fluctuations 
(biological variation) or measurement uncertainty (analytical variation). Although 
experienced physicians rely on their intuition and clinical experience to distinguish 
‘real’ changes from fluctuations of a coincidental nature, this intuitive approach 
can, in fact, be objectified by calculating the so-called ‘critical difference’.
For a change between consecutive measurements to become significant, the 
difference must be larger than the change that can reasonably be expected due 
to normal biological and analytical variation. This threshold value is termed the 
Reference Change Value (RCV). The RCV can be calculated for each laboratory test 
and depends on the biological within-person variability (CVI) and the analytical 
variability (CVA) (1, 2).
𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅 =  √2 ∗ 𝑍𝑍𝑍𝑍 ∗  �𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝐴𝐴𝐴𝐴2 + 𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝐼𝐼𝐼𝐼2 
In this formula, the Z-score represents the number of standard deviations and 
correspond to the desired probability. Commonly used Z-scores are 1.96 and 2.56.
These Z-scores calculate the percentage increase or decrease that is required to 
become statistically significant, with a false positive rate of 5%, (p <0.05) and 1% 
(p <0.01) respectively.
For easy calculation of the RCV we developed Labtracker (3), a free, CE certified, 
medical smartphone app for iOS and Android. The RCV principle is used to calculate 
the probability of a true change between serial laboratory results. Over 100 
laboratory parameters are currently available in Labtracker. Decision support by 
Labtracker, using the RCV principle, may be a useful addition to clinical intuition.
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The critical difference
There is no single critical difference; it varies according to the lab test results. It 
primarily depends on 2 types of variation: (a) the physiological fluctuation of the 
relevant parameter in individuals (intra-individual biological variation, CVI); and (b) 
the measurement uncertainty of the relevant test result (analytical variation, CVA). 
The critical difference, or reference change value (RCV) is easy to calculate since 
the intra-individual biological variation is quite constant and has been examined 
and reported for a great many laboratory test results (3). The laboratories know 
the analytical variation for each measurement.
𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅 =  √2 ∗ 𝑍𝑍𝑍𝑍 ∗  �𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝐴𝐴𝐴𝐴2 + 𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝐼𝐼𝐼𝐼2 
Frequently used Z-scores are 1.96 and 2.58. These Z-scores are used to calculate the 
required percentage increase or decrease for which the chance of a false positive 
change of 5% (p < 0.05) and 1% (p < 0.01) respectively is acceptable.
If we take a Z-score of 1.96, we can work out that the critical difference for patient 
A’s cholesterol concentration is 21% and for patient B’s TSH concentration 60%. 
The percentage changes in cholesterol (7.6%) and TSH (17.2%) are smaller than the 
calculated critical differences and, therefore, statistically insignificant.
Statistical significance versus clinical relevance
In calculating a critical difference, it is important to note that not all medical 
decisions are based on statistical probabilities of ≥ 95% or ≥ 99%. In other words: 
some changes are strictly speaking not statistically significant, but great enough 
to justify clinical treatment or therapy.
An example here is a patient whose hemoglobin concentration is measured at 6.1 
mmol/L. After a week, it has fallen to 5.8 mmol/L. Although the probability of a 
‘real’ decrease in this patient is less than 95% - namely approximately 70% - their 
physician might be inclined towards further diagnostic investigation or treatment.
In practice, therefore, it is more useful to rephrase the formula for the critical 
difference so that the Z-score – and thus the probability – will be the unknown (see 
‘calculating the probability’ for this second formula). This second formula can then 
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be used to calculate the probability of a change being ‘real’. If we do so for patients 
A and B, the probability of a real change works out to be 53% and 43% respectively.
Labtracker smartphone app
The calculation above is rather time-consuming in daily practice. That is why we 
have incorporated the calculation principle for the critical difference into the 
Labtracker smartphone app (4-6). This app allows a physician to determine the 
probability of a change in test results in a very simple way. The outcome is also far 
more objective compared to the intuitive, mostly experience-based interpretation 
of lab tests.
The RCV principle is used to calculate the probability of a true change between 
consecutive laboratory results. Over 100 laboratory parameters are currently 
available in Labtracker. Decision support by Labtracker, using the RCV principle, 
may be a useful addition to clinical intuition.
Calculating the probability
Changes in a patient’s consecutive lab results may be due to clinical improvement 
or deterioration, but can also be caused by natural fluctuation (biological variation) 
or measurement uncertainty (analytical variation). A change in consecutive results, 
therefore, may only be viewed as highly likely ‘real’ when the difference between 
these results is greater than the critical difference. This is the minimum percentage 
change between two lab results that can be said to be statistically significant.
But not all decisions are taken when the statistical probability is 95% or higher. That 
is why, in practice, it is more useful to rephrase the formula for the critical difference 
so that the Z-score – and, therefore, the probability – will be the unknown. This new 
formula can subsequently be used to calculate the probability of a ‘real’ change:
Z-score = 
𝑝𝑝𝑝𝑝𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑠𝑠𝑠𝑠 𝑠𝑠𝑠𝑠ℎ𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑠𝑠𝑠𝑠 𝑏𝑏𝑏𝑏𝑠𝑠𝑠𝑠𝑝𝑝𝑝𝑝𝑏𝑏𝑏𝑏𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑝𝑝𝑝𝑝 𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑝𝑝𝑝𝑝𝑠𝑠𝑠𝑠 𝑚𝑚𝑚𝑚𝑠𝑠𝑠𝑠𝑝𝑝𝑝𝑝𝑠𝑠𝑠𝑠𝑚𝑚𝑚𝑚𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑚𝑚𝑚𝑚𝑠𝑠𝑠𝑠𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑠𝑠𝑠𝑠
�2 ∗  �𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝐴𝐴𝐴𝐴2 + 𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝐼𝐼𝐼𝐼2
 
Case 1; when applied to the case of patient A, it works out that the critical difference 
of the cholesterol concentration is 21% (Z-score: 1.96; CVI for cholesterol: 6.7%; 
supposed CVA: 3.4%). A 6.6 change to 6.1 mmol/L (7.6%) is smaller than the calculated 
critical difference and is, therefore, strictly speaking statistically insignificant.
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The probability for this case is calculated as follows: the percentage change 
between the first and the second measurements is 7.6%, CVI is 6.7%, and CVA is 
3.4%. The calculated Z-score is 0.72. This corresponds to a probability of 53%.
Case 2; the critical difference for the TSH concentration is 60% (Z-score: 1.96; TSH 
CVI: 19.3%; supposed CVA: 9.7%). A 6.4 change to 7.5 mU/L (17.2%) in the case of 
patient B is smaller than the calculated critical difference and so, once again, 
statistically insignificant.
The probability for this case is calculated as follows: the percentage change 
between the first and the second measurements is 17.2%, CVI is 19.3%, and CVA is 
9.7%. The calculated Z-score here is 0.56. This corresponds to a probability of 43%.
In the calculation of the probability in the Labtracker smartphone app, the 
percentage figure is expressed in a ‘probability term’, which varies from ‘unlikely’(< 
50%) to ‘highly likely’ (>95%) (6). The application of semantics to probability using 
different clarifying terms has been described earlier (5). The semantics used for 
the probability percentages in Labtracker were determined by the authors.
Reference values
Classic reference or ‘normal’ values are useful in setting diagnoses and in a 
situation where no historical lab results are available for a certain patient. But 
when a patient is followed over the course of time, the usability of reference values 
is limited, for reference values are based on the biological variation as existing 
between individuals. For monitoring a patient over time, it is, in fact, the biological 
variation within an individual that is important. This within-person variation is 
usually smaller than the variation between people. The fictitious experiment in 
Figure 2.1 clarifies this phenomenon.
The distribution of the values that are ‘normal’ for an individual is usually just a 
small part of the reference value framework for the entire population. It may well 
be, therefore, that a patient’s consecutive lab results show a statistically significant 
difference – and that this change is also clinical relevant - but that all the values 
are still within the reference value framework for the population (see Figure 2.1). 
Quite the opposite can also occur: a patient’s consecutive results first fall within 
and later outside the reference value framework (or the other way around), without 
this change having any statistical significance or clinical relevance.
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The average value of an individual’s certain lab parameter is referred to as the 
individual equilibrium concentration. This person’s values fluctuate around this 
concentration. Figure 2.1 shows that the equilibrium concentration differs for 
each individual. The equilibrium concentration may sometimes shift, due to illness 
or old age, for instance, but the distribution around the individual equilibrium 
concentration is quite constant (5).
Figure 2.1. In a fictitious experiment, the serum cholesterol concentration is determined every 
month for a year in 10 apparently healthy persons. The average cholesterol concentration of 
each individual (equilibrium concentration) and the absolute distribution of values  around this 
concentration are shown. This range reflects the intra-individual biological variation of the cho-
lesterol concentration, that is, the inherent natural fluctuation around an individual’s equilibrium 
concentration. This fluctuation is caused by, for example, diet, physical activity, the day-night 
rhythm or seasonal influences. The magnitude of the fluctuation strongly determines how much 2 
laboratory results must differ from each other to be statistically significant: the critical difference. 
The figure also shows that the spread between people is much larger than the spread between 
people; this applies to most laboratory parameters. The differences between the individual equi-
librium concentrations are called the inter-individual biological variation and form the basis of 
population reference values
Time-dependent relationship
For a number of lab tests, the intra-individual biological variation (CVI) changes over 
time. The CVI sometimes increases as the time interval between the measurements 
increases.
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Here is an example. When someone’s cholesterol level is determined twice a day, 
virtually the same value will be found in both occasions. But as the time interval 
between the measurements for the same person increase, the measured values will 
be wider apart without there necessarily having been any clinical changes. In other 
words: there is a time relationship in the intra-individual biological variation for a 
number of results. For the laboratory results for which sufficient information about 
their biological variation has been published, we modeled these time relationships 
and incorporated them into the calculation algorithm of the smartphone app. For 
the purpose of illustration, the increase in the biological variation of the total 
cholesterol value over time is shown in Figure 2.2.
Figure 2.2. There is a clear time relationship between the biological variation and the time between 
measurements. The biological variation of the total cholesterol value varies from 1.5-9.3%, depend-
ing on the time period between the 2 measurements. Each point in the figure reflects a study on 
biological variation of this value. The time relationship is modeled as follows and programmed in 
the Labtracker smartphone app:
y = a + b * log (x) + cx
with a =  3.19, b  = 0.71 and c -0.001. The time period between measurements (in days) is indicated 
by x.
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Measurement uncertainty and its effect on test variability
As described above, the critical difference is determined by 2 components: natural 
fluctuations (biological variation) and measurement uncertainty (analytical 
variation). Since biological variation is quite constant, the measurement uncertainty 
determines the amount of additional ‘noise’ that should be added to the variation 
in lab results.
The analytical variation is different for each laboratory result. It can be calculated 
that when the analytical variation is as great as the biological variation, the amount 
of additional noise that is added to the test result amounts to approximately 40% 
(5). If the measurement can be more precise and the analytical variation is three-
quarters of the biological variation, the additional noise falls to approximately 25%. 
When the analytical variation is even smaller and is merely half of the biological 
variation, the analytical noise added to the biological variation is a mere 12%. Within 
laboratory medicine, an analytical variation that is half of the biological variation 
is deemed acceptable. This ratio is an important quality criterion for the desired 
precision with which analyses should be performed (7).
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Middle and long-term biological variation data for hematological parameters 
have been reported in the literature. Within-day 24-hour variability profiles 
for hematological parameters are currently lacking. However, comprehensive 
hour-to-hour variability data is critical to detect diurnal cyclical rhythms, and to 
take into account the ‘time of sample-collection’ as a possible determinant of 
natural fluctuation. In this study, we assessed 24-hour variation profiles for 20 
hematological parameters. 
Method
Blood samples were collected under standardized conditions from 24 subjects 
every hour for 24 hours. At each measurement, 20 hematological parameters were 
determined in duplicate. Analytical variation, within-subject biological variation, 
between-subject biological variation, index of individuality and reference change 
values were calculated. For the parameters with a diurnal rhythm, hour-to-hour 
reference change values were determined.
Results
All parameters showed higher between-subject biological variation than within-
subject biological variation. Highest between-subject biological variation was 
found for eosinophils (46.6% [95% CI 34.9-70.1%]) and the lowest value was 
mean corpuscular hemoglobin concentration (3.2% [95% CI 2.4-4.8%]). Within-
subject biological variation varied from 0.4% [95% CI 0.32-0.42%] to 20.9% [95% 
CI 19.4-22.6%] for red cell distribution width and eosinophils, respectively. Six 
hematological parameters showed a diurnal rhythm.
Conclusions
We present complete 24 hour variability profiles for 20 hematological parameters. 
Hour-to-hour reference changes values may help to better discriminate between 
random fluctuations and true changes in parameters with rhythmic diurnal 
oscillations.
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Background
When interpreting changes in serial laboratory test results, health care professionals 
rely on their intuition and clinical experience to distinguish ‘real changes’ from 
physiological fluctuations. A more objective interpretation of changes in serial 
laboratory results can be achieved by calculating the ‘reference change value’ 
(RCV), i.e.  the required threshold for a change between serial measurements to 
be statistically significant (1). For a change to become significant, the difference 
between two measurements must exceed the total inherent variation. The 
calculated RCV can provide information to prevent random fluctuations from being 
interpreted as true changes.
Two factors can influence the RCV; the analytical variation (CVA) and the within-
subject biological variation (CVI). In laboratories that meet contemporary quality 
and precision specifications, CV I is the strongest determinant of test result 
variability (2). Studies of biological variation can provide insight in the natural 
fluctuations within and between subjects for a given parameter. Extensive biological 
variation studies are laborious and most studies of hematological parameters have 
only assessed biological variation between days (3-8). A few studies report within-
day variation with a limited number of measurements (8-11). Complete 24-hour 
variability profiles for hematological parameters are currently lacking. Within day, 
hour-to-hour variability data is however critical to detect diurnal cyclical rhythms, 
and take into account the ‘time of sample-collection’ as a possible determinant of 
natural fluctuation. According to laboratory statistics from Maastricht University 
Medical Center, the assessment of repeated within-day hematological testing is 
common in hospitalized patients (up to 10%).
The present study was conducted to provide comprehensive 24-hour variation 
profiles for 20 hematological parameters in 24 subjects. Specifically, within-day 
components variation and index of individuality were assessed. The index of 
individuality (II) is the ratio between the CVG and CVI. It determines the utility of 
conventional population-based reference values (12). Finally, within-day RCVs were 
calculated for parameters with random variability over the day, whereas hour-to-
hour RCVs were calculated for hematological parameters with rhythmic oscillations 
during the day. 
// De magenta omlijning geeft de netto maat aan en zal niet zichtbaar zijn in het eindproduct //
// Let op: Dit proef bestand is niet geschikt om correcties in te maken //
555031-L-sub01-bw-Hilderink
Processed on: 24-2-2021 PDF page: 32
32 Chapter 3
Materials and methods 
This study conforms to the principles of the Declaration of Helsinki and was 
approved by the institutional review board and the ethics committee at Maastricht 
University Medical Center. This study was registered at clinicaltrials.gov as 
NCT02091427. The current study meets the critical appraisal checklist criteria for 
studies of biological variation as proposed by Bartlett et al (13). 
The routine hematological parameters we studied were: leukocytes, lymphocytes, 
neutrophils, monocytes, eosinophils, basophiles, erythrocytes, reticulocytes 
(percentage), reticulocytes (count), hemoglobin, hematocrit, mean corpuscular 
volume (MCV), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin 
concentration (MCHC), red cell distribution width (RDW), mean platelet volume 
(MPV) and platelets. Research-hematological parameters included immature 
platelet fraction (IPF), plateletcrit (PCT) and platelet distribution width (PDW).
Table 3.1. Participants’ baseline characteristics
n 24
Age, years 72 ± 7
Male, gender 19 (79%)
BMI, kg/m2 27 ± 5
Systolic blood pressure, mm Hg 140 ± 15
Diastolic blood pressure, mm Hg 68 ± 8
Anti-hypertensive medication a 10 (42%)
Type 2 Diabetes Mellitus b 7 (29%)
Fasting glucose c, mmol/L 5.9 (5.2-6.7)
HbA1cc, % 5.7 (5.3 – 6.5)
Oral blood glucose lowering medication a 7 (29%)
Total cholesterol c, mmol/L 3.7 (4.8 – 5.4)
HDL cholesterol c, mmol/L 1.3 (1.6 – 1.9)
LDL cholesterol c, mmol/L 1.7 (2.5 – 3.0)
Triglycerides c, mmol/L 1.2 (0.8 – 1.8)
Lipid lowering medication a 12 (50%)
eGFR c, d, ml/min/1.73m² 75 (61 – 92)
Data is presented as n (%), mean ± SD or median (IQR). BMI, body mass index, eGFR, estimated glomerular 
filtration rate. a Medication status was stable for at least three months prior to inclusion, and continued as 
normal during the entire study period, including the test-days. b The diagnosis type 2 Diabetes Mellitus 
was defined as fasting plasma glucose ≥ 7.0 mmol/L and/or HbA1c ≥ 6.5% ( = 48 mmol/mol) (14) c Value 
at 8:30 a.m. d According to CKD-EPI Creatinine-cystatin C equation (15)
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Study population
The study population consisted of 24 volunteers (19 males and 5 females). These 
subjects were previously described in the study of Klinkenberg et al. (16). All 
participants provided written informed consent. The median age was 72 years 
(range 65-79 years). Baseline characteristics of the study population are shown in 
table 3.1. Exclusion criteria were: a change in medication use in the three months 
prior to the inclusion and a history of severe cardiovascular problems (acute 
myocardial infarction or stroke) within 12 months prior to inclusion. All participants 
were free from acute diseases at the time of the study.
Study design
After an overnight fast, participants arrived at 8 a.m. at the laboratory. Participants 
were asked to refrain from heavy physical labor and exercise training two days 
before the test day. They were sampled every hour by using an indwelling venous 
cannula in an antecubital vein during a time span of twenty-five hours. The 
participants spent the day seated in a chair or couch.
Standardized meals were consumed at 8:30 a.m. (breakfast), 12:30 p.m. (lunch) and 
6:00 p.m. (dinner).  The participants went to bed at 11:30 p.m. and got up the next 
morning at 7:00 a.m. At night, all subjects received a polyethylene coiled extending 
line (Vygon) that was attached to the indwelling venous catheter in order to obtain 
the blood samples and to minimize sleep disturbance. 
Laboratory measurements
Blood sampling was performed under standardized conditions in order to 
minimize sources of pre-analytical variation. Blood samples were collected in 
ethylenediaminetraacetic acid (EDTA)-containing tubes (4 ml) every hour over a 
time span of 25 hours. Within 1 hour after collection, samples were analyzed in 
duplicate on a Sysmex XE-5000 analyzer (Sysmex Corporation, Kobe, Japan). 
Statistical analysis
The outlier method of Burnett was used to check for analytical outliers (17). As 
suggested by Fraser and Harris (18), we tested for homogeneity in the analytical- 
and within-subject biological variances using the method described by Cochran. 
Briefly, analytical variances were tested for homogeneity by examining the ratio of 
the maximum variance to the sum of the variances and compare this with a critical 
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value (19, 20). Subjects were excluded until homogeneity of variance was achieved 
(data not shown) (21). Finally, the criteria of Reed were used to identify between-
subject outliers (20, 22, 23). 
Between-subject-(CVG), within-subject biological variation (CVI), and analytical 
variation (CVA) were calculated by using a balanced analysis of variance (ANOVA) 
with a nested random design in two levels. Verified assumptions for using this 
model include a normally distributed error term of the means and constant 
variances (24). 95% confidence intervals (CI) of these variance components were 
calculated using the method described by Burdick and Graybill (24, 25). The index 
of individuality (II) was calculated by the method described by Petersen et al. (26) 
and the RCVs were calculated according to the method of Fraser and Harris (18, 27). 
The residuals of the parameters followed a Gaussian distribution on the analytical 
and within-subject level. Therefore, no transformation into the natural logarithm 
was required.






𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅 =  √2 ∗ 𝑍𝑍𝑍𝑍 ∗  �𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝐴𝐴𝐴𝐴2 + 𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝐼𝐼𝐼𝐼2 
In the RCV formula, Z represents the number of standard deviation appropriate 
for the desired level of statistical significance for a bidirectional change (e.g. 1.96 
for p=0.05 and 2.58 for p=0.01 (3). For the RCV-calculations in this study, a Z-score 
of 1.96 was used. 
In parameters with rhythmic diurnal variation, the assumption of constant variances 
is violated, precluding the calculation of an ‘overall’ within-day RCV. Instead, hour-
to hour RCVs were calculated for parameters with rhythmic diurnal oscillations, 
taking into account the systematic increase or decrease at all time-points (18, 28, 29). 
Briefly, the average systematic change for each time point (as a percentage from the 
baseline value) was subtracted from the original individual data. Hence, variation 
due to rhythmic diurnal oscillations was eliminated and an artificial ‘steady state’ 
concentration with random fluctuation over the day was created. 
With these adjusted data, assumptions for ANOVA were fulfilled, and components of 
biological variation could be calculated. Finally, the percentage hourly changes (𝛽) 
were added again to the individual time points. To calculate adjusted asymmetric 
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RCVs that take into account rhythmic diurnal oscillations, the following formulae 
were used (28): 
𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑢𝑢𝑢𝑢𝑢𝑢𝑢𝑢𝑢𝑢𝑢𝑢𝑢𝑢𝑢𝑢𝑢𝑢𝑢𝑢 𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙 =  𝛽𝛽𝛽𝛽 +  √2 ∗ 1.96 ∗  �𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝐴𝐴𝐴𝐴  2 + 𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝐼𝐼𝐼𝐼 2  
𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑢𝑢𝑢𝑢𝑢𝑢𝑢𝑢 𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙 =  𝛽𝛽𝛽𝛽 𝛽  √2 ∗ 1.96 ∗  �𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝐴𝐴𝐴𝐴 2 + 𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝐼𝐼𝐼𝐼 2  
All statistical calculations were performed using SPSS version 20 (IBM SPSS 
Statistics, IBM Corporation, Armonk, New York) and Matrix Laboratory (Matlab & 
Simulink Student Suite R2015b). 
Figure 3.1 (A-C): Subject-specific concentrations over 24h with hourly sampling. Parameters 
were shown as absolute ranges (min-max).
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Figure 3.1 (continued)
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Sample collection was incomplete for four subjects. Two subjects left the study 
prematurely, with respectively 12 and 4 hours of consecutive missing data (subject 
1 and subject 8. Since the missing values were not ‘at random’, a balanced design 
was required (30).  In order to maintain a balanced design, in line with the statistical 
conditions for a balanced ANOVA with a nested random design in two levels, these 
subjects were excluded from all analyses. In two other individuals (subjects 15 and 
23, night samples were missing due to technical problems with the intravenous 
cannula. Analyses in these subjects were restricted to the samples obtained 
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between 8:30 a.m. and 11:30 p.m. Subject 20 became sick during the test day and 
due to a lack of a stable situation, this subject was excluded from all analyses.
Outliers and excluded subjects per parameter are listed in supplemental table 
3.1. Concentration ranges of all hematological parameters are shown in figure 3.1.
Posture-dependent changes of hematological parameters
Concentrations of 7 parameters (hemoglobin, hematocrit, erythrocytes, 
reticulocytes, platelets and plateletcrit) were posture-dependent with an acute 
concentration drop at 11:30 p.m. (during transition from upright position to sleep 
position) and a prominent rise at 7 a.m. (change from sleep to upright position) 
(31). Figure 3.1 shows the average concentrations during the day of the parameters 
with posture-dependent changes. For these parameters, variation components 
were analyzed separately for the day and night. Since biological variation within 
both timeframes was similar (data not shown), only day- variation components 
(08:30 a.m. – 11:30 p.m. and 07:30 a.m. the next morning) are listed in table 3.2 for 
these parameters.
24-hour variation components
Variation components (CVA, CVI, and CVG), indexes of individuality and RCVs are 
listed in table 3.2. The uncertainties regarding the calculations are reflected in the 
95% confidence intervals (CI) given for all CV values (24, 25).
All parameters showed higher CVG than CVI values. Highest CVG was found for 
eosinophils (46.6% [95% CI 34.9-70.1%]) and the lowest value was MCHC (3.2%[95% 
CI 2.4-4.8%]). CVI was much lower and varied from 0.4% [95% CI 0.32-0.42%] to 
20.9% [95% CI 19.4-22.6%] of red cell distribution width (RDW) and eosinophils, 
respectively. Duplicate measurements of all parameters offered the advantage 
of analytical variation estimation at the same level as subject samples (20), and 
yielded an analytical variation range  from 0.17% [95% CI 0.16-0.18%] to 21.2% [95% 
CI 19.9-22.7%] (of MCV and basophils, respectively).
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Figure 3.2: Diurnal variation of posture-dependent parameters.
  
Values represent means ± SEM of posture-dependent parameters. At 11:30 PM, there was a 
transition from upright position to sleep position and at 07:00 AM, posture changed from sleep 
to upright position
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Table 3.2. Analytical variation, biological variation, indexes of individuality and reference 
change values for hematological parameters
n Measured 
unit




Leukocytes 17 10^9/L 6.6 13.7 (10.2 – 21.0) 7.0 (6.6 – 7.6) 1.4 (1.3 – 1.5) * 0.5
Neutrophils 18 10^9/L 3.8 22.3 (16.7 – 33.5) 11.1 (10.3 – 11.9) 1.9 (1.8 – 2.0) * 0.5
Lymphocytes 18 10^9/L 1.9 26.0 (19.4 – 36.1) 15.0 (14.1 – 16.1) 2.7 (2.5 – 2.9) * 0.6
Eosinophils 18 10^9/L 0.2 46.6 (34.9 – 70.1) 20.9 (19.4 – 22.6) 9.3 (8.7 – 9.9) * 0.5
Basophils 19 10^9/L 0.03 32.2 (24.2 – 47.7) 8.8 (5.4 – 11.4) 21.2 (19.9 – 22.7) * 0.7
Monocytes 18 10^9/L 0.6 16.8 (12.5 – 25.3) 12.3 (11.4 – 13.3) 6.2 (5.8 – 6.6) * 0.8
Erythrocytesb 20 10^12/L 4.4 8.1 (6.1 – 11.8) 2.9 (2.7 – 3.1) 0.65 (0.61 – 0.71) 8.2 0.4
Reticulocytes, 
countb
21 10^9/L 57.2 23.5 (17.9 – 33.9) 5.1 (4.5 – 5.7) 4.7 (4.4 – 5.0) 19.2 0.3
Reticulocytes, 
percentageb
20 % 1.3 23.3 (17.7 – 34.1) 4.0 (3.5 – 4.6) 4.6 (4.3 – 4.9) 16.9 0.3
Hemoglobinb 20 mmol/L 8.5 7.2 (5.4 – 10.5) 2.7 (2.5 – 2.9) 0.55 (0.51 – 0.59) 7.6 0.4
Hematocrit b 17 L/L 0.4 4.1 (3.0 – 6.3) 3.0 (2.8 – 3.3)) 0.6 (0.55 – 0.65) 8.5 0.8
MCV 17 fL 90.7 4.1 (3.1 – 6.3) 0.45 (0.42 – 0.48) 0.17 (0.16 - 0.18) 1.3 0.1
MCH 19 fmol 1.9 4.0 (3.0 – 5.9) 0.8 (0.78 – 0.89) 0.17 (0.16 – 0.17) 2.4 0.2
MCHC 19 mmol/L 21.3 3.2 (2.4 – 4.8) 0.8 (0.7 – 0.9) 0.8 (0.77 - 0.88) 3.2 0.4
MPV 18 fL 10.1 7.2 (5.4 – 10.8) 1.9 (1.7 – 2.1) 1.4 (1.3 – 1.5) 6.4 0.3
RDW 17 % 13.2 4.2 (3.1 – 6.3) 0.37 (0.32 – 0.42) 0.47 (0.44 - 0.50) 1.7 0.1
Platelets b 19 10^9/L 228 20.2 (15.2 - 29.8) 3.2 (2.9 - 3.5) 1.5 (1.4 - 1.6) 9.8 0.2
Research hematological parameters
IPF 17 % 2.1 42.3 (31.4 – 64.5) 12.8 (11.6 – 14.0) 10.2 (9.5 – 10.9) 45.2 0.4
Plateletcrit b 16 % 0.2 20.1  (14.9 – 31.2) 3.5  (3.1 – 4.0) 2.8  (2.6 – 3.1) 12.6 0.2
PDW 18 fL 11.6 14.6  (10.9 – 21.9) 3.7  (3.2 – 4.2) 3.8  (3.5 – 4.2) 14.7 0.4
95% confidence intervals are shown in brackets.  a on the basis of duplicate measurements. b This 
parameter has a diurnal rhythm and therefore, hour-to-hour RCVs are calculated (see Table 3 
and Supplemental Table 1). c Concentrations are posture-dependent, hence only data from 08:30 
a.m. – 11:30 p.m. and 07:30 a.m.  were used. n number of subjects after removing outliers. CV, 
coefficient of variation, CVG, between-subject biological variation, CVI, within-subject biological 
variation, CVA, analytical variation, II, index of individuality, RCV, reference change value, MCV, 
mean corpuscular volume, MCH, mean corpuscular haemoglobin, MCHC, mean corpuscular 
haemoglobin concentration, MPV, mean platelet volume, RDW, red cell distribution width, IPF, 
immature platelet fraction, PDW, platelet distribution width
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All parameters, except hematocrit, basophils and monocytes, showed marked 
individuality, with individuality indexes <0.6. The lowest calculated individuality index 
was 0.1 for MCV and RDW and the highest calculated index of individuality was 0.8 
for hematocrit and monocytes. The RCVs ranged from 1.3% (MCV) to 45.2% (IPF).
Rhythmic diurnal variation in hematological parameters
Six hematological parameters showed a diurnal rhythm unrelated to posture-
changes in blood volume: leukocytes, neutrophils, lymphocytes, eosinophils, 
basophils and monocytes. These intrinsic diurnal rhythms were previously 
described by Druzd et al. (32), Lasselin et al. (33) and Sennels et al. (10).
Rhythmic diurnal oscillations precluded calculation of overall variation components 
and RCVs. Instead, hour-to-hour RCVs were calculated, which take into account the 
structural change according to the diurnal rhythm. Hour-to-hour RCVs facilitate 
accurate interpretations of changes between two serial laboratory measurements 
within 24 hours, taking into account the rhythmic diurnal oscillations. Hour-to-
hour RCVs of neutrophils range from -41% to 46%, depending on the time points 
chosen (table 3.3). Hour-to-hour RCVs for other parameters with a diurnal rhythm 
are presented in supplemental tables 3.2A-E. 
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08:30 AM -12 37 -7 42 -5 45 -4 45 -3 46 -7 42 -8 41 -10 39 -14 35 -15 35
09:30 AM -20 29 -18 31 -17 32 -17 33 -20 29 -21 28 -23 26 -26 23 -27 22
10:30 AM -22 27 -22 28 -21 28 -24 25 -26 24 -27 22 -30 19 -31 18
11:30 AM -24 25 -23 26 -26 23 -28 22 -29 20 -32 17 -33 16
12:30 AM -24 25 -27 22 -28 21 -30 19 -33 16 -34 16
01:30 PM -28 22 -29 20 -30 19 -33 16 -34 15
02:30 PM -26 23 -27 22 -31 19 -31 18
03:30 PM -26 23 -29 20 -30 19
04:30 PM -28 21 -29 21















The vertical column corresponds to the time of the first measurement and the horizontal row 
corresponds to the time of the second measurement. Each box indicates the percentage change 
range that is considered ‘normal’ (95% CI), relative to the first measurement. If a percentage 
change between two consecutive measurements is outside this range, the change can be 
considered statistically significant. 
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-14 35 -14 35 -17 32 -18 31 -18 31 -22 27 -18 31 -19 30 -22 27 -24 26 -22 27 -22 27 -11 39
-26 23 -26 23 -29 20 -30 20 -30 20 -34 16 -30 20 -31 19 -33 16 -35 15 -34 16 -33 16 -23 26
-31 19 -30 19 -33 16 -34 16 -34 16 -38 12 -34 16 -35 15 -37 12 -39 11 -37 12 -37 12 -28 22
-33 17 -32 17 -35 14 -36 14 -36 14 -39 10 -36 14 -36 13 -39 10 -40 9 -39 10 -39 10 -30 20
-33 16 -33 16 -35 14 -36 13 -36 13 -40 9 -36 13 -37 12 -40 10 -41 8 -40 9 -40 10 -30 19
-34 16 -33 16 -36 13 -37 13 -37 13 -40 9 -37 13 -38 12 -40 9 -41 8 -40 9 -40 9 -31 19
-31 18 -31 19 -33 16 -34 15 -34 15 -38 11 -34 15 -35 14 -38 12 -39 10 -38 12 -38 12 -28 21
-30 20 -29 20 -32 17 -33 17 -33 16 -37 13 -33 17 -34 16 -36 13 -38 12 -36 13 -36 13 -27 23
-28 21 -28 21 -31 19 -31 18 -31 18 -35 14 -31 18 -32 17 -35 14 -36 13 -35 14 -35 14 -25 24
-25 24 -25 25 -27 22 -28 21 -28 21 -32 17 -28 21 -29 20 -32 17 -33 16 -32 17 -32 17 -22 27
-24 25 -24 25 -27 23 -28 22 -28 22 -32 18 -28 22 -29 21 -31 18 -33 17 -32 18 -31 18 -21 28
-24 25 -27 22 -28 21 -28 21 -32 17 -28 21 -29 20 -32 18 -33 16 -32 17 -32 18 -21 28
-27 22 -28 21 -28 21 -32 17 -28 21 -29 20 -32 17 -33 16 -32 17 -32 17 -22 27
-25 24 -26 24 -30 19 -25 24 -27 23 -29 20 -31 18 -30 20 -29 20 -19 30
-25 25 -29 20 -25 25 -26 24 -29 21 -30 19 -29 21 -29 21 -18 31
-29 20 -25 25 -26 24 -28 21 -30 19 -29 21 -28 21 -18 31
-20 29 -21 28 -24 25 -26 24 -24 25 -24 25 -13 36
-26 24 -28 21 -30 19 -29 21 -29 21 -18 31
-27 22 -29 20 -28 22 -28 22 -17 32
-26 23 -25 24 -25 25 -14 36
-23 26 -23 26 -12 37
-24 25 -13 36
-14 36
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Physiological basis of rhythmic diurnal variation
Rhythmic oscillations of parameters can be either intrinsic or in response to 
circadian variation of other parameters such as cortisol. As an illustration, 
we measured cortisol in all subjects of this study and plotted diurnal cortisol 
concentrations and lymphocytes together in supplemental figure 3.1. In this 
figure, exactly the opposite rhythmic oscillations are evident. This is in line with 
the established physiological effects of cortisol on lymphocyte levels (34, 35).
Discussion
This study presents novel 24-hour variability profiles for 20 hematological 
parameters. We have calculated variation components (CVA, CVI and CVG), indexes 
of individuality and RCVs of these parameters in order to better differentiate true 
changes from random fluctuations when interpreting changes between serial 
laboratory measurements within a day. Repeated within-day testing is customary 
in various clinical settings, e.g. the evaluation of therapeutic interventions, 
or when monitoring the disease course. The availability of comprehensive, 24-
hour variability data in the scientific literature represents a major gap for most 
laboratory parameters. 
Comprehensive 24-hour sampling allowed to investigate diurnal cyclical rhythms 
and, if present, to take into account the ‘time of sample-collection’ as a determinant 
of natural fluctuation. For the six parameters with a detectable diurnal rhythm, we 
present for the first time hour-to hour RCVs that may help to objectively evaluate 
changes between any two time-points of the day.
Hour-to-hour RCVs
RCV values describe the maximum non- significant hour-to hour changes that might 
be seen in a ‘steady state situation’. In a parameter with a diurnal rhythm, there is 
no steady state situation, because the level of the parameter changes randomly as 
well as systematically over time. If the systematic component is ignored, the CVI’s 
will be inflated and the RCVs will be systematically biased up or down depending 
on the hour. As a result, the RCVs will not properly reflect the bandwidth within 
which values are to be expected with a 95% probability. 
To calculate unbiased RCVs, we calculated the β value for each time point as a 
percentage from the first result. The data was then adjusted according to the 
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β value, and an adjusted steady state was achieved. After calculating the CVI’s 
and CVA’s, the β’s were combined with the CV I’s and CVA’s in order to get an 
asymmetrical hour-to-hour RCV with an upper-and lower limit. This method was 
first described by Aakre et al.(28). 
By implementing the β’s the way we did, we were able to fully correct for any 
variation in parameter levels during the day. The advantage of our approach is 
that it yields unbiased results, but the downside is that it requires a substantial 
number of betas to be estimated on the data, potentially increasing estimation 
error. Other approaches, such as fitting a (co)sinus function to the data, make 
stronger assumptions about the nature of the fluctuations in the parameter during 
the day, which allows them to be implemented with fewer betas to estimate and, 
accordingly, reduced estimation error. However, if the inherent assumptions about 
the nature of the fluctuations are not correct, they yield biased results. In this 
trade-off, we chose to avoid making additional assumptions and, with that, to 
avoid introducing bias, at the cost of estimating more betas. What approach is 
optimal in the context of diurnal parameter rhythms is to our knowledge still an 
open question, and may vary per parameter. However, for parameters such as 
neutrophils, any of these approaches is an improvement over the old assumption 
of a constant diurnal level.
The asymmetry of the calculated hour-to-hour RCVs in table 3.3 shows how 
different they can be from standard symmetrical RCVs and underlines the clinical 
importance of letting go of the restricting assumption of a constant diurnal level.
Influence of fasting vs non-fasting
To the best of our knowledge, fasting does not have a direct influence on the 
parameters that were studied. As all conditions including mealtimes were 
standardized, we cannot empirically prove that any fasting leaves our results 
unaffected.
Comparison of CVI values to those in previous studies
In general, the CVI values of this study were comparable to those in previous studies 
about biological variation of hematological parameters. Overall, other studies 
about within-day biological variation of hematological parameters found slightly 
higher CVI values, except for MCV and Platelet Distribution Width (PDW) (9, 10). 
However, when comparing the CVI values of the current study with previous studies 
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about between-day biological variation, some parameters showed slightly lower 
CVI values in other studies. The study of Fraser et al. reported CVI values of 9.4 for 
lymphocytes, compared to 15.0 (14.1 – 16.1) in our study (36). A potential explanation 
for this difference could be that the time of sample collection was standardized in 
Fraser’s study. Hereby, the intrinsic rhythmic oscillations during the day are not 
included in the CVI and therefore the CVI is lower.
Gradual decrease of hemoglobin and hematocrit during the day
A remarkable finding is the gradual decrease of hemoglobin, hematocrit and 
erythrocytes during the day, before the ‘acute concentration drop’ due to the 
transition from an upright to lying position in the evening. The other parameters 
that were posture-dependent did not show such a gradual decrease during the 
day. A dilution effect for the gradual decrease is unlikely since other parameters 
such as platelets are unaffected.
Hemoglobin concentration decreased from 8.2 mmol/L in sitting position to 7.9 
mmol/L in lying position (-3.8%) and increased from 8.0 mmol/L to 8.7 mmol/L 
(+8.8%) during the transition from a lying to an upright position. Parallel changes 
were found for hematocrit, 0.37 L/L to 0.38 L/L (-2.6%) and from 0.37 L/L to 0.40 
L/L (+8.1%), respectively.
Index of individuality
Parameters with individuality indexes of >1.4 show very little individuality and, 
therefore, the use of reference values is considered appropriate because unusual 
values for almost all subjects will lie outside the reference limits (18, 26, 37). For 
parameters with individuality indexes of <0.6 however, population based reference 
values have limited utility, and the use of RCVs may have added value. Analysis of 
the samples obtained from participants in this study revealed that all parameters, 
except hematocrit, basophils and monocytes, showed substantial individuality 
indexes below 0.6 (table 3.2). Consequently, for almost all of the studied parameters, 
calculated RCVs may offer substantial benefit when monitoring a patient within 
a day.
Study Limitations
Some limitations in the study population merit attention. We have included 
16-21 subjects (depending on the parameter) in biological variation analyses. 
Although the number of excluded subjects was rather high for some parameters 
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(i.e. plateletcrit, 8 subjects), 16 subject still afforded sufficient power to make 
reliable estimations for the various components of variation (24). However, due to 
disproportional inclusion of both sexes (men n=19, women n=5), we were unable 
to assess the appropriateness of partitioning CVI and CVG by sex. Besides, the age 
range of the subjects was 65-79 years. Although this age category corresponds 
to the age of the average hospitalized patient, the results of this study cannot be 
extrapolated to other age categories.
Another limitation that should be mentioned is that RCV calculations in this study 
were based on the CVA values we reported in table 3.2. However, CVA is to some 
degree concentration-dependent and RCVs may vary according to the concentration 
of the parameter. However, for the majority of the routine hematological 
parameters (65%), CVA was ≤ ½ CVI, which diminishes the contribution of CVA to 
the overall variation to less than 12% (20). 
Conclusion
This is the first study that assesses the within-day biological variation of most of the 
relevant hematological parameters by using hourly blood samples. Moreover, it is 
the first to study the hour-to-hour fluctuations in parameter levels that occur for 
certain parameters during the day. It presents CVG, CVI, CVA, indexes of individuality 
and RCVs for 20 hematological parameters, and where appropriate adjusts the 
RCVs for diurnal rhythms. 24-hour biological variation profiles are an important 
part of the scientific basis for better interpretation of serial within-day laboratory 
measurements.
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Supplementary figures and tables
Supplemental table 3.1: Overview of outliers and excluded subjects per parameter
Parameter Excluded subjects because of 
incompleteness of sample collec-
tion or instable medical situation
Cochran’s C test 
(analytical outliers)
Neutrophils Subjects 1, 8, 15, 20 and 23 Subject 5, measurement 5
Subject 12, measurement 8
Subject 16, measurement 1
Leukocytes Subjects 1, 8, 15, 20 and 23 Subject 12, measurement 8
Subject 16, measurement 1
Lymphocytes Subjects 1, 8, 15, 20 and 23 None
Eosinophils Subjects 1, 8, 15, 20 and 23 None
Basophils Subjects 1, 8, 15, 20 and 23 None
Monocytes Subjects 1, 8, 15, 20 and 23 Subject 12, measurement 20
Hemoglobin Subjects 1, 8 and 20 Subject 2, measurement 11
Subject 11, measurement 1
Subject 23, measurement 6
Hematocrit Subjects 1, 8 and 20 Subject 10, measurement 12
Subject 24,measurement 14
Erythrocytes Subjects 1, 8 and 20 None
Reticulocytes, count Subjects 1, 8 and 20 Subject 7, measurement 24
Subject 11, measurement 24
Subject 17, measurement 13
Reticulocytes, percentage Subjects 1, 8 and 20 Subject 7, measurement 24
Platelets Subjects 1, 8 and 20 Subject 4, measurement 4
Subject 9, measurement 9
Subject 10, measurement 8
Subject 12, measurement 8
Subject 14, measurement 1
Subject 15, measurement 3
Subject 17, measurement 24
Subject 24, measurement 15
Plateletcrit Subjects 1, 8 and 20 Subject 13, measurement 7
Platelet Distribution Width (PDW) Subjects 1, 8, 15, 20 and 23 None
Mean Platelet Volume (MPV) Subjects 1, 8, 15, 20 and 23 None
Immature Platelet Fraction (IPF) Subjects 1, 8, 15, 20 and 23 Subject 9, measurement 9
Red Cell Distribution Width (RDW) Subjects 1, 8, 15, 20 and 23 None
Mean Corpuscular Volume (MCV) Subjects 1, 8, 15, 20 and 23 Subject 11, measurement 12
Subject 21, measurement 19
Mean Corpuscular Hemoglobin (MCH) Subjects 1, 8, 15, 20 and 23 Subject 7, measurement 20
Mean Corpuscular Hemoglobin 
Concentration (MCHC)
Subjects 1, 8, 15, 20 and 23 Subject 7, measurement 20
Subject 16, measurement 20
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None Subject 19 None
Subject 10, measurement 24
Subject 12, measurement 1
Subject 24, measurement 16
Subjects 14 and 19 None
None Subject 12 None
None Subject 5 None
Subject 4, measurement 14 None None
Subject 24, measurement 16 Subject 18 None
None Subject 19 None
None Subjects 6, 7, 16 and 19 None
None Subject 19 None
None None None
None Subject 2 None
Subject 12, measurement 16 Subject 18 None
None Subjects 14, 16, 22 and 24 None
Subject 14, measurement 17 Subject 18 None
Subject 4, measurement 16
Subject 11, measurement 19
Subject 14, measurement 17
Subject 19, measurement 2
Subject 18 None
Subject 11, measurements 11, 19 and 22
Subject 14, measurement 17
Subject 18, measurement 19
Subject 24, measurement 23
Subjects 3 and 18 None
None Subject 22 None
Subject 2, measurement 3 Subjects 16, and 22 None
None None None
None None None
// De magenta omlijning geeft de netto maat aan en zal niet zichtbaar zijn in het eindproduct //
// Let op: Dit proef bestand is niet geschikt om correcties in te maken //
555031-L-sub01-bw-Hilderink
Processed on: 24-2-2021 PDF page: 52
52 Chapter 3
Supplemental figure 3.1.  Diurnal rhythms of cortisol versus lymphocytes
Values represent means ± SEM (n  = 18) of lymphocytes and cortisol within a day. Subjects slept 
between 11:30 p.m. and 7:00 a.m. (shaded area).
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08:30 AM -11 21 -9 22 -4 27 -1 31 -1 30 -5 27 -5 27 -2 29 -2 29 -5 27
09:30 AM -15 17 -10 22 -6 25 -7 25 -10 21 -11 21 -8 24 -8 24 -10 21
10:30 AM  -11 20 -8 24 -8 23 -12 20 -12 20 -9 22 -9 22 -12 20
11:30 AM -13 19 -13 19 -16 15 -16 15 -14 18 -14 18 -16 15
12:30 AM -16 15 -19 12 -20 12 -17 15 -17 14 -19 12
01:30 PM -19 13 -19 12 -17 15 -17 15 -19 13
02:30 PM -16 16 -14 18 -14 18 -16 16
03:30 PM -13 18 -13 18 -16 16
04:30 PM -16 16 -18 14















The vertical column corresponds to the time of the first measurement and the horizontal row 
corresponds to the time of the second measurement. Each box indicates the percentage change 
range that is considered ‘normal’ (95% CI),  relative to the first measurement. If a percentage 
change between two consecutive measurements is outside this range, the change can be 
considered statistically significant. 
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-5 27 -1 30 -2 29 -2 30 0 32 -7 24 -6 25 -6 25 -8 23 -10 22 -11 21 -11 20 1 33
-11 21 -7 25 -8 24 -7 24 -6 26 -13 19 -12 20 -12 20 -14 18 -15 16 -16 16 -16 15 -4 27
-12 20 -8 23 -9 22 -9 23 -7 25 -14 18 -13 19 -13 19 -15 17 -17 15 -17 14 -18 14 -6 26
-16 15 -13 19 -14 18 -13 18 -12 20 -19 13 -18 14 -17 14 -19 12 -21 11 -21 10 -22 10 -11 21
-20 12 -16 15 -17 14 -17 15 -15 17 -22 10 -21 11 -21 11 -22 9 -24 8 -24 7 -25 7 -14 18
-19 12 -16 16 -17 15 -16 15 -15 17 -21 10 -20 11 -20 11 -22 10 -24 8 -24 8 -25 7 -13 18
-16 16 -13 19 -14 18 -13 19 -11 20 -18 13 -17 14 -17 15 -19 13 -21 11 -21 11 -22 10 -10 21
-16 16 -12 19 -13 18 -13 19 -11 21 -18 14 -17 15 -17 15 -19 13 -20 11 -21 11 -21 10 -10 22
-18 13 -15 17 -16 16 -15 16 -14 18 -20 11 -19 12 -19 12 -21 10 -23 9 -23 8 -24 8 -13 19
-18 13 -15 17 -16 16 -15 16 -14 18 -20 11 -19 12 -19 12 -21 10 -23 9 -23 8 -24 8 -12 19
-16 16 -13 19 -14 18 -13 19 -11 20 -18 13 -17 14 -17 15 -19 13 -21 11 -21 11 -22 10 -10 21
-12 19 -13 18 -13 19 -11 21 -18 14 -17 15 -17 15 -19 13 -20 11 -21 11 -21 10 -10 22
-17 15 -16 15 -15 17 -21 10 -20 11 -20 11 -22 10 -24 8 -24 8 -25 7 -13 18
-15 16 -14 18 -20 11 -19 12 -19 12 -21 11 -23 9 -23 8 -24 8 -12 19
-14 17 -21 11 -20 12 -20 12 -22 10 -23 8 -24 8 -24 7 -13 19
-22 9 -21 10 -21 10 -23 8 -25 7 -25 6 -26 6 -15 17
-15 17 -15 17 -17 15 -18 13 -19 13 -19 12 -8 24
-16 16 -18 14 -19 12 -20 12 -20 11 -9 23
-18 14 -19 12 -20 12 -20 11 -9 23
-17 14 -18 14 -19 13 -7 25
-16 15 -17 15 -5 27
-16 15 -4 27
-4 28
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08:30 AM -26 22 -29 20 -22 26 -16 33 -15 33 -17 32 -12 36 -3 45 5 54 0 48
09:30 AM -27 22 -20 28 -13 35 -13 35 -15 34 -10 38 -1 47 8 56 2 51
10:30 AM -18 31 -10 38 -10 39 -12 37 -7 41 2 51 12 60 6 54
11:30 AM -18 31 -17 31 -19 30 -14 34 -5 43 3 52 -2 46
12:30 AM -24 25 -25 23 -21 27 -13 36 -5 44 -10 38
01:30 PM -26 23 -22 27 -13 35 -5 43 -11 38
02:30 PM -20 28 -12 37 -4 45 -9 39
03:30 PM -16 32 -8 40 -13 35
04:30 PM -17 31 -22 27















The vertical column corresponds to the time of the first measurement and the horizontal row 
corresponds to the time of the second measurement. Each box indicates the percentage change 
range that is considered ‘normal’ (95% CI),  relative to the first measurement. If a percentage 
change between two consecutive measurements is outside this range, the change can be 
considered statistically significant. 
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-3 45 6 55 9 57 14 63 19 67 2 50 -1 47 2 51 2 51 -3 46 -8 40 -8 40 12 61
-1 47 9 57 11 60 17 66 22 70 5 53 1 50 5 53 5 53 0 48 -6 42 -6 42 15 63
2 51 13 61 15 64 21 70 26 74 8 57 5 53 8 57 8 57 3 52 -3 46 -3 46 19 67
-5 43 4 52 6 55 12 60 16 65 0 48 -3 45 0 48 0 48 -5 44 -10 38 -10 38 10 58
-13 36 -4 44 -2 47 4 52 8 56 -8 41 -11 38 -8 41 -8 41 -12 36 -17 31 -18 31 1 50
-13 35 -5 44 -2 46 3 51 7 55 -8 40 -11 37 -8 40 -8 40 -13 36 -18 30 -18 30 1 49
-12 37 -3 46 0 48 5 53 9 57 -7 42 -10 39 -7 42 -7 42 -11 37 -16 32 -16 32 3 51
-16 32 -7 41 -5 43 0 48 4 52 -11 37 -14 34 -11 37 -11 37 -15 33 -20 28 -21 28 -2 46
-24 24 -16 32 -14 34 -9 39 -6 43 -20 29 -22 26 -20 29 -20 29 -24 25 -28 20 -28 20 -11 37
-31 17 -23 25 -22 27 -17 31 -14 34 -27 22 -29 19 -27 22 -27 22 -30 18 -35 14 -35 13 -19 29
-27 22 -19 30 -17 32 -12 36 -9 40 -22 26 -25 24 -22 26 -22 26 -26 22 -31 18 -31 18 -14 34
-16 32 -14 34 -9 39 -6 43 -20 29 -22 26 -20 29 -20 29 -24 25 -28 20 -28 20 -11 37
-22 26 -18 30 -15 34 -27 21 -30 18 -27 21 -27 21 -31 17 -35 13 -36 13 -20 29
-20 28 -17 32 -29 19 -32 17 -29 19 -29 19 -33 16 -37 11 -37 11 -22 27
-21 27 -33 15 -35 13 -33 15 -33 15 -36 12 -41 8 -41 8 -26 23
-36 13 -38 10 -36 13 -36 13 -39 9 -43 5 -43 5 -29 20
-27 22 -24 24 -24 24 -28 20 -32 16 -33 16 -16 32
-21 27 -22 27 -25 23 -30 18 -30 18 -13 35
-24 24 -28 20 -33 16 -33 16 -16 32
-28 20 -32 16 -33 16 -16 32
-29 19 -29 19 -12 36
-24 24 -7 42
-6 42
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08:30 AM -65 28 -75 18 -74 19 -73 20 -73 20 -67 26 -62 31 -53 40 -53 40 -52 41
09:30 AM -58 35 -58 35 -56 37 -56 37 -49 44 -44 49 -33 60 -32 61 -31 62
10:30 AM -46 47 -44 49 -44 49 -36 57 -30 63 -17 76 -17 76 -15 78
11:30 AM -44 49 -44 49 -36 57 -30 63 -17 76 -17 76 -16 77
12:30 AM -47 46 -39 54 -32 61 -20 73 -20 73 -19 74
01:30 PM -38 55 -32 61 -20 73 -20 73 -18 75
02:30 PM -41 52 -30 63 -29 64 -28 65
03:30 PM -36 57 -36 57 -34 59
04:30 PM -46 47 -45 48















The vertical column corresponds to the time of the first measurement and the horizontal row 
corresponds to the time of the second measurement. Each box indicates the percentage change 
range that is considered ‘normal’ (95% CI),  relative to the first measurement. If a percentage 
change between two consecutive measurements is outside this range, the change can be 
considered statistically significant. 
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-44 49 -41 52 -43 50 -44 49 -37 56 -38 55 -34 59 -35 58 -38 55 -33 60 -33 60 -34 59 -32 61
-22 72 -17 76 -19 74 -21 72 -12 81 -14 79 -9 84 -11 82 -14 79 -7 86 -7 86 -9 84 -6 87
-4 89 0 93 -2 91 -4 89 6 99 4 97 9 102 8 101 4 97 12 105 12 105 9 102 13 106
-5 88 0 93 -2 91 -4 89 6 99 3 97 9 102 8 101 4 97 11 104 11 104 9 102 13 106
-8 85 -3 90 -6 87 -8 85 3 96 0 93 5 98 4 97 1 94 8 101 8 101 6 99 9 102
-8 85 -3 90 -5 88 -7 86 3 96 0 93 6 99 5 98 1 94 8 101 8 101 6 99 9 102
-18 75 -14 79 -16 77 -18 75 -8 85 -11 82 -6 87 -7 86 -10 83 -3 90 -3 90 -6 87 -2 91
-25 68 -21 72 -23 70 -25 68 -16 77 -18 75 -13 80 -14 79 -18 75 -11 82 -11 82 -13 80 -10 83
-37 56 -33 60 -35 58 -36 57 -28 65 -30 63 -26 67 -27 66 -30 63 -24 69 -24 69 -26 67 -23 70
-37 56 -33 60 -35 58 -37 56 -28 65 -30 63 -26 67 -27 66 -30 63 -24 69 -24 69 -26 67 -23 70
-38 55 -35 58 -36 57 -38 55 -30 63 -32 61 -28 65 -29 64 -32 61 -26 67 -26 67 -28 65 -25 68
-43 50 -45 48 -46 47 -39 54 -41 52 -37 56 -38 55 -40 53 -35 58 -35 58 -37 56 -34 59
-48 45 -49 44 -42 51 -44 49 -40 53 -41 52 -44 49 -39 54 -39 54 -40 53 -38 55
-48 45 -41 52 -42 51 -39 54 -39 54 -42 51 -37 56 -37 56 -39 55 -36 57
-39 54 -41 52 -37 56 -38 55 -41 52 -35 58 -35 58 -37 56 -35 58
-48 45 -45 48 -45 48 -48 45 -43 50 -43 50 -45 48 -42 51
-43 50 -44 49 -46 47 -41 52 -41 52 -43 50 -40 53
-47 46 -50 43 -45 48 -45 48 -46 47 -44 49
-49 44 -44 49 -44 49 -46 47 -43 50
-42 51 -42 51 -43 50 -41 52
-47 47 -48 45 -46 47
-48 45 -46 47
-44 49
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08:30 AM -79 67 -80 66 -76 70 -75 70 -72 74 -76 70 -71 75 -72 74 -66 80 -71 75
09:30 AM -75 71 -70 75 -69 76 -66 80 -70 75 -65 81 -66 80 -59 87 -65 81
10:30 AM -68 77 -68 78 -64 82 -68 77 -63 83 -64 82 -57 89 -63 83
11:30 AM -72 74 -68 78 -73 73 -68 78 -69 77 -62 84 -68 78
12:30 AM -69 77 -74 72 -68 77 -70 76 -63 83 -69 77
01:30 PM -77 68 -72 74 -73 72 -67 79 -72 73
02:30 PM -68 78 -69 77 -62 84 -68 78
03:30 PM -74 72 -68 78 -73 73
04:30 PM -66 79 -72 74















The vertical column corresponds to the time of the first measurement and the horizontal row 
corresponds to the time of the second measurement. Each box indicates the percentage change 
range that is considered ‘normal’ (95% CI),  relative to the first measurement. If a percentage 
change between two consecutive measurements is outside this range, the change can be 
considered statistically significant.
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-70 75 -70 76 -69 77 -62 84 -69 77 -82 64 -79 67 -79 66 -76 70 -81 65 -66 79 -76 70 -61 85
-64 82 -63 82 -63 83 -55 91 -63 83 -76 69 -73 73 -74 72 -70 75 -75 70 -60 86 -70 75 -54 92
-62 83 -61 84 -61 85 -53 93 -61 85 -75 71 -71 75 -72 74 -68 77 -74 72 -58 88 -68 77 -52 94
-67 79 -66 80 -66 80 -58 88 -65 80 -79 67 -75 70 -76 70 -73 73 -78 68 -63 83 -73 73 -57 89
-68 78 -67 79 -66 79 -59 87 -66 80 -80 66 -76 70 -77 69 -74 72 -79 67 -64 82 -74 72 -58 88
-72 74 -71 75 -70 75 -63 83 -70 76 -83 63 -80 66 -81 65 -77 68 -82 64 -68 78 -77 68 -62 84
-67 79 -66 80 -66 80 -58 88 -65 80 -79 67 -75 70 -76 70 -73 73 -78 68 -63 83 -73 73 -57 89
-72 73 -72 74 -71 75 -64 82 -71 75 -84 62 -80 65 -81 65 -78 68 -83 63 -68 77 -78 68 -63 83
-71 74 -70 75 -70 76 -62 83 -70 76 -83 63 -79 66 -80 66 -77 69 -82 64 -67 79 -77 69 -62 84
-77 68 -77 69 -76 70 -69 77 -76 70 -88 58 -85 61 -86 60 -83 63 -87 58 -74 72 -83 63 -68 77
-72 74 -71 74 -71 75 -63 82 -70 75 -83 62 -80 66 -81 65 -78 68 -82 63 -68 78 -78 68 -62 83
-72 74 -72 74 -64 82 -71 74 -84 62 -81 65 -82 64 -78 67 -83 63 -69 77 -78 67 -63 82
-72 73 -65 81 -72 74 -85 61 -82 64 -82 63 -79 67 -84 62 -70 76 -79 67 -64 82
-66 80 -73 73 -85 61 -82 64 -83 63 -80 66 -84 61 -70 75 -80 66 -65 81
-79 66 -91 55 -88 58 -89 57 -86 60 -90 55 -77 69 -86 60 -72 74
-85 60 -82 64 -83 63 -80 66 -85 61 -71 75 -80 66 -65 81
-69 76 -70 76 -67 79 -72 74 -56 90 -67 79 -50 96
-74 72 -70 75 -75 70 -60 86 -70 75 -54 92
-69 76 -75 71 -59 87 -69 76 -53 93
-78 68 -63 83 -73 73 -57 89
-57 89 -68 78 -51 95
-82 64 -68 78
-57 89
// De magenta omlijning geeft de netto maat aan en zal niet zichtbaar zijn in het eindproduct //
// Let op: Dit proef bestand is niet geschikt om correcties in te maken //
555031-L-sub01-bw-Hilderink
Processed on: 24-2-2021 PDF page: 62
62 Chapter 3





























08:30 AM -40 26 -48 17 -33 32 -18 47 -30 36 -37 28 -32 34 -24 42 -19 46 -34 31
09:30 AM -42 24 -25 40 -9 56 -22 44 -30 35 -24 42 -15 50 -11 55 -27 39
10:30 AM -15 51 3 68 -10 55 -20 46 -13 53 -3 62 2 67 -16 49
11:30 AM -18 48 -29 36 -37 28 -31 34 -23 42 -19 47 -34 31
12:30 AM -43 23 -49 16 -44 21 -37 28 -34 32 -47 19
01:30 PM -40 25 -35 31 -27 39 -23 43 -37 28
02:30 PM -27 39 -18 47 -14 52 -30 36
03:30 PM -25 41 -21 45 -36 30
04:30 PM -29 37 -43 23















The vertical column corresponds to the time of the first measurement and the horizontal row 
corresponds to the time of the second measurement. Each box indicates the percentage change 
range that is considered ‘normal’ (95% CI),  relative to the first measurement. If a percentage 
change between two consecutive measurements is outside this range, the change can be 
considered statistically significant. 
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-30 36 -19 47 -20 46 -18 48 -16 50 -25 40 -25 41 -29 36 -28 37 -29 37 -27 38 -26 39 -21 44
-22 44 -10 56 -11 54 -9 56 -7 59 -17 48 -17 49 -21 44 -20 45 -21 45 -19 47 -18 48 -13 53
-10 55 3 68 1 67 3 69 6 71 -5 60 -5 61 -10 56 -9 57 -9 56 -7 58 -6 59 0 65
-29 36 -18 47 -19 46 -18 48 -15 50 -25 41 -25 41 -29 37 -28 38 -28 37 -27 39 -26 40 -21 45
-43 23 -33 32 -34 31 -32 33 -31 35 -39 27 -39 27 -42 23 -41 24 -42 24 -40 25 -40 26 -35 30
-33 33 -22 43 -23 42 -22 44 -19 46 -29 37 -28 37 -32 33 -31 34 -32 34 -30 35 -29 36 -25 41
-25 41 -13 52 -14 51 -12 53 -10 55 -20 45 -20 46 -24 41 -23 43 -24 42 -22 44 -21 45 -16 50
-31 35 -20 46 -21 45 -19 46 -17 48 -27 39 -26 39 -30 35 -29 36 -30 36 -28 37 -27 38 -22 43
-38 27 -28 37 -29 36 -28 38 -26 40 -34 31 -34 32 -38 28 -37 29 -37 28 -36 30 -35 30 -31 35
-42 24 -32 33 -33 32 -32 34 -30 36 -38 27 -38 28 -41 24 -41 25 -41 24 -40 26 -39 27 -34 31
-28 38 -17 49 -18 48 -16 50 -14 52 -23 42 -23 42 -27 38 -26 39 -27 39 -25 40 -24 41 -19 46
 -22 43 -23 42 -21 44 -19 46 -29 37 -28 37 -32 33 -31 34 -32 34 -30 35 -29 36 -25 41
  -34 32 -32 33 -30 35 -39 27 -38 27 -42 23 -41 24 -42 24 -40 25 -39 26 -35 31
   -31 34 -29 36 -38 28 -37 28 -41 24 -40 25 -41 25 -39 26 -38 27 -34 32
    -31 35 -39 26 -39 27 -43 23 -42 24 -42 23 -41 25 -40 26 -36 30
     -41 25 -41 25 -44 21 -43 22 -44 22 -42 23 -42 24 -37 28
      -32 33 -36 29 -35 30 -36 30 -34 31 -34 32 -29 37
       -37 29 -36 30 -36 29 -35 31 -34 32 -29 36
        -32 34 -32 33 -31 35 -30 36 -25 41
         -33 32 -32 34 -31 35 -26 39
          -31 34 -30 35 -25 40
           -32 34 -27 38
            -28 37
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Within-day biological variation data is important to be able to make reliable 
estimates whether changes between two serial laboratory results within the 
day, are ‘real changes’ or not. Biological variation is believed to be of the same 
magnitude in health and disease, if the illness is chronic and the disease is stable. 
However, it is unclear if this holds true for within-day biological variation and for 
parameters that have not been studied yet.
This study was performed to present an overview of within-day biological variation 
data of 26 biochemical parameters, some routine and some research parameters. 
The assumption was tested if within-day biological variation is similar for people 
with and without a chronic kidney disease (CKD).
Methods
During 24h, hourly blood samples were collected from 24 subjects without CKD and 
20 subjects with CKD. Components of variation, as well as Reference Change Values 
(RCV’s) were calculated for both study groups. Outlier and homogeneity analyses were 
performed before using a nested ANOVA test to determine components of biological 
variation, including within-subject biological variation (CVI), between-subject biological 
variation (CVG), analytical variation (CVA) and index of individuality (II).
Results
CVG was larger than CVI for all parameters in both study groups, except for sodium 
and phosphate. CVI was similar for the two study groups in 20 parameters (77%). 
In the other parameters, CVI values differed. In both study groups, 24 out of 26 
parameters (92%) had an index of individuality <0.6.
In general, RCVs were of similar magnitudes for subjects with- and without CKD. 
The highest RCVs were found for triglycerides (59.1% and 48.8%, respectively). The 
lowest RCVs were found for sodium (2.6% and 3.1%, respectively).
Conclusion
Our findings imply that the within-day CVI is not affected by the presence of chronic 
(kidney) disease for most biochemical parameters. Observed RCV’s were of similar 
magnitude for subjects with- and without CKD. Thus, the use of RCV’s derived from 
healthy subjects for monitoring patients seems to be reasonable.
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Background
Biological variation studies have been widely performed in laboratory medicine. The 
past two decades, there has been an ever-increasing interest in the dissemination 
of guidelines from biological variation working groups (1-3). This initiative was 
designed to strive for more uniformity in the implementation of biological variation 
studies and to deliver ‘high quality biological variation data’ (4).
For most of the parameters, biological variation has already been studied and 
reported before. However, these studies are mostly about between-day biological 
variation (5, 6) Few papers report the within-day biological variation. Moreover, to 
the best of our knowledge, for some parameters, such as soluble transferrin receptor 
(sTfR) and homocystein (within-day) biological variation was never studied before.
Within-day biological variation data is important to be able to make reliable 
estimates whether changes between two serial laboratory results within the day, 
are ‘real changes’ or not. Besides, if a parameter has an intrinsic diurnal rhythm, 
within-day biological variation data can contribute if this parameter is measured 
on two different time points.
Also, with reliable biological variation data, reference change values (RCV) 
can be calculated to assess the significance of a change between two serial 
laboratory results from an individual. Moreover, availability of reliable (within-day) 
biological variation data is important for the definition of analytical performance 
specifications (7). Furthermore, the utility of population based reference values can 
be assessed by the calculation of the index of individuality (II), which is the ratio 
of the between-subject biological variation (CVG) and the within-subject biological 
variation (CVI) (8).
Biological variation is believed to be of the same magnitude in health and disease, 
if the illness is chronic and the disease is stable (9, 10). However, it is unclear if this 
holds true for within-day biological variation and for parameters that have not 
been studied yet.
This study was performed to present an overview of within-day biological variation 
data of 26 biochemical parameters, some routine and some research parameters. 
Besides, we assessed if within-day biological variation is similar for people with 
and without a chronic illness.
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Materials and methods
This study was approved by the Institutional Review Board and the ethics 
committee at Maastricht University, the Netherlands, and agrees with the World 
Medical Association Declaration of Helsinki. The study was performed in the period 
2013-2015 at Maastricht University Medical Center. The registration numbers at 
www.clinicaltrials.org were: NCT02091427 and NCT02210897. All subjects provided 
written informed consent.
Sample collection and handling
This study included 44 subjects, 33 men and 11 women, aged between 39 and 83 
years. Baseline characteristics were shown in table 1. The subjects were divided into 
two study groups. The first study group consisted of 24 subjects without clinically 
diagnosed CKD (19 males and 5 females). The other study group consisted of 20 
patients with CKD stage 3 or higher (eGFR ≤59 mL/min/1.73 m²) (11) (14 males and 
6 females). This number of subjects per group provides adequate power to make 
reliable estimations about biological variation (power = 1.00, α = 0.05) (12). The 
subjects are described in more detail in previous studies of our group (13-16).
Subjects were invited for a test day in sets of two or three persons per test day. 
On a test day, subjects arrived at the laboratory at 8:00 AM after an overnight fast. 
During the test day, subjects were restricted to the laboratory environment and 
were refrained from strenuous exercise. Mealtimes were standardized at 08:30 AM 
(breakfast), 12:30 AM (lunch) and 6:00 PM (dinner). Subjects went to bed at 11:30 PM 
and got up the next morning at 07:00 AM. Venous blood samples were drawn every 
hour, during 24 hour in ethylenediaminetraacetic acid (EDTA)-containing tubes 
using an intravenous cannula. During the night, an extending line was attached 
to the cannula to prevent sleep disturbance during blood sampling.
The first (baseline) blood sample was taken at 8:30 AM, and from then every hour 
during 24h (9:30 AM, 10:30 AM, etc.). Most of the blood samples were drawn by 
the same phlebotomist.
After each sample collection, serum/plasma was separated by centrifugation at 
2700g for 12 minutes at room temperature. Samples were then aliquoted and 
stored at -80°C until analysis.
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Analytical methods
Measurements of all parameters were performed on a Cobas 8000 (Roche 
Diagnostics, Basel, Switzerland). All samples from half of the study population 
were analyzed in duplicate within a single run in order to estimate CVA.
Data analysis
Data were CV-transformed in order to perform the CV-ANOVA (17). This non-
parametric calculation has been shown to be robust and distribution-independent, 
which makes it suitable for estimating components of biological variation (17). 
Briefly, the CV-ANOVA method is based
Table 4.1. Baseline characteristics of the study participants (n  = 43)
Subjects without CKD (n =23) Subjects with CKD (n  = 20)
Age, years 72 ± 7 66 ± 12
Male gender 19 (83) 14 (70)
Body Mass Index 26 ± 4.5 28 ± 4
Systolic blood pressure, mmHg 138.9 ± 13.8 136 ± 19
Diastolic blood pressure 67.4 ± 7.5 86 ± 14
eGFR, ml/min/1.73m2 a 76 ± 19 19.0 ± 7.0
a for the estimation of GFR the CKD-EPI creatinine – cystatin C formula was used (21).
on the CV transformation with normalization of the data by dividing by each 
subject’s mean value, and then performing the ANOVA. As recommended for 
biological variation studies, data were checked for homogeneity and outliers (18). 
Replicates were excluded until homoscedasticity was achieved on analytical and 
within-subject level (3). To verify the normality of the residuals, the Shapiro Wilk 
test was used (19).
Since some parameters are posture dependent and show a concentration drop 
during nighttime (such as albumin, total protein, transferrin, see figures 1 and 2), 
we calculated biological variation by using the first 15 consecutive measurements 
(08:30 AM – 11:30 PM), to make sure there was a steady state for each parameter. 
Besides, biological variation data were determined identically for all parameters 
since the number of time points was the same.
// De magenta omlijning geeft de netto maat aan en zal niet zichtbaar zijn in het eindproduct //
// Let op: Dit proef bestand is niet geschikt om correcties in te maken //
555031-L-sub01-bw-Hilderink
Processed on: 24-2-2021 PDF page: 70
70 Chapter 4
The Dixon–Reed criterion was used to detect any outliers between subjects (19). 
Between-subject biological variation (CVG) was calculated by the standard ANOVA 
method (16). Again, the Shapiro–Wilk test was used to verify the normality of the 
residuals (18).
The RCV values were calculated using the RCV formula as extensively described by 
Roraas et al. (17). For the RCV calculations in this study, a Z-score of 1.96 was used 
and the probability level of a significant change was set at 95%.
The index of individuality was calculated following the method of Fraser and Harris (18):






All statistical calculations were performed using SPSS for Windows version 23 (IBM 
SPSS Statistics, IBM Corporation, Armonk, New York) and Excel 2010.
Results
One individual (participant 21) was excluded from analysis in advance, since this 
participant developed a severe cold during the test day and therefore, the clinical 
situation could not be considered stable.
An overview of the numbers of excluded samples and individuals is given 
in supplemental table 4.1. In total, 5.9% of the data was excluded. Since some 
parameters are posture-dependent and show concentration drops during 
nighttime (for instance total protein, albumin, homocystein and apolipoprotein 
A), only daytime data were used to calculate biological variation.
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Baseline concentrations were similar for most of the studied parameters 
(supplemental figures 4.1 and 4.2). No diurnal rhythms were observed in the studied 
parameters, since we excluded the nighttime values. Some parameter showed 
some non-rhythmical diurnal variation. However, the observed variation in these 
parameters was smaller than the corresponding RCV. Therefore, all parameters, 
except triglycerides, could be considered as having a steady state situation. In 
triglycerides however, the increase in triglycerides concentration during the day 
has a physiological reason and can be declared by food consumption.
In table 4.2, biological variation data of all parameters were shown for subjects 
with- and without CKD.
CVG was larger than CVI for all parameters in both study groups, except for sodium 
and phosphate. CVI was similar for the two study groups in 20 parameters (77%). 
In the other parameters, CVI values differed.
In both study groups, 24 out of 26 parameters (92%) had an index of individuality 
(II) <0.6. An II < 0.6 indicates significant individuality which means that, for these 
parameters, population-based reference values are of limited utility and screening 
methods using these reference values will not detect (early or latent) disease in 
many subjects (8, 22). The highest II was found for sodium (1.03), which is known 
for this parameter. CVA varied from 0.8% (sodium and calcium) to 6.3% (lipase).
In general, RCVs were of similar magnitudes for subjects with- and without CKD. 
The highest RCVs were found for triglycerides (59.1% and 48.8%, respectively), 
which can be explained by the strong influence of food consumption on the 
triglycerides concentration. The lowest RCVs were found for sodium (2.6% and 
3.1%, respectively).
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Figure 4.1. 24h variation profiles in people without Chronic Kidney Disease
Values represent means ± SEM. Participants slept between 11:30 PM and 7 AM (shaded area).
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Figure 4.1. 24h variation profiles in people without Chronic Kidney Disease (continued)
Values represent means ± SEM. Participants slept between 11:30 PM and 7 AM (shaded area).
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Figure 4.1. 24h variation profiles in people without Chronic Kidney Disease (continued)
Values represent means ± SEM. Participants slept between 11:30 PM and 7 AM (shaded area).
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Figure 4.1. 24h variation profiles in people without Chronic Kidney Disease (continued)
Values represent means ± SEM. Participants slept between 11:30 PM and 7 AM (shaded area).
Discussion
In this study we report within-day biological variation data of 26 biochemical 
parameters. Most of these parameters are frequently ordered from clinical 
laboratories in daily practice and make an important contribution to diagnosing 
or monitoring diseases.
This study partially fills the gap in knowledge about within-day biological variation 
of these parameters.
The main finding in the present study is that the within-subject biological variation 
(CVI) was found to be of similar magnitude for people with and without CKD for 
most of the parameters. This is in line with the claim that, for majority of parameters 
CVI values are of the same magnitude in health and stable chronic disease (9, 10). 
For these parameters, physicians do not have to distinguish between diseased and 
healthy people when they use the CVI to interpret consecutive laboratory results. 
However, for some parameters (for instance creatine kinase and LDH), CVI showed 
different values between the study groups.
The difference in CVI of creatine kinase could be attributed to sex-related 
differences. Carobene et al. described a higher CVI in creatine kinase for men (22). 
In our study, the group without CKD consisted of 83% men vs. 70% in the CKD 
group. For LDH, the explanation of the higher CVI value in the CKD group, is more 
complicated and could be multifactorial. Factors that have been described to induce 
diurnal LDH changes are for instance diet, environment temperature and exercise. 
The RCV values of both CK and LDH however are more similar and we believe these 
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biological variation shifts are not of a magnitude that would invalidate the use of 
RCV’s, calculated with CVI data from healthy subjects, in these patients.
Since few within-day biological variation studies have been performed, it is not 
possible to compare our results of all parameters with other studies. However, 
Bailey et al. report within-day CVI values of 17 corresponding parameters (23). The 
CVI values reported in this study were slightly lower than the CVI values we found. 
The most striking difference was sTfR, where Bailey et al. reported a CVI of 1.4% 
and we found CVI values of 4.4% and 4.0%. However, this study does not seem to 
be entirely comparable, since it is based on a pediatric population (24).
The CVI values reported by Sennels et al. were higher in general, compared to the 
current study (26). The fact that they found higher CVI values may have multiple 
reasons; the absence of outlier analyses is probably an important one.
Despite the fact that within-day biological variation and between-day biological 
variation are two different concepts, we have compared our results of some 
parameters with a between-day biological variation study to get an impression 
of the magnitude of the differences. Carobene et al. performed a study in which 
the CVI of ALAT, ASAT, gamma GT, LDH, creatine kinase, amylase and lipase was 
investigated according to the exact same methods as this study (21). The most 
striking differences were the CVI’s of gamma GT (8.9% vs. 3.8% and 3.6%) and 
creatine kinase (14.5 vs. 8.8% and 5.1%). However, the CVI of lipase reported by 
Carobene et al. was considerably lower (7.7% vs. 13.8% and 12.8%).
Our study differs from existing literature in two important ways. First, the sample 
collection of most within-day biological variation studies is based on just a few 
time points (24, 26). The calculations in this study were based on 15 consecutive 
measurements. Second, this study incorporates data from both subjects with 
and without a chronic illness, which is a positive point compared to many other 
biological variation studies, which are only performed in healthy subjects. We 
believe the results of our study are generalizable to the average hospital and 
outpatient patient and are therefore applicable for the user’s clinical practice.
Of course, this study also has some limitations. Unfortunately, it was not possible to 
stratify biological variation data for gender, since the number of included men and 
women was unequal. The second limitation concerns the relatively small number 
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of participants. Because of the exclusion of outliers, the number of subjects in a 
group sometimes drops to 16 (in Ferritin for people with CKD). However, outlier 
exclusion is considered as an absolute requirement for biological variation studies 
and it is essential that studies on biological variation identify that outlier tests were 
undertaken as part of the data processing (2, 3, 21).
In conclusion, variation components from most of the parameters were of the same 
magnitude in subjects with or without CKD. Our findings imply that the within-day 
CVI is not affected by the presence of chronic (kidney) disease for most biochemical 
parameters. Thus, the use of RCV’s derived from healthy subjects for monitoring 
patients seems to be reasonable.
Figure 4.2. 24h variation profiles in people with Chronic Kidney Disease
Values represent means ± SEM. Participants slept between 11:30 PM and 7 AM (shaded area).
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Figure 4.2. 24h variation profiles in people with Chronic Kidney Disease (continued)
Values represent means ± SEM. Participants slept between 11:30 PM and 7 AM (shaded area).
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Figure 4.2. 24h variation profiles in people with Chronic Kidney Disease (continued)
Values represent means ± SEM. Participants slept between 11:30 PM and 7 AM (shaded area).
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Figure 4.2. 24h variation profiles in people with Chronic Kidney Disease (continued)
Values represent means ± SEM. Participants slept between 11:30 PM and 7 AM (shaded area).
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ALAT 0 2 0 918 41 7.3%
Albumin 4 2 0 939 41 5.2%
Amylase 0 5 0 822 38 16.9%
Apolipoprotein A 3 0 0 987 43 0.3%
Apolipoprotein B 1 2 0 917 41 7.4%
ASAT 1 3 0 870 39 12.1%
Chloride 1 0 0 989 43 0.1%
Cholesterol 0 3 0 870 40 12.1%
Creatine kinase 1 5 0 845 38 14.6%
Ferritin 1 6 0 845 35 14.6%
Folic acid 0 5 1 750 37 24.2%
gamma GT 0 3 1 846 39 14.5%
HDL Cholesterol 0 2 0 894 41 9.7%
Homocystein 3 2 0 891 41 10.0%
LDH 0 2 1 870 41 12.1%
LDL Cholesterol 1 1 0 941 42 4.9%
Lipase 1 4 0 869 39 12.2%
Phosphate 1 3 1 845 39 14.6%
Sodium 0 1 0 942 42 4.8%
sTfR 0 4 0 894 39 9.7%
Total protein 2 0 0 988 43 0.2%
Transferrin 2 1 0 965 42 2.5%
Triglycerides 2 2 0 916 41 7.5%
Urea 0 3 0 870 40 12.1%
Uric acid 0 2 1 870 40 12.1%
Vitamin B12 1 1 0 941 42 4.9%
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Supplemental figure 4.2. 24h variation profiles in people with Chronic Kidney Disease
In the box-and whisker plots, the tips of the bars represent the lowest and highest concentrations 
and the central box covers the 25, 50, and 75 percentiles. Individuals in grey were excluded since 
they were found to be outliers.
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Supplemental figure 4.2. 24h variation profiles in people with Chronic Kidney Disease 
(continued)
In the box-and whisker plots, the tips of the bars represent the lowest and highest concentrations 
and the central box covers the 25, 50, and 75 percentiles. Individuals in grey were excluded since 
they were found to be outliers.
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Supplemental figure 4.2. 24h variation profiles in people with Chronic Kidney Disease 
(continued)
In the box-and whisker plots, the tips of the bars represent the lowest and highest concentrations 
and the central box covers the 25, 50, and 75 percentiles. Individuals in grey were excluded since 
they were found to be outliers.
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Supplemental figure 4.2. 24h variation profiles in people with Chronic Kidney Disease 
(continued)
In the box-and whisker plots, the tips of the bars represent the lowest and highest concentrations 
and the central box covers the 25, 50, and 75 percentiles. Individuals in grey were excluded since 
they were found to be outliers.
Supplemental figure 4.2 (A-E). Concentration ranges of all parameters for people with CKD
In the box-and whisker plots, the tips of the bars represent the lowest and highest concentrations 
and the central box covers the 25, 50, and 75 percentiles. Individuals in grey were excluded since 
they were found to be outliers.
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Supplemental figure 4.2 (A-E). Concentration ranges of all parameters for people with CKD 
(continued)
In the box-and whisker plots, the tips of the bars represent the lowest and highest concentrations 
and the central box covers the 25, 50, and 75 percentiles. Individuals in grey were excluded since 
they were found to be outliers.
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Supplemental figure 4.2 (A-E). Concentration ranges of all parameters for people with CKD
In the box-and whisker plots, the tips of the bars represent the lowest and highest concentrations 
and the central box covers the 25, 50, and 75 percentiles. Individuals in grey were excluded since 
they were found to be outliers.
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Supplemental figure 4.2 (A-E). Concentration ranges of all parameters for people with CKD
In the box-and whisker plots, the tips of the bars represent the lowest and highest concentrations 
and the central box covers the 25, 50, and 75 percentiles. Individuals in grey were excluded since 
they were found to be outliers.
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Estimated glomerular filtration rate (eGFR) is widely used in clinical practice. This 
study assessed the within-subject biological variation (CVI) of different eGFR 
equations in people with chronic kidney disease (CKD) and people without CKD. 
The aims of this study were: 1) to determine the 24h biological variation profiles of 
creatinine, cystatin C and eGFR and 2) to determine if CVI of creatinine, cystatin C 
and eGFR changes upon deterioration of glomerular filtration.
Methods
Hourly blood samples were analyzed from 37 individuals (17 without CKD, 20 with 
CKD) during 24h. Creatinine (enzymatic method) and cystatin C were measured 
using a Cobas 8000 (Roche Diagnostics). eGFR was estimated using the Modification 
of Diet in Renal Disease (MDRD) and the Chronic Kidney Disease Epidemiology 
Collaboration (CKD-EPI) based on creatinine and/or cystatin C. Plasma samples 
were stored at -80°C before analysis. Outlier and homogeneity analyses were 
checked before performing a nested ANOVA to determine biological variation.
Results
CVI of creatinine was higher in people without CKD than with CKD (6.4% versus 
2.5%) owing primarily to the more profound effect of meat consumption on 
creatinine variability in individuals with lower baseline creatinine concentrations. 
Unlike creatinine, cystatin C concentrations were unaffected by meat consumption. 
Cystatin C showed some diurnal rhythmic variation, less in people with CKD. 
Reference change values (RCV) of all eGFR equations were within 13-20% in both 
study groups.
Conclusion
Despite differences in CVI of creatinine, the CVI and RCV of the eGFR equations 
were relatively similar for people with or without CKD.
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Background
The estimated glomerular filtration rate (eGFR) is widely applied for the diagnosis of 
kidney disease and the monitoring of renal function in patients with chronic kidney 
disease (CKD)(1). CKD is defined as the presence of kidney damage or a glomerular 
filtration rate (GFR) <60 mL/min/1.73 m2 for three months or longer, irrespective of 
the cause (1, 2). The Chronic Kidney Disease- Epidemiology Collaboration equation 
(CKD-EPI) and the Modification of Diet in Renal Disease (MDRD) are the equations 
most commonly used in clinical practice to estimate the GFR (3, 4). Although the 
equations are constructed differently, the calculation of both CKD-EPI and MDRD 
is based on the two renal biomarkers: creatinine and / or cystatin C (3-5). Serum 
creatinine and cystatin C concentrations can fluctuate during the day, either from 
‘true’ circadian differences in GFR or from random biological variation, without 
reflecting ‘real’ changes (6, 7). These fluctuations could affect the interpretation 
of eGFR values based on creatinine and / or cystatin C. Insight regarding the 
magnitude of diurnal fluctuations may prevent physicians from erroneously 
interpreting random variations as clinically relevant changes (8).
Biological variation studies allow a systematic assessment of random diurnal 
variation of biomarkers. Thus far, most studies that have assessed the biological 
variation of renal biomarkers and eGFR reported on between-day variation (6, 9-17), 
but data on within-day biological variation are scarce (18). Moreover, most studies 
focused either on healthy volunteers, or on people with impaired renal function, 
but data from a direct comparison of people with and without CKD are not available 
(6, 15, 19, 20). In this study, we aimed to construct 24h profiles of creatinine and 
cystatin C concentrations, as well as GFR estimations that are based on creatinine 
and/ or cystatin C. In addition, we assessed whether variation over the day is of 
similar magnitude in people with CKD and people without CKD.
Materials and methods
Study design and population
This study on 24h variability in renal function and eGFR was performed between 
January 2013 and October 2015, as described previously (21, 22). It conformed to the 
principles of the Declaration of Helsinki (23) and was approved by the institutional 
review board and the ethics committee at Maastricht University Medical Center 
(MUMC). Each participant provided written informed consent.
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The design of this study complied with the current checklists regarding biological 
variation as much as possible (24, 25).
In total 44 individuals were included, and divided into two study groups: The first 
study group consisted of 24 individuals without clinically diagnosed CKD (79% males 
and 21% females), and the second group (70% males and 30% females) consisted of 
20 patients (subject number 25 – 44) with clinically diagnosed CKD stage 3 or higher 
(eGFR <60 mL/min/1.73 m²) (2). This number of individuals per group afforded 
sufficient power to make reliable estimations about biological variation (26). All 
individuals were Caucasian and aged between 39 – 83 years. Diabetes was defined 
as fasting plasma glucose ≥ 126 mg/dL and/or HbA1c ≥ 6.5% (=47 mmol/mol) (27). 
Exclusion criteria were: current dialysis treatment, an acute myocardial infarction 
(AMI) in the 12 months prior to the study, active cardiac disease (angina pectoris, 
cardiomyopathy or myocarditis), and anemia (hemoglobin <10.5 g/dL).
Table 5.1. Subject’s baseline characteristics
Subjects without CKD
(n  = 17)
Subjects with CKD
(n  = 20)
Age (years) 72 ± 7 66 ± 12
Male sex 14 (82) 14 (70)
Body mass index (kg/m2) 26 ± 3 28 ± 4
Diabetes Mellitus a 6 (35) 7 (35)
Cholesterol concentration (mg/dL) 176 ± 35 157 ± 33
Systolic blood pressure (mmHg) 140 ± 15 136 ± 19
Diastolic blood pressure (mmHg) 68 ± 8 86 ± 14
Creatinine (mg/dL) 1.0 ± 0.2 3.3 ± 1.0
Cystatin C (mg/L) 1.0 ± 0.2 2.8 ± 0.8
MDRD (ml/min /1.73 m2) 73.4 ± 18.5 19.2 ± 6.4
CKD-EPI creatinine (ml/min /1.73 m2) 72.9 ± 17.2 18.9 ± 6.6
CKD-EPI cystatin C (ml/min /1.73 m2) 74.2 ± 17.2 20.2 ± 8.5
CKD-EPI creatinine – cystatin C (ml/min /1.73 m2) 74.2 ± 17.2 19.0 ± 7.0
Chronic Kidney Disease 0 (0) 20 (100)
Glomerular disease NA 7 (35)
Tubulointerstitial disease NA 4 (20)
Vascular disease NA 8 (40)
Cystic and congenital disease NA 1 (5)
Continuous data is presented as mean ± SD and categorical data is presented as n (%)
a Diabetes was defined as fasting plasma glucose ≥ 126 mg/dL and/or HbA1c ≥ 6.5% (=47 mmol/mol) (27)
NA, not applicable. SD, standard deviation.
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Sample collection and handling
Creatinine and cystatin C were measured on a Cobas® 8000 (Roche Diagnostics) 
using the following Roche reagents: CREP2, Creatinine plus ver.2, code 05168589 
and CYSC2, Tina-quant Cystatin C Gen.2, code 06600239. We used an enzymatic 
method to measure creatinine, based on the conversion of creatinine with the aid 
of creatininase, creatinase and sarcosine oxidase to glycine, formaldehyde and 
hydrogen peroxide. We used Bio-rad controls for creatinine and ‘Cystatin C Control 
Set Gen. 2’ for cystatin C (Roche Diagnostics).
The eGFR was calculated using MDRD and CKD-EPI formulae (3, 5). Three CKD-EPI 
estimations were calculated: CKD-EPI creatinine, CKD-EPI cystatin C, and CKD-EPI 
creatinine-cystatin C (4).
Hourly blood samples were drawn in ethylenediaminetraacetic acid (EDTA)-
containing tubes (8 ml). The plasma samples were centrifuged immediately 
(centrifugation at 2700g for 12 minutes at room temperature) after collection and 
plasma was stored at -80°C until analysis. The plasma samples were then thawed 
and all samples from the same individual were analyzed within a single run.
To estimate analytical variation (CVA), samples from eight randomly selected 
individuals (four individuals without CKD and four individuals with CKD, 18% of all 
samples) were analyzed in duplicate.
Study procedure
To study the within-day biological variability, blood samples were drawn every 
hour during 24h using an intravenous cannula. The participants arrived at 8:00 
AM at the laboratory after an overnight fast. During the test day, participants 
were restricted to the laboratory under sedentary conditions. Mealtimes were 
standardized at 8:30 AM (breakfast), 12:30 AM (lunch) and 6:00 PM (dinner). The 
participants could select from approximately four dinner options. The majority of 
dinner options consisted of dishes containing meat. The meal options and meat 
content were not standardized. Breakfast and lunch consisted of sandwiches with 
cheese, ham or sweet toppings. The participants went to bed at 11:30 PM and got 
up the next morning at 7:00 AM. During the night, an extension line was attached 
to the cannula to prevent sleep disturbance during blood sampling.
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Statistical analysis
As recommended for biological variation studies, we performed outlier analyses 
on three levels (analytical, within-subject and between-subject) (7, 26). The Cochran 
test was used to identify outliers on the analytical and within-subject level and 
the Dixon-Reed criterion was performed to identify outliers on the between-
subject level (7, 8, 28, 29). People with outlying within-subject variances were 
rejected from calculations, due to their heterogeneity of variance (24). Since data 
on the analytical, within-subject and between-subject levels followed a Gaussian 
distribution (Shapiro-Wilk test), transformation of the data was not required. For the 
analytical normality check, we used data of eight individuals which were measured 
in duplicate (192 replicates). For the within-subject level we verified normality for 
each individual subject. For the between-subject level, we verified normality for 
the means of each individual. The variation on three levels, the between-subject 
variation (CVG), within-subject biological variation (CVI), and CVA were calculated 
using a nested ANOVA with 95% confidence intervals determined according to the 
method of Burdick and Graybill (8, 26, 30).
Reference change values (RCVs) (Z-score of 1.96) and the index of individuality (II) 
were calculated according to the method of Fraser and Harris (8):
𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅 =  √2 ∗ 𝑍𝑍𝑍𝑍 ∗  �𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝐴𝐴𝐴𝐴2 + 𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝐼𝐼𝐼𝐼2 
II  = 
�𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝐴𝐴𝐴𝐴2 +  𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝐼𝐼𝐼𝐼2
𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝐺𝐺𝐺𝐺
 
We used an F-test to monitor whether the degree of renal impairment was stable 
in the people with CKD. To investigate this, we examined the eGFR one week, one 
month, and three months after the initial test day. P-values <0.05 were considered 
statistically significant.
To visualize the diurnal rhythm of cystatin C, 24h concentration curves were fitted 
for both study groups using cosinor rhythmometry.
All statistical calculations were performed using SPSS for Windows version 23 (IBM 
SPSS Statistics, IBM Corporation).
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A total of 44 individuals, 24 without CKD and 20 with CKD, participated in this 
biological variation study. Two participants (1 and 8) left the study prematurely 
and two other participants (15 and 23) had missing data due to problems with 
the venous cannula overnight. In order to maintain a balanced design, and in line 
with the statistical conditions for a nested ANOVA, these people were considered 
‘not eligible’ and excluded from further analyses (31). Additionally, participant 20 
was excluded, because this participant developed a severe cold during the test 
day and therefore, the clinical situation of this participant was unstable. Although 
participants 10 and 18 were not clinically diagnosed with CKD, these participants 
were excluded because the creatinine concentrations were not appropriate for 
the non-CKD group (mean concentrations 1.8±0.2 mg/dL and 2.0±0.08 mg/dL, 
respectively). In online Supplemental Figure 5.1, a flowchart of the study was 
shown. Eventually, 37 individuals were considered eligible for analyses. Baseline 
characteristics of the two study groups are shown in Table 5.1.
Clinical stability of people with CKD
To verify that the people with CKD were clinically stable and not rapidly progressive 
in terms of their CKD, additional blood samples were taken at one week, one month, 
and three months after the test day at the same time as the baseline measurement 
on the initial test day (08:30 AM). The eGFR values (calculated with MDRD, CKD-EPI 
creatinine, CKD-EPI cystatin C, and CKD-EPI creatinine – cystatin C) did not decrease 
significantly during this follow-up period (min-max follow-up concentration 
ranges: MDRD 18.7 – 19.3 mL/min/1.73 m2, p=0.63; CKD-EPI creatinine 18.3 – 18.9 
mL/min/1.73 m2, p=0.99; CKD-EPI cystatin C 20.1 – 20.3 mL/min/1.73 m2, p=0.49; 
CKD-EPI creatinine-cystatin C 18.6 – 19.0 mL/min/1.73 m2, p=0.99). Therefore, the 
participants with CKD were considered as having a stable chronic disease.
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Table 5.2. Components of biological variation, indexes of individuality and reference 
change values for renal biomarkers and different eGFR equations in both study groups
n Mean CVA CVI CVG II RCV
Subjects without CKD
Creatinine 16 1.0 mg/dL 1.1 (1.0 – 1.3) 6.4 (6.0 – 6.9) 21.2 (15.7 – 32.9) 0.3 18.2
Cystatin C 17 1.0 mg/dL 1.1 (1.0 – 1.3) 4.1 (3.8– 4.4) 15.3 (11.3 – 23.2) 0.3 11.6
MDRD 16 75.3 mL/
min/1.73 m2
1.6 (1.4 – 1.9) 6.1 (5.7 – 6.6) 27.3 (20.2 – 42.3) 0.2 16.9
CKD-EPI creatinine 16 73.8 mL/
min/1.73 m2
1.2 (1.0 – 1.4) 5.3 (5.1 – 5.6) 24.3 (18.0 – 37.7) 0.2 14.6
CKD-EPI cystatin C 17 76.7 mL/
min/1.73 m2
2.0 (1.8 – 2.3) 5.5 (5.2 – 5.9) 21.2 (15.8 – 32.3) 0.3 15.3
CKD-EPI creatinine-cystatin C 16 75.2 mL/
min/1.73 m2
1.2 (1.1 – 1.4) 4.6 (4.3 – 5.0) 20.3 (16.5 – 34.5) 0.2 13.2
Subjects with CKD
Creatinine 19 3.3 mg/dL 1.3 (1.1 – 1.5) 2.5 (2.4 – 2.7) 28.1 (21.2 – 41.6) 0.1 7.9
Cystatin C 18 2.7 mg/L 0.8 (0.7 – 1.0) 3.2 (3.0 – 3.4) 27.2 (20.4 – 40.8) 0.1 9.1
MDRD 19 20.2 mL/
min/1.73 m2
2.4 (2.1 – 2.8) 5.5 (5.2 – 5.9) 28.4 (21.5 – 42.0) 0.2 13.3
CKD-EPI creatinine 19 20.1 mL/
min/1.73 m2
2.6 (2.3 – 3.0) 5.2 (4.9 – 5.6) 30.0 (22.7 – 44.4) 0.2 14.4
CKD-EPI cystatin C 18 23.8 mL/
min/1.73 m2
1.2 (1.1 – 1.4) 7.3 (6.8 – 7.8) 38.7 (29.1 – 58.1) 0.2 20.1
CKD-EPI creatinine-cystatin C 17 20.9 mL/
min/1.73 m2
1.6 (1.4 – 1.8) 5.4 (5.1 – 5.8) 35.2 (26.4 – 52.9) 0.2 15.1
Except where stated otherwise, the data are percentage (%) values. 95% Confidence Intervals (CI) 
are shown between brackets
CVA, analytical variation, CVI, within-subject biological variation, CVG, between-subject variation, 
II, index of individuality, RCV, reference change value
24h variability profiles
Figures 5.1 and 5.2 show 24h variability profiles of creatinine, cystatin C, and 
all eGFR equations for both study groups. The mean creatinine and cystatin C 
concentrations were by definition significantly lower in people without CKD than 
in those with CKD (creatinine: 1.0 ± 0.3 mg/dL vs. 3.3 ± 1.0 mg/dL, P <0.01; cystatin 
C: 1.0 ± 0.3 mg/L vs. 2.7 ± 0.8 mg/L, P<0.01). Consequently, all average eGFR values 
were significantly higher in people without CKD, as compared to the people with 
CKD (MDRD: 75 ± 21 mL/min/1.73 m2 vs. 20 ± 9 mL/min/1.73 m2 P<0.01; CKD-EPI 
creatinine: 74 ± 18 mL/min/1.73 m2 vs. 20 ± 10 mL/min/1.73 m2, P<0.01; CKD-EPI 
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cystatin C; 77 ± 17 mL/min/1.73 m2 vs. 24 ± 14 mL/min/1.73 m2, P<0.01; CKD-EPI 
creatinine-cystatin C: 76 ± 17 mL/min/1.73 m2 vs. 21 ± 12 mL/min/1.73 m2, P<0.01).
Creatinine concentrations increased up to 50% (0.46 mg/dL) in people without CKD 
after dinner (participant 11, individual 24h profile of this participant was not shown). 
The increase was numerically similar in people with CKD (0.40 mg/dL) compared 
to people without CKD, but as a percentage the increase was substantially lower 
(18%) due to the high baseline concentrations of creatinine in the people with CKD.
Unlike creatinine, cystatin C concentrations were not affected by dinner. 
Interestingly however, cystatin C showed a small, but clearly evident diurnal 
rhythm, with decreasing cystatin c concentrations during daytime and increasing 
concentrations during the evening and night. This circadian rhythm of cystatin 
C was less prominent in people with CKD (Figures 5.1 and 5.2). In Supplemental 
Figure 5.2, the diurnal rhythm of cystatin C was visualized by fitting a cosinor 
model through the average data points. For people without CKD the amplitude 
of the diurnal cosinor rhythm was 4.9±0.8, whereas the amplitude was reduced to 
1.6±0.5% for people with CKD.
Components of variation in people with and without CKD
Variation components of all parameters in both study groups are shown in table 
5.2. CVG was comparable for the study groups. In both groups, CVG was significantly 
larger than CVI for all parameters. Due to the relatively high CVG values, all indexes 
of individuality were low (0.1 - 0.3).
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Figure 5.1. 24h variation profiles in subjects without CKD
Values represent means ± SEM. Subjects slept between 11:30 PM and 7 AM (shaded area).
CKD, chronic kidney disease. SEM, standard error of the mean
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Figure 5.2. 24h variation profiles in subjects with CKD
Values represent means ± SEM. Subjects slept between 11:30 PM and 7 AM (shaded area).
CKD, chronic kidney disease. SEM, standard error of the mean
// De magenta omlijning geeft de netto maat aan en zal niet zichtbaar zijn in het eindproduct //
// Let op: Dit proef bestand is niet geschikt om correcties in te maken //
555031-L-sub01-bw-Hilderink
Processed on: 24-2-2021 PDF page: 106
106 Chapter 5
In Figure 5.3, the min-max concentration ranges of creatinine and cystatin C are 
presented for the people without and with CKD. The people without CKD (panel 
A) exhibit a higher relative range in creatinine concentrations than the people 
with CKD (panel C). This difference in concentrations contributes to a significantly 
higher CVI expressed as percent in people without CKD (6.4% vs. 2.5%), and also 
the RCV was significantly higher in people without CKD (18% vs. 8%). The CV I 
values of cystatin C, CKD-EPI cystatin C and CKD-EPI creatinine – cystatin C were 
also significantly different between the groups. However, these differences were 
smaller than for creatinine.
In people without CKD, the CKD-EPI based on the combination of creatinine and 
cystatin C (CKD-EPI creatinine-cystatin C) was the eGFR equation with lowest 
CVI. In people with CKD, the CKD-EPI based on creatinine (CKD-EPI creatinine) 
demonstrated the lowest CVI over the day. However, in this group the difference 
with CKD-EPI creatinine – cystatin C was minimal (5.2% vs. 5.4%, with overlapping 
confidence intervals).
CVA was low in both study groups (maximum 2.0% for people without CKD and 2.6% 
for people with CKD). All CVA values met the ‘desirable ratio’ between CVI and CVA, 
which is 1:2. A ratio below 0.5 assures that the analytical ‘noise’ contributes less 
than 12% to the total variation (7).
Sensitivity analysis
According to the Cochran within-subject outlier test, the ‘after-dinner increase’ 
of creatinine demanded the exclusion of some individuals (participants 14 and 
30, respectively) (Supplemental Table 5.1 and Supplemental Figure 5.3. However, 
this strict statistical perspective may neglect the fact that the creatinine rises 
are in fact ‘physiological changes’, which also occur in hospitalized patients. We 
believe that excluding these participants may be too stringent and can lead to 
an underestimation of biological variation data. A sensitivity analysis included 
individuals that were excluded in the primary analysis due to heterogeneity 
of variance. In this analysis, slightly larger CVI values were revealed for most 
biomarkers (Supplemental Table 5.2). The difference was more pronounced for 
creatinine than for cystatin C (which lacks the after dinner rise), and the effect was 
stronger in people without CKD than in people with CKD.
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Discussion
In the current study, we present 24h variation profiles of creatinine, cystatin C, and 
their derived estimates of glomerular filtration rate (MDRD, CKD-EPI creatinine, 
CKD-EPI cystatin C, and CKD-EPI creatinine-cystatin C) in people without CKD, and 
in people with CKD. In addition, separate variation components were calculated 
and compared between both study groups.
An important finding of this study is that the CV I of creatinine is significantly 
higher in people without CKD than in people with CKD. In our study, the effect 
of the post-dinner creatinine spike on CVI was substantial especially for people 
without CKD, given that these people have low baseline creatinine concentrations 
(mean 1.0 mg/dL). For people with CKD, the effect on CVI‘s due to higher baseline 
creatinine concentrations (mean 3.3 mg/dL) was smaller. This difference was even 
more pronounced in the sensitivity analysis that included the individuals with a 
(physiological) high post-dinner creatinine increase, likely due to meat consumption, 
increasing their CVI‘s and marking them for removal based on statistical criteria. 
However, the variation in creatinine concentrations caused by dinner content is of 
interest for clinical practice, given that patients often have dinner with unknown 
meat and other content.
For clinical practice, this variation might ideally be included, even if this variation 
is statistically large and seemingly divergent. Rivara et al. performed a similar 
sensitivity analysis in which they showed a slight increase of the CVI of creatinine 
after including the individuals that were excluded in the primary analysis due to 
heterogeneity of variances (19).
The CVI for creatinine in this study was higher than reported in the EUBIVAS 
project (6.2% vs. 4.4%), which can likely be attributed to the fact that the creatinine 
concentrations measured in the EUBIVAS project were between-day CVI values 
based on fasting blood samples collected once per day at the same hour between 
08.00 and 10.00 (20) (32). Therefore, creatinine increase after meat consumption 
is not integrated in the EUBIVAS CVI value. Since within-day CVI and between-day 
CVI are different concepts, the results of this study are not directly comparable to 
those of the EUBIVAS project.
The design of this study complies with the current checklists regarding biological 
variation as much as possible (24, 25). Only on item 7 of the most recent biological 
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variation checklist, which is about the steady state condition do we deviate from the 
checklist by not including meat consumption in the model for the concentration of 
creatinine to create a ‘steady state’. Whether or not meat consumption is included 
in a model for the concentration of creatinine, has consequences for the amount 
of variation left unexplained, and with that the size of the CVI.
In a clinical setting, neither the time of dinner of a patient, nor the meat content of 
the dinner (or other meal), are known to the physician interpreting the creatinine 
laboratory results.
Figure 5.3. Min-max concentration ranges of creatinine and cystatin C in subjects without 
and with CKD
Panel A. Creatinine concentration ranges over 24h, subjects without CKD
Panel B. Cystatin C concentration ranges over 24h, subjects without CKD
Panel C. Creatinine concentration ranges over 24h, subjects with CKD
Panel D. Cystatin C concentration ranges over 24h, subjects with CKD
Subjects in grey were excluded according to the outlier analyses
CKD, chronic kidney disease
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Hence for clinical purposes, variation resulting from meat consumption should not 
be excluded from the model and should be included in the CVI estimate to allow 
for this additional uncertainty. Since most people consume meat in their diet, our 
CVI estimate for a 24 hour period can be considered to reflect typical physiologic 
conditions facing interpretation of creatinine and eGFR results.
Since this study was not originally designed to investigate the influence of meat 
consumption on creatinine concentrations, no detailed individual data of the 
participants regarding their meat consumption during the day were available. 
However, the study of Nair et al. standardized the meat consumption of all 
participants and compared their results with a non-meat meal. The Nair study 
described a significant increase of creatinine concentration after a meat meal for all 
study participants (33). For healthy volunteers and individuals with CKD stage 1 or 
2, the study reported statistically significant creatinine increases of 5 µmol/L (0.06 
mg/dL) and 8 µmol/L (0.09 mg/dL), respectively. We observed a similar average 
increase of 0.07 mg/dL (6.2 µmol/L) between 6PM-10PM presumably related to 
dinner composition. For people with CKD, the Nair study reported maximum 
creatinine increases of up to 0.25 mg/dL (22 µmol/L), which is more pronounced 
than the average increase of 0.13 mg/dL (12 µmol/L) we observed in the people 
with CKD.
Nevertheless, the study of Nair et al. emphasizes the finding that the relative fall 
in eGFR after meat consumption is proportionately less in patients with more 
advanced CKD stages (33), which is consistent with our findings. Another study by 
Preiss et al. demonstrated that the effect of meat consumption could even have an 
impact on diagnosis, due to misclassification of CKD staging if measurements are 
made after consuming a cooked-meat meal (34). The authors of this study state 
that physicians should ensure that, when classifying the stage of CKD, samples are 
taken under appropriate conditions (34). We endorse this conclusion, especially 
in the context of a 24-hour biological variation study. Creatinine was included in 
our study in order to be able to determine the calculated eGFR’s and not to be an 
indicator for GFR (35).
Unlike creatinine, the CVI of cystatin C was in the same range for both people 
with or without CKD, and its 24h profile was not characterized by a post-dinner 
spike. Despite substantial differences in biological variation and RCVs between 
cystatin C and creatinine, especially in people without CKD, these differences do 
// De magenta omlijning geeft de netto maat aan en zal niet zichtbaar zijn in het eindproduct //
// Let op: Dit proef bestand is niet geschikt om correcties in te maken //
555031-L-sub01-bw-Hilderink
Processed on: 24-2-2021 PDF page: 110
110 Chapter 5
not translate to similar differences in the biological variation and RCV’s of the eGFR 
equations that are derived from these biomarkers. In fact, CVI values and RCVs of 
the CKD-EPI creatinine equation are of the same magnitude in both study groups. 
However, CVI values and RCVs of the CKD-EPI cystatin C are of different magnitude. 
The transformation from cystatin C to CKD-EPI cystatin C leads to more dispersed 
CKD-EPI values than the transformation from creatinine to CKD-EPI creatinine.
Diurnal cystatin C profiles showed modest intrinsic diurnal rhythmicity, with a 
slight decrease during daytime, and increase during the evening and night. This 
is in line with modestly reduced glomerular filtration at nighttime compared to 
daytime (36, 37). A similar diurnal rhythmicity may be apparent in the creatinine 
profiles (at least a declining pattern from morning until evening), but is obscured 
by the post dinner-creatinine peak. Interestingly, the diurnal cystatin C rhythm is 
somewhat diminished in people with CKD. This effect can be explained by reduced 
renal clearance in people with CKD, leading to accumulation of cystatin C, and 
consequent reduction in its diurnal rhythm (38).
Large rhythmic diurnal oscillations preclude calculation of overall variation 
components and RCVs, as they would become time-of day- dependent. Instead, 
hour-to-hour RCVs can be calculated, which take into account the structural change 
according to the diurnal rhythm. Such approach has been previously applied by our 
group and others for the calculation of RCVs for various hematological biomarkers 
and cardiac troponin T (39, 40). However, rhythmic variation of cystatin C in this 
study was so small that the calculation of hour-to-hour variation components and 
RCVs would have complicated their interpretation without offering substantial 
benefit in terms of mathematical accuracy.
Some limitations of this study merit consideration: First, the design of the study 
was not limited to the assessment of the biological variation of kidney biomarkers. 
Although mealtimes were standardized across study participants, the content of 
the meals were not. Hence, the consumption of meat among meals was variable, 
and may have accounted for the highly variable creatinine rises, especially after 
dinner.
Second, the ratio between men and women was skewed (77% men and 23% 
women), precluding robust assessment of potential gender differences. Third, the 
generalizability of this study to other ethnicities may be limited due to the fact that 
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all participants were Caucasian. Fourth, most individuals, including those without 
CKD, had comorbidities. Nevertheless, the presence of comorbidities, and also 
the fact that the meals were not standardized, is representative for the average 
patient (both hospitalized and outpatient) and provides ‘real world’ estimates of 
the biological variation of interest when interpreting results.
In conclusion, we show that the CVI of creatinine is higher in people without CKD 
than in people with CKD. Despite differences in biological variation, RCVs of all 
derived estimates of glomerular filtration rate (MDRD, CKD-EPI creatinine, CKD-EPI 
cystatin C, and CKD-EPI creatinine-cystatin C) are within the same range (13-20%) 
and are similar for people with or without CKD.
// De magenta omlijning geeft de netto maat aan en zal niet zichtbaar zijn in het eindproduct //
// Let op: Dit proef bestand is niet geschikt om correcties in te maken //
555031-L-sub01-bw-Hilderink
Processed on: 24-2-2021 PDF page: 112
112 Chapter 5
References
1. Stevens PE, Levin A, Kidney Disease: Improving Global Outcomes Chronic Kidney Disease 
Guideline Development Work Group M. Evaluation and management of chronic kidney 
disease: Synopsis of the kidney disease: Improving global outcomes 2012 clinical practice 
guideline. Ann Intern Med 2013;158:825-30.
2. Levey AS, Stevens LA, Coresh J. Conceptual model of CKD: Applications and implications. Am 
J Kidney Dis 2009;53:S4-16.
3. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate 
glomerular filtration rate from serum creatinine: A new prediction equation. Modification 
of Diet in Renal Disease Study Group. Ann Intern Med 1999;130:461-70.
4. Inker LA, Schmid CH, Tighiouart H, Eckfeldt JH, Feldman HI, Greene T, et al. Estimating 
glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med 2012;367:20-9.
5. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, 3rd, Feldman HI, et al. A new equation 
to estimate glomerular filtration rate. Ann Intern Med 2009;150:604-12.
6. Carter JL, Parker CT, Stevens PE, Eaglestone G, Knight S, Farmer CK, Lamb EJ. Biological 
variation of plasma and urinary markers of acute kidney injury in patients with chronic 
kidney disease. Clin Chem 2016;62:876-83.
7. Fraser CG. Biological variation: From principles to practice AACC Press, Washington DC 2001.
8. Fraser CG, Harris EK. Generation and application of data on biological variation in clinical 
chemistry. Crit Rev Clin Lab Sci 1989;27:409-37.
9. Ozturk OG, Paydas S, Balal M, Sahin G, Karacor ED, Ariyurek SY, Yaman A. Biological variations 
of some analytes in renal posttransplant patients: A different way to assess routine 
parameters. J Clin Lab Anal 2013;27:438-43.
10. Delanaye P, Cavalier E, Depas G, Chapelle JP, Krzesinski JM. New data on the intraindividual 
variation of cystatin C. Nephron Clinical practice 2008;108:c246-8.
11. Larsson A, Akerstedt T, Hansson LO, Axelsson J. Circadian variability of cystatin C, creatinine, 
and glomerular filtration rate (GFR) in healthy men during normal sleep and after an acute 
shift of sleep. Chronobiol Int 2008;25:1047-61.
12. Carobene A, Graziani MS, Lo Cascio C, Tretti L, Cremonese E, Yabarek T, et al. Age dependence 
of within-subject biological variation of nine common clinical chemistry analytes. Clin Chem 
Lab Med 2012;50:841-4.
13. Reinhard M, Erlandsen EJ, Randers E. Biological variation of cystatin C and creatinine. Scand 
J Clin Lab Invest 2009;69:831-6.
14. Fraser CG, Williams P. Short-term biological variation of plasma analytes in renal disease. 
Clin Chem 1983;29:508-10.
15. Selvin E, Juraschek SP, Eckfeldt J, Levey AS, Inker LA, Coresh J. Within-person variability in 
kidney measures. Am J Kidney Dis 2013;61:716-22.
16. Pascoe PJ, Gallagher CS, Fraser CG. Components of biological variation of some serum 
analytes in hospitalized pregnant women. Clin Chem 1984;30:583-4.
17. Gowans EM, Fraser CG. Biological variation of serum and urine creatinine and creatinine 
clearance: Ramifications for interpretation of results and patient care. Ann Clin Biochem 
1988;25 ( Pt 3):259-63.
18. Ravn B, Larsson A, Martensson J, Martling CR, Bell M. Intra-day variability of cystatin C, 
creatinine and estimated GFR in intensive care patients. Clin Chim Acta 2016;460:1-4.
19. Rivara MB, Zelnick LR, Hoofnagle AN, Newitt R, Tracy RP, Kratz M, et al. Diurnal and long-term 
variation in plasma concentrations and renal clearances of circulating markers of kidney 
proximal tubular secretion. Clin Chem 2017;63:915-23.
// De magenta omlijning geeft de netto maat aan en zal niet zichtbaar zijn in het eindproduct //
// Let op: Dit proef bestand is niet geschikt om correcties in te maken //
555031-L-sub01-bw-Hilderink
Processed on: 24-2-2021 PDF page: 113
11324h biological variation of creation, cystatin C and eGFR
5
20. Carobene A, Marino I, Coskun A, Serteser M, Unsal I, Guerra E, et al. The EuBIVAS project: 
Within-and between-subject biological variation data for serum creatinine using enzymatic 
and alkaline picrate methods and implications for monitoring. Clin Chem 2017;63:1527-36.
21. Klinkenberg LJ, Wildi K, van der Linden N, Kouw IW, Niens M, Twerenbold R, et al. Diurnal 
rhythm of cardiac troponin: Consequences for the diagnosis of acute myocardial infarction. 
Clin Chem 2016;62:1602-11.
22. van der Linden N, Hilderink JM, Cornelis T, Kimenai DM, Klinkenberg LJJ, van Doorn WP, et 
al. Twenty-four-hour biological variation profiles of cardiac troponin i in individuals with or 
without chronic kidney disease. Clin Chem 2017;63:1655-6.
23. Association WM. Declaration of helsinki: Ethical principles for medical research involving 
human subjects. JAMA 2013;310:2191-4.
24. Bartlett WA, Braga F, Carobene A, Coskun A, Prusa R, Fernandez-Calle P, et al. A checklist for 
critical appraisal of studies of biological variation. Clin Chem Lab Med 2015;53:879-85.
25. Aarsand AK, T RR, Fernandez-Calle P, Ricos C, Diaz-Garzon J, Jonker N, et al. The biological 
variation data critical appraisal checklist:A standard for evaluating studies on biological 
variation. Clin Chem 2017 Dec 8. as doi: 10.1373/clinchem.2017.281808. [Epub ahead of print]
26. Roraas T, Petersen PH, Sandberg S. Confidence intervals and power calculations for within-
person biological variation: Effect of analytical imprecision, number of replicates, number 
of samples, and number of individuals. Clin Chem 2012;58:1306-13.
27. de Leur K, Vroemen JP, Vos DI, Elmans L, van der Laan L. Outcome after osteosynthesis of 
hip fractures in nonagenarians. Clin Interv Aging 2014;9:41-9.
28. Reed AH, Henry RJ, Mason WB. Influence of statistical method used on the resulting estimate 
of normal range. Clin Chem 1971;17:275-84.
29. Dixon WJ. Processing data for outliers. Biometrics 1953;9:74-89.
30. Burdick RK GF. Confidence intervals on variance components. New York, NY: Marcel Dekker 1992.
31. McDonald JH. Handbook of biological statistics reB-m, Maryland: Sparky House Publishing, 2014.
32. Carobene A, Strollo M, Jonker N, Barla G, Bartlett WA, Sandberg S, et al. Sample collections 
from healthy volunteers for biological variation estimates’ update: A new project undertaken 
by the working group on biological variation established by the European Federation of 
Clinical Chemistry and Laboratory Medicine. Clin Chem Lab Med 2016;54:1599-608.
33. Nair S, O’Brien SV, Hayden K, Pandya B, Lisboa PJ, Hardy KJ, Wilding JP. Effect of a cooked 
meat meal on serum creatinine and estimated glomerular filtration rate in diabetes-related 
kidney disease. Diabetes Care 2014;37:483-7.
34. Preiss DJ, Godber IM, Lamb EJ, Dalton RN, Gunn IR. The influence of a cooked-meat meal on 
estimated glomerular filtration rate. Ann Clin Biochem 2007;44:35-42.
35. Diskin CJ. Creatinine and glomerular filtration rate: Evolution of an accommodation. Ann 
Clin Biochem 2007;44:16-9.
36. Wuerzner G, Firsov D, Bonny O. Circadian glomerular function: From physiology to molecular 
and therapeutical aspects. Nephrol Dial Transplant 2014;29:1475-80.
37. Koopman MG, Koomen GC, Krediet RT, de Moor EA, Hoek FJ, Arisz L. Circadian rhythm of 
glomerular filtration rate in normal individuals. Clin Sci (Lond) 1989;77:105-11.
38. van der Linden N, Cornelis T, Kimenai DM, Klinkenberg LJJ, Hilderink JM, Luck S, et al. Origin 
of cardiac troponin T elevations in chronic kidney disease. Circulation 2017;136:1073-5.
39. Hilderink JM, Klinkenberg LJJ, Aakre KM, de Wit NCJ, Henskens YMC, van der Linden N, et al. 
Within-day biological variation and hour-to-hour reference change values for hematological 
parameters. Clin Chem Lab Med 2017;55:1013-24.
40. Aakre KM, Roraas T, Petersen PH, Svarstad E, Sellevoll H, Skadberg O, et al. Weekly and 90-
minute biological variations in cardiac troponin T and cardiac troponin I in hemodialysis 
patients and healthy controls. Clin Chem 2014;60:838-47.
// De magenta omlijning geeft de netto maat aan en zal niet zichtbaar zijn in het eindproduct //
// Let op: Dit proef bestand is niet geschikt om correcties in te maken //
555031-L-sub01-bw-Hilderink
Processed on: 24-2-2021 PDF page: 114
114 Chapter 5
Supplemental material
Supplemental figure 5.1. Study flow diagram
CKD, chronic kidney disease
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Creatinine Subjects 1, 8, 10, 
15, 18, 20 and 23
None Subject 14 None
Cystatin C Subjects 1, 8, 10, 





Creatinine None None Subject 30 None
Cystatin C None None Subjects 27 and 28 None
Supplemental Figure 5.2. Diurnal rhythm of cystatin C
Panel A: Mean data points ± SEM and cosine curve on the group level of the people without CKD. 
Amplitude  = 4.9±0.8% (R²=0.88). SEM, standard error of the mean
Panel B: Mean data points ± SEM and cosine curve on the group level for the people with
CKD. Amplitude =1.6±0.5% (R²=0.32). SEM, standard error of the mean
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Supplemental Table 5.2. Sensitivity analysis: Components of biological variation of 
creatinine, cystatin C and eGFR for both study groups, including individuals excluded from 
primary analysis due to heterogeneity of variances in creatinine (subjects 14 and 30)
n Mean CVA CVI CVG II RCV
Subjects without CKD
Creatinine 17 1.0 mg/dL 1.1 (1.0 – 1.3) 8.7 (8.2 – 9.4) 20.4 (15.2 – 31.2) 0.4 24.4
Cystatin C 17 1.0 mg/dL 1.1 (1.0 – 1.3) 4.1 (3.8– 4.4) 15.3 (11.3 – 23.2) 0.3 11.6
MDRD 17 75.3 mL/
min/1.73 m2
1.6 (1.4 – 1.9) 8.6 (8.0 – 9.2) 26.4 (19.7 – 40.3) 0.3 23.8
CKD-EPI creatinine 17 73.8 mL/
min/1.73 m2
1.2 (1.0 – 1.4) 7.6 (7.1 – 8.2) 23.5 (17.5 – 35.9) 0.3 21.1
CKD-EPI cystatin C 17 76.7 mL/
min/1.73 m2
2.0 (1.8 – 2.3) 5.5 (5.2 – 5.9) 21.2 (15.8 – 32.3) 0.3 15.3
CKD-EPI creatinine-cystatin C 17 75.9 mL/
min/1.73 m2
1.2 (1.1 – 1.4) 5.8 (5.4 – 6.2) 21.7 (16.1 – 33.0) 0.3 16.3
Subjects with CKD
Creatinine 20 3.2 mg/dL 1.3 (1.1 – 1.5) 2.8 (2.6 – 2.9) 28.2 (21.4 – 41.2) 0.1 8.4
Cystatin C 18 2.7 mg/L 0.8 (0.7 – 1.0) 3.5 (3.3 – 3.8) 25.1 (19.1 – 36.7) 0.1 10.1
MDRD 20 20.8 mL/
min/1.73 m2
2.4 (2.1 – 2.8) 4.8 (4.5 – 5.1) 30.8 (23.4 – 44.9) 0.2 15.2
CKD-EPI creatinine 20 20.8 mL/
min/1.73 m2
2.6 (2.3 – 
3.0)
5.9 (5.5 – 6.3) 32.2 (24.5 – 47.0) 0.2 16.3
CKD-EPI cystatin C 18 23.8 mL/
min/1.73 m2
1.2 (1.1 – 1.4) 7.3 (6.8 – 7.8) 38.3 (29.1 – 56.0) 0.2 20.2
CKD-EPI creatinine-cystatin C 18 21.6 mL/
min/1.73 m2
1.6 (1.4 – 1.8) 5.4 (5.1 – 5.8) 34.3 (26.1 – 50.2) 0.2 15.0
Except where stated otherwise, the data are percentage (%) values. 95% Confidence Intervals (CI) 
are shown between brackets. CVA, analytical variation, CVI, within-subject biological variation, CVG, 
between-subject variation, II, index of individuality, RCV, reference change value
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Supplemental figure 5.3. Individual 24h creatinine curves of ‘outlier’ subjects
Values represent creatinine concentrations (mg/dL). Subjects slept between 11:30 PM and 7 AM 
(shaded area).
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 Correct interpretation of serial cardiac troponin measurements is of profound 
importance for the diagnosis of acute myocardial infarction, especially in 
populations with a high prevalence of persistently elevated cardiac troponin levels. 
To gain more insight in physiological cardiac troponin I fluctuations, we performed 
a biological variation study in which we examined and compared the hour-to-hour 
biological variation in cardiac troponin I over 24-hours in subjects with and subjects 
without chronic kidney disease.
Methods
During 24h, hourly blood samples were collected from 20 subjects with and 24 
subjects without chronic kidney disease. Cardiac troponin I was determined in 
duplicate. Analytical variation (CVA), within-subject biological variation (CVI) and 
between-subject biological variation (CVG) were calculated for 1-hour, 3-hour and 
6-hour intervals in both groups.
Results
Baseline cardiac troponin I levels were higher in subjects with chronic kidney 
disease compared to those without (6.8 [3.5–9.2] ng/L vs. 4.7 [2.8–6.9] ng/L; 
p=0.09). The within-day variation showed no diurnal pattern. Variation components 
remained constant for all time-intervals. Whereas CVG (49-95%) and CVI (8-9%) were 
not significantly different between both groups, CVA was significantly lower in the 
group with the highest concentrations, the subjects with chronic kidney disease 
(6% vs. 10%).
Conclusions
Cardiac troponin I concentrations fluctuate at random during the day. Except 
from the analytical variation, variation components were of the same magnitude 
in subjects with or without CKD. Our findings imply that the variation in cardiac 
troponin I levels is not affected by the presence of chronic kidney disease.
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Background
The interpretation of cardiac troponin concentrations at presentation and their 
dynamics over time is a key aspect in the diagnostic workup of acute myocardial 
infarction in the absence of characteristic ECG-abnormalities (1, 2). Whereas 
subjects with very low or high cardiac troponin concentrations at presentation 
can immediately be ruled-out or ruled-in respectively, serial measurements are 
particularly indicated in patients with moderately elevated cardiac troponin 
concentrations (3-6). A majority of these patients does not have an acute myocardial 
infarction, but shows persistently elevated cardiac troponin concentrations which 
are associated with the presence of underlying (subclinical) diseases like diabetes, 
coronary artery disease, hypertension and chronic kidney disease (CKD) (7-9). 
Especially in these patients it is of profound importance to distinguish pathology 
associated changes from physiological fluctuation in serial cardiac troponin 
measurements.
Biological variation studies provide insight in the magnitude of physiological 
variation. On the basis is the assumption that the biomarker concentrations 
fluctuate around an individual set point, and that the totally observed variation can 
be subdivided in a between-subject, a within-subject and an analytical component 
(10). These individual components facilitate the estimation of the reference change 
value (RCV), the required threshold for a change between serial measurements 
to be significantly different from a physiological variation. Additionally it is also 
possible to calculate the index of individuality (II), which represents the variation 
between the individual set points (11-13).
During the last decade, the duration of the diagnostic workup for acute myocardial 
infarction shortened, which was reflected in the recent introduction of the 0h/1h-
algorithm (1, 14, 15). Since most biological variation studies focus on long(er)-term 
variation in cardiac troponin I (cTnI) (16-19), less is known about the hour-to-hour 
variation. In addition, all previous studies were limited to a certain time interval 
and it is hence not clear whether the derived values apply to both day and night, 
or may be affected by a diurnal rhythm (20). The present biological variation study 
was the first to examine and compare the hour-to-hour biological variation in cTnI 
over 24-hours in subjects with and subjects without CKD.
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Material and Methods
This study was carried out according to the principles of the Declaration of Helsinki, 
approved by the Institutional Review Board and Ethics Committee of Maastricht 
University Medical Center, and registered at clinicaltrial.gov (NCT02091427 and 
NCT02210897). All participants provided written informed consent. The current 
study meets the critical appraisal checklist criteria for studies of biological variation 
as proposed by Bartlett et al. (21).
Study population
The study population consisted of 44 adult subjects, 24 subjects (19 males and 
5 females) without CKD and 20 subjects (14 males and 6 females) with CKD. The 
subjects without CKD were previously described in more detail (20). Subjects 
with CKD stage 3 or higher (estimated glomerular filtration rate (eGFR) < 59 mL/
min/1.73m2)(22) were included at the nephrology outpatient department of the 
Maastricht University Medical Center (MUMC), and suffered from various types 
of kidney disease (glomerular (n=7), tubulointerstitial (n=4), vascular (n=8) and 
congenital kidney disease (n=1)). Exclusion criteria were: history of acute myocardial 
infarction less than 12 months prior to exclusion, (current) dialysis regimen, active 
cardiac disease (angina pectoris, cardiomyopathy and myocarditis) and anemia 
(Hb < 10.5 g/dL). To monitor whether the degree of renal impairment was stable 
in CKD subjects, we examined kidney function (eGFR) one week and one month 
after the initial test day.
Study design
After an overnight fast, subjects arrived at 8 a.m. at the laboratory by car of public 
transport. For 25h, from 8.30 A.M. till 9.30 A.M. the next day, subjects were restricted 
to the laboratory environment, and samples were collected every hour from an 
antecubital venous catheter. Extension lines for blood sampling were used to prevent 
disturbance of participants’ sleep during the night. Meals were consumed at 8.30 
A.M., 12.30 P.M. and 6.00 P.M. (breakfast, lunch and dinner, respectively). Subjects 
went to bed at 11.30 P.M., lights were off between 11.35 P.M. and 7.00 A.M., and they 
slept in a supine position. Participants were asked to refrain from exhaustive physical 
activities and exercise training, two days before the test day.
Laboratory measurements
Blood samples were collected in ethylenediaminetetraacetic acid containing (EDTA) 
tubes. Samples were centrifuged and the plasma was stored at -80°C until analysis. 
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cTnI was measured with the STAT high-sensitivity troponin I assay (Architect, 
Abbott Diagnostics). According to the manufacturer, the 99th percentile of this 
assay is 26.2 ng/L with a corresponding coefficient of variation of <5%. To enable 
the determination of analytical variation, all samples were measured in duplicate. 
Creatinine and cystatin C were both measured on the COBAS 6000 analyzer. The 
estimated glomerular filtration rate (eGFR) was calculated according to the Chronic 
Kidney Disease Epidemiology Collaboration (CKD-EPI) formula based on creatinine 
and cystatin C (23).
Statistical analysis
For the comparison between the baseline characteristics in both groups, continuous 
variables were compared with the Mann-Whitney U test, and categorical variables 
were compared by use of the Pearson χ2 test.
For our 24-hour analyses, we used the data obtained between 10.30 AM (first day) 
till 9.30 (AM) (second day). As suggested by Fraser and Harris (24), we tested for 
homogeneity in the analytical- and within-subject biological variances using the 
method described by Cochran. Finally, the criteria of Reed were used to identify 
between-subject outliers level (10).
Two-fold nested ANOVA was used to calculate the coefficients of variation on a 
between-subject (CVG), within-subject (CVI) and an analytical (CVA) level, including 
95% confidence intervals (25, 26). We calculated the reference change value (RCV) 
using the formula:
RCV  = Z * �2 ∗  (𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐴𝐴𝐴𝐴2 +  𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐼𝐼𝐼𝐼2 
In the RCV formula, Z represents the number of standard deviations appropriate 
for the desired level of statistical significance for a bidirectional change (10). For the 
RCV calculations in this study, a Z-score of 1.96 was used. The index of individuality 
(II) was calculated using the formula (13, 27):
II = 
�(𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐼𝐼𝐼𝐼2 +  𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐴𝐴𝐴𝐴2)
𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐺𝐺𝐺𝐺
 
All hypothesis testing was two-tailed, and values of P<0.05 were considered 
statistically significant. Statistical analyses were performed with SPSS for Windows 
23.0 (IBM Corporation).
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Results
A total of 44 subjects, 20 with and 24 without CKD disease, participated in this 
biological variation study. We plotted the range in observed cTnI concentrations over 
24h for all individual subjects in Figure 6.1. Complete data sets were available for 40 
subjects (subjects 1, 8, 15 and 23 had missing data). In addition, one subject had no 
measurable levels of cTnI (subject 36), and another subject became sick during the 
test day (subject 20). Two subjects (subjects 3 and 44) were identified as outliers and 
were therefore excluded from further analyses. A total of 36 subjects, 18 subjects 
with and 18 subjects without CKD, were included in the final data analyses.
Figure 6.1. Subject specific concentrations over 24h with hourly sampling
Absolute ranges (min – max) of cTnI concentrations over 24h in subjects without CKD (panel A) 
and with CKD (panel B).
Figure 6.2 shows the in- and exclusion of subjects, including baseline characteristics. 
In subjects with CKD the eGFR remained for at least one month after the initial test 
day (data not shown).
Baseline cTnI levels where higher in subjects with CKD compared to those without 
CKD (6.8 [3.5–9.2] ng/L vs. 4.7 [2.8–6.9] ng/L; p=0.09). The within-day variation in 
these concentrations showed no diurnal pattern, and biological variation seemed 
to be constant over 24h in both groups (Figure 6.3, Supplemental Figure 6.1) 
(individual curves of subjects without CKD have been previously published (20)). 
Consecutively, we calculated the variation components of 1-hour, 3-hour and 
6-hour intervals during the day, which are presented in Table 6.1. We detected 
no significant differences in the components of variation for the different time 
intervals. When the variation components where compared between subjects 
without and subjects with CKD, CVG and CVI were not significantly different. In 
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contrast, CVA was significantly smaller in subjects with CKD, the group with the 
higher cTnI concentrations. This lower CVA contributed to lower RCV’s among these 
subjects. Besides, we observed a trend towards a higher between-subject variation 
and a lower index of individuality in this group.





















































Normal 36.7 26.4 37.9 28.6 37.5 29.5
Log-normal 44.0; -30.6 30.18; -23.16 45.8; -31.4 33.0; -24.8 45.7; -31.4 34.2; -25.5
Index of 
individuality
0.27 0.15 0.28 0.17 0.28 0.17
Values are % (95% CI); CI  = confidence interval; CVA  = analytical coefficient of variation; CVG  = 
between-subject coefficient of variation; CV I  = within-subject biological coefficient of variation; 
RCV  = reference change value
a on the basis of duplicate measurements
b on the basis of a Z-score of 1.96
c 3-hour intervals: 10:30AM-01:30PM, 01:30PM-04:30PM, 04:30PM-07:30PM, 07:30PM-10:30PM, 
01:30AM-4:30AM and 4:30AM-7:30AM
d 6-hour intervals: 10:30AM-04:30PM, 04:30PM-10:30PM and 10:30PM-04:30AM
Discussion
This study examined the hour-to-hour biological variation of cTnI, and calculated 
its variation components over 24-hours in subjects with or without CKD. We report 
four major findings: First, we observed randomly fluctuating cTnI levels over the 
day. In the absence of a circadian rhythm, we calculated the 1-hour, 3-hour and 
6-hour variation over the day without any additional transformations. The fact that 
the CVI remained constant (8-9%) during all time-intervals over 24-hours, supports 
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our observation of random variation. Second, the CVI was not significantly different 
in subjects with or without CKD. This seems to be in line with the claim that for the 
majority of parameters CVI values are in the same order in health and disease (10, 
28). Third, we identified a substantial amount of variation between individuals (CVG  
= 48-62%). This finding corresponds to that of previous studies (16-18, 29, 30), and, 
since the CVI is rather limited, it produces a low index of individuality (<0.3). The 
observation that the CVG is slightly higher in subjects with CKD may be due to a high 
variety in comorbidities characteristic for this population (31). Fourth, we showed that 
the CVA is significantly higher in subjects without than in those with CKD (10% vs. 6%). 
This can be explained by the concentration-dependency of the CVA. As a consequence 
of these differences in CVA, the RCV is slightly lower in subjects with CKD.
Figure 6.2. Flowchart of the in- and exclusion of subjects, including baseline characteristics
eGFR, estimated glomerular filtration rate according to the CKD-EPI Creatinine-Cystatin C 
equitation (23) b Comparison between subjects with or without CKD
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From a clinical point of view, the finding of a substantial CVG and a low index of 
individuality emphasizes the wide variety in cardiac troponin concentrations 
among the population, the limited utility of population-based reference intervals 
and the importance of the use of delta-change values (13, 32). Nevertheless, it 
is important to consider that the recent development of increasingly short time 
intervals between serial measurements and detection of small delta-change values, 
will come to a stop at the point where the changes are so small that there is no 
distinction more with the physiological variation within a person. This can only be 
partially overcome by increasing the sensitivity and precision of the assay: Based 
on a CVI of approximately 8%, the RCV may decrease from approximately 37% to 
22% for cTnI values in the lower range, but will not drop below this 22%.
Figure 6.3. No diurnal pattern in cTnI variation in subjects with or without CKD
We calculated the deviation (in %) from the mean concentration (over 24h) of each individual on 
every time point. This variation is random and is not subject to a circadian pattern.
Potential limitations of our study merit consideration. First, most subjects included 
in the final data analyses have relatively low concentrations of cTnI, therefore it is 
hard to extrapolate our findings to higher concentration ranges. However, when 
cTnI values at presentation are much higher, serial measurements are not relevant 
anymore (1, 3). Second, since the prevalence of comorbidities in both populations 
is relatively high (20), we cannot make an unbiased comparison between health 
and disease. Therefore, we were only able to examine the effect of the presence 
of chronic kidney disease.
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In conclusion, with this biological variation study we were the first to examine 
the hour-to-hour biological variation in cTnI over 24-hours. We showed a random 
variation over the day. Except from the analytical variation, variation components 
were of the same magnitude in subjects with or without CKD. Our findings imply 
that the CVI of cardiac troponin I is not affected by the presence of chronic kidney 
disease.
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Supplemental information
Supplemental figure 6.1. Individual diurnal cardiac troponin I profiles
Depicted are the mean of the duplicate measurements of subjects with chronic kidney disease. 
The numbering is identical to Figure 1. Subjects slept in a supine position between 11:30 P.M. and 
7:00 A.M. (shaded area)
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Incorporation of cardiac biomarkers hold potential to be of value in the follow up 
and management of aortic valve stenosis. However, we lack knowledge about the 
biological variation of these biomarkers, which is an essential component of correct 
interpretation of serial biomarker management. Therefore, the aim of the current 
study was to determine the biological variation of a panel of cardiac biomarkers 
in subjects with stable aortic valve stenosis.
Methods
Serial blood sampling was performed in 25 subjects with (echocardiographic 
confirmed) moderate aortic valve stenosis (echocardiographic confirmed), all 
free from acute cardiovascular events in the past six months. Each subject visited 
the outpatient clinic seven times during one year, and blood samples were taken 
under standardized conditions. Analytical variation (CVA), within-subject biological 
variation (CVI), between-subject biological variation (CVG), index of individuality (II) 
and reference change values (RCV) were calculated for brain natriuretic peptide 
(BNP), NT-pro BNP, high-sensitivity troponin T and I and ST2 (suppression of 
tumourigenicity 2).
Results
Within-subject biological variation was highest for BNP (62.03%, 95% CI 17.05;23.43) 
and lowest for troponin I (9.18%, 95% CI 2.83;13.75). Between-subject biological 
variation was considerably higher in all biomarkers except BNP, and ranged from 
19.82% (95% CI 13.76;33.36) for ST2 to 57.19% (95% CI 40.39;97.29) for troponin-T. 
NT-pro BNP, troponin-T and ST2 revealed analytical variation <5%, whilst BNP and 
troponin-I showed a higher CVA (19.74 and 14.86 respectively). All biomarkers except 
BNP showed marked individuality, with II ranging from 0.21 to 0.67 (BNP 1.34).
Conclusion
Biological variation indices of subjects with stable aortic valve stenosis approximate 
those of healthy subjects.
Key words
Aortic valve stenosis, progression, cardiac biomarkers, biological variation, 
echocardiography
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Introduction
Being indicators of biological processes, circulating biomarkers are commonly used 
in clinical decision making for diagnosing, risk stratification and management of 
various cardiovascular diseases (1,2).  However, incorporation of biomarkers in 
the management of aortic valve stenosis (AVS), the most common type of valvular 
disease in the Western world, is a matter of debate. The 2017 ESC/EACTS guidelines 
recommend to incorporate repeated measurements of only one markedly elevated 
biomarker: B-type natriuretic peptide (BNP) in asymptomatic severe AVS forms a class 
IIa (level C) indication for surgical or trans-catheter valve replacement, while the 2014 
AHA/ACC guidelines do not make reference to biomarkers in the recommendations 
(3, 4). Once present, AVS is a progressive disease with poor understanding of 
exact underlying mechanisms, and echocardiography forms the golden standard 
for diagnosis and evaluation (5). Parameters used during echocardiography 
provide limited insight in the pathophysiology though, and are poor predictors for 
progression rates (6). Therefore, biomarkers hold potential as a complementary 
approach to gain insight in AVS progression and timing of intervention. Theoretically, 
serial measurements of biomarkers showing changes over time in parallel with AVS 
progression are of potential use in tailored AVS management. However, to interpret 
whether changes over time are ‘real’ and not just a physiological fluctuation, 
knowledge on the magnitude of physiological variation of a biomarker is essential. 
This principle is known as biological variation (7). Biological variation assumes that 
biomarker concentrations fluctuate around a homeostatic set point, driven by within-
subject and analytical variation (CVI and CVA respectively). These components enable 
estimation of the reference change value (RCV), which represents the required 
threshold for a change between measurements to be statistically significant and 
with that, a ‘ true’ change (8). (2) Additionally, the variation between specific set 
points, known as the index of individuality (II), can be calculated (9,10).
Studies investigating biological variation of cardiac biomarkers have been 
performed in a few specific patient populations for instance with heart failure 
or kidney dysfunction, but remain sparse to date (11-16). Biological variation of 
biomarkers in patients with aortic valve stenosis has not been determined.
Several cardiac biomarkers have been investigated in AVS, such as BNP (brain 
natriuretic peptide), the N-terminal fragment of BNP (NT-pro BNP), troponin-T and 
-I and ST2 ST2 (suppression of tumourigenicity 2) with variable results (17). Taking 
the potential role of biomarkers in the course of AVS into account, it would be of 
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importance to gain insight in the variation of biomarkers for the interpretation 
of serial biomarker results. Therefore, the aim of the current study was to assess 
the analytical and biological variation of cardiac biomarkers BNP, NT-pro BNP, 
troponin-T, troponin-I and ST2 in patients with AVS.
Methods
Study population
The study population consisted of 25 subjects (>18 years) with known moderate aortic 
valve stenosis who were followed up at the outpatient clinics in the department of 
Cardiology in the Maastricht University Medical Center (MUMC), the Netherlands. 
Severity of aortic valve stenosis was defined by echocardiographic measurement 
(mean gradient 20-40 mmHg, AVA 1.0-1.5 cm2 or maximal transvalvular velocity 3-3.9 
m/s). Prior to inclusion, subjects had to be in a stable medical condition and without 
complaints directly related to aortic valve stenosis. Exclusion criteria consisted of 
presence of severe aortic valve stenosis, left ventricular ejection fraction (LVEF) 
<50%, documented atrial fibrillation in the last year, chronic kidney disease (eGFR 
<45 mL/min/1.73m2) and a history of acute myocardial infarction, hospitalization 
for heart failure or a pulmonary embolism within 6 months prior to inclusion. 
Subjects who met any of the exclusion criteria and those unable to provide written 
informed consent were not included. At the end of the study period, subjects 
were evaluated to monitor progression of aortic valve stenosis and indication for 
surgical intervention. Subjects with symptomatic aortic valve stenosis and those 
showing an increase in mean gradient >7 mmHg or maximum velocity >0.3m/s 
were reported as progressive (18,19). This study was performed according to the 
Declaration of Helsinki and was approved by the local Institutional Review Board. It 
was registered at www.clinicaltrials.gov as NCT02510482. All study subjects provided 
written informed consent. This study was executed according to the critical appraisal 
checklist criteria for biological variation studies by Bartlett et al (20).
Study design
All subjects visited the outpatient clinics of Cardiology of our center 7 times during 
1 year (baseline and 1 day, 1 week, 1 month, 3 months, 6 months and 12 months 
after baseline respectively). Visits and blood samplings were performed in a 
standardized manner and all patients were asked to refrain from intense physical 
heavy physical labor and exercise training 2 days before each visit. All patient visits 
took place between 08.00 and 09.00 AM, during which standard history taking and 
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a standardized questionnaire (including medication use) were performed. Blood 
sampling was performed through standard venipuncture in seated position.
Laboratory measurements
Blood samples were collected in serum, ethylenediaminetraacetic acid (EDTA) and 
citrate tubes. Immediately after collection, standard hematological parameters 
(hemoglobin, hematocrit, white blood cells, neutrophils) were measured in EDTA-
samples using the Sysmex XE-5000 analyzer (Sysmex Corporation, Kobe, Japan). 
After this measurement (approx. 5 minutes), EDTA samples were centrifuged 
(12 min, 2500 g), and were aliquoted. Citrate samples were centrifuged together 
with the EDTA samples, and were additionally centrifuged (10 min, 10.000 g). The 
serum samples were centrifuged after 25 minutes (12 min, 2500 g). Directly after 
aliquoting, samples were stored at -80°C until further analyses.
The estimated glomerular filtration rate (eGFR) was calculated according to the 
Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula (21).
NT-pro BNP and high-sensitivity troponin-T levels were measured on the COBAS 
6000 analyzer, and measurements of high-sensitivity troponin-I were measured 
with the STAT high-sensitivity troponin I assay (Architect, Abbott Diagnostics). 
BNP was measured on the Architect analyzer (Abbott Diagnostics) and ST2 using 
the Presage® ST2 Assay (Critical Diagnostics). To estimate analytical variation, all 
samples of BNP, NT-pro BNP, troponin-T and troponin-I were measured in duplicate. 
61% of samples of ST2 were measured in duplicate.
Echocardiography
Standard two-dimensional transthoracic echocardiography was performed by an 
independent observer prior to inclusion and during regular visits to the outpatient 
clinics (Sonos 5500 and IE33, Philips Medical Systems, Andover, MA, USA) according 
to the European Association of Echocardiography (EAE) guidelines (22).
Statistical analyses
Cochran’s C test was used to test data for homogeneity in analytical and within-
subject biological variances as suggested by Fraser and Harris (23). In short, 
variances were tested for homogeneity by examination of the (maximum variance): 
(sum of variances)-ratio and compared with a prior determined critical value for both 
analytical and within-subject biological variances (23, 24). Subjects were excluded 
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until homogeneity of variances was achieved. Between-subject outliers were 
identified using the criteria of Reed (7, 25, 26). Between-subject (CVG) and within-
person subject biological variation (CVI) and analytical variation (CVA) were calculated 
using a balanced analysis of variance with a nested random design in two levels (27). 
The method of Burdick and Graybill was used accordingly to calculate 95% confidence 
intervals (CI) of the variance components (27, 28). The index of individuality (II) and 
Reference Change Value (RCV) were calculated according to the method described by 
Petersen et al. and Fraser and Harris (23, 29, 30). II was calculated using the formula:
II  = 
�𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐴𝐴𝐴𝐴2 +  𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐼𝐼𝐼𝐼2
𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐺𝐺𝐺𝐺
 
The RCV was calculated using the formula:
𝑅𝑅𝑅𝑅𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 =  √2 ∗ 𝑍𝑍𝑍𝑍 ∗  �𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐴𝐴𝐴𝐴2 + 𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐼𝐼𝐼𝐼2 
In this formula, Z represents the number of standard deviations appropriate for 
the desired level of statistical significance for a bidirectional change. For RCV 
calculations in this study, a Z-score of 1.96 was used. Additionally, RCVs were 
calculated and evaluated after log-normal transformation (31). All statistical 
analyses were performed using SPSS statistics version 22 (IBM Corp, Armonk, NY).
Results
Baseline population characteristics
A total of 25 subjects with moderate aortic valve stenosis participated in the current 
study. Mean age (±SD) was 66 ±6 years, and 44% (n=11) subjects were female. All 
subjects had moderate aortic valve stenosis on baseline echocardiography (median 
[IQR] mean gradient 25 [11] mmHg, maximum velocity 340 [65] cm/s and aortic valve 
area 1.3 [0.2] cm2) and median [IQR] left ventricular ejection fraction (LVEF) 63 [5]%. 
None had complaints attributable to aortic valve stenosis. Baseline concentrations 
of all biomarkers are shown in figure 7.1.
Biological variation in stable aortic valve stenosis
The ranges observed in biomarkers in all subjects (BNP, NT-pro BNP, troponin-T, 
troponin-I and ST2) are plotted in figure 7.2. Sample collection was complete for 
all subjects. Figure 1 shows the baseline characteristics of the total population.
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In 9 subjects, aortic valve stenosis was progressive (figure 7.1). Therefore, the 
primary analysis to determine biological variation was performed in the stable 
population (n=16). An overview of outliers and excluded subjects per biomarker is 
provided in Supplemental table 7.1.
Within-subject variation (CVI) and between-subject variation (CVG) of BNP, NT-pro 
BNP, troponin-T, troponin-I and ST2 were determined accordingly. NT-pro BNP, 
troponin-T, troponin-I and ST2 revealed lower within-subject than between-subject 
values. BNP showed highest within-subject variation (62.03%, 95% CI 17.05;23.43) 
and troponin-I lowest (9.18%, 95% CI 2.83;13.75). Between-subject biological 
variation was considerably higher in all biomarkers (except BNP), and ranged from 
19.82% (95% CI 13.76;33.36) for ST2) to 57.19% (95% CI 40.39;97.29) for troponin-T, 
respectively. NT-pro BNP, troponin-T and ST2 revealed CVA < 5% (ranging from 
1.90% to 3.67%), whereas BNP and troponin-I showed higher analytical variation 
(19.74 and 14.86 respectively).
Additionally, the variation between specific set points, known as the index of 
individuality (II) was calculated. All biomarkers except BNP showed marked 
individuality, with II ranging from 0.21 to 0.67 (BNP 1.34). Table 7.1 depicts biological 
variation parameters of all biomarkers, including RCV.
Biological variation of the total population: does progressive aortic valve stenosis 
change biological variation indices?
A secondary, explorative analysis was performed to determine biological variation 
in the total population (n=25) thus including the subpopulation of subjects showing 
progressive aortic valve disease (n=9). Of the last group, 5 patients progressed to 
symptomatic aortic valve stenosis after their 6 months visit. Another 4 remained 
asymptomatic, but showed progressive disease during echocardiographic 
examination after 1 year of follow up. Supplemental table 7.2 provides an overview of 
outliers and excluded subjects per biomarker. Consecutively, variation components 
were calculated for the total population, which are presented in Table 7.2.
BNP showed a higher between-subject variation and lower RCV and index of 
individuality were observed in the total population. NT-pro BNP showed a marked 
increase in between- and within-subject variation and the latter contributed to the 
increased RCV observed in this group. For troponin-I the within-subject variability 
and RCV increased markedly. At last, between-subject variability of ST2 increased 
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and with similar within-subject variation in both groups, the index of individuality 
of ST2 decreased in the total population.
Figure 7.1: Flowchart of baseline and follow-up populations, including baseline characteristics.
Continuous variables are expressed as mean±SD or median [IQR] depending on their distribution. 
Categorical variables are reported as n(%).
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Figure 7.2: Subject-specific concentrations of BNP, NT-pro BNP, troponin-T (hsTnT), troponin-I 
(hsTnI) and ST2 over 7 measurement point during 1 year of follow-up.
Parameters are shown in absolute ranges (minimum-maximum concentration). Red lines indicate 
subjects with progressive AVS
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Table 7.1: Analytical variation, biological variation, indexes of individuality and reference 
change values of all measured biomarkers in stable aortic valve stenosis.
Mean 
concentration Variance components RCV 
b II
CVG CVI CVA a Normal Log-normal















61.20 44.62 ; -30.85 0.51






32.72 16.82 ; -14.40 0.21






48.41 72.98 ; -42.19 0.50







Values are % (95% CI); CI  = confidence interval; CVA  = analytical coefficient of variation; CVG  = 
between-subject coefficient of variation; CV I  = within-subject biological coefficient of variation; 
RCV: reference change value. BNP: brain natriuretic peptide; NT-pro-BNP: N-terminus pro-
brain natriuretic peptide; hs-TnT: high-sensitivity troponin T; hs-TnI: high-sensitivity troponin 
I; IST2: suppression of tumourigenicity 2. II: index of individuality. a On the basis of duplicate 
measurements. b On the basis of a Z-score of 1.96. *Normal distribution
Table 7.2: Analytical variation, biological variation, indexes of individuality and reference
Mean 
concentration Variance components RCV 
b II
CVG CVI CVA a Normal Log-normal















106.65 42.91 ; -30.03 0.51






40.79 33.67 ; -25.19 0.30






72.17 65.67 ; -39.64 0.76







Values are % (95% CI); CI  = confidence interval; CVA  = analytical coefficient of variation; CVG  = 
between-subject coefficient of variation; CV I  = within-person biological coefficient of variation; 
RCV  = reference change value
BNP: brain natriuretic peptide; NT-pro-BNP: N-terminus pro-brain natriuretic peptide; hs-TnT: 
high-sensitivity troponin T; hs-TnI: high-sensitivity troponin I; ST2: suppression of tumourigenicity 
2. II: index of individuality
a On the basis of duplicate measurements
b On the basis of a Z-score of 1.96
*Normal distribution
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Discussion
Several (combinations of) biomarkers are associated with adverse outcome in 
patients with aortic valve stenosis and are suggested to be of value in future 
clinical care (32-35).  Ideally; changes in serial measurements of a biomarker should 
reflect progression. However, to interpret serial measurements, knowledge about 
variation components of biomarkers is essential.
Therefore, this study is the first to examine biological variation of several cardiac 
biomarkers (BNP, NT-pro BNP, troponin-T, troponin-I and ST2) in subjects with 
stable moderate aortic valve stenosis. We report three major findings: First, 
we found a substantial variation within and between subjects with AVS (CVI  = 
9-62% and CVG  = 20-58%), corresponding with previous studies. Within-subject 
variability was relatively small for ST2 and troponin-T and I, whilst large within-
subject variation was found for BNP and NT-pro BNP. These results suggest that 
values of BNP and NT-pro BNP have to vary substantially to hint toward relevant 
changes, whilst smaller variations in serial measurements in troponin-T and ST2 
might indicate a relevant change. Studies examining biological variation have been 
performed in healthy populations, but a growing interest in variation components 
of biomarkers in populations with (cardiovascular) disease resulted in newer studies 
addressing biological variation in heart failure and chronic kidney disease (11, 13, 
16, 36). We found that indices of biological variation in stable aortic valve stenosis 
approximated indices found in studies investigating biological variation in healthy 
subjects and chronic and stable heart failure (13, 16, 36).
Second, we found substantial differences in various biological variation indices 
of BNP, NT-pro BNP, troponin-T, troponin-I and ST2 in the population with stable 
aortic valve stenosis in comparison to our total AVS population, suggesting that 
progressive aortic valve disease affects biological variation.
Third, between-subject variation was higher than within-subject variation in all 
biomarkers but BNP in our population. Both affect the index of individuality and 
therefore, we found low indexes of individuality in all biomarkers (except BNP) 
and thus marked individuality in our population. Therefore, the use of population 
based reference values is of limited utility (8, 10, 37). Instead, the use of reference 
change values (RCV) is of value in these biomarkers.
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From a clinical perspective, a low index of individuality and marked between-
subject variation underline the extensive ranges of biomarker concentrations 
found in the population. This underlines the importance to use of reference change 
values instead of general population-based reference intervals to interpret serial 
measurements in an individual. However, the individual variation is undervalued in 
daily practice, as we tend to interpret biomarkers above or below general thresholds 
to identify a patient with low or high risk. The use of RCVs with serial biomarker 
measurements bears potential to integrate in the development of tailored 
treatment strategies in personalized medicine. In the context of interpretation of 
true changes in serial measurements, a little difference between measurements of 
biomarkers with a large RCV challenge the interpretation, while a little difference 
in measurements of biomarkers with a limited RCV suggest a true change. Thus, 
absolute changes of biomarkers should be placed in perspective and hold potential 
to improve estimation of the true risk of a patient.
Study limitations
Potential limitations of the current study merit attention. First, we included 25 
patients with stable moderate aortic valve stenosis at baseline for analysis of 
biological variation. After 1 year of follow up, 9 patients showed progressive 
disease. Sixteen patients with stable aortic valve stenosis were left for primary 
analysis, providing us with sufficient power to make reliable estimations for 
variation components for primary analyses (27). Second, the size of our population 
did not allow stratification in sex- or- age-groups. Given the potential differences 
in pathophysiology between men and women, further exploration would be 
interesting.
Conclusion
This is the first study to present biological variation of cardiac biomarkers BNP, 
NT-pro BNP, troponin-T, troponin-I and ST2 in a population with stable aortic valve 
stenosis. Indices of biological variation approximate those in healthy subjects 
(derived from previous studies). BNP and NT-pro BNP show a high within-subject 
variation and RCV, whereas troponin-T, troponin-I and ST2 show lower variation 
indices.
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Labtracker, a medical 
smartphone app for the 
interpretation of consecutive 
laboratory results: an 
external validation study
J.M. Hilderink, R.J.M.W. Rennenberg, F.H.M. Vanmolkot, O. Bekers,
R.P. Koopmans, S.J.R. Meex
BMJ Open. 2017 Sep 1;7(9):e015854. doi: 10.1136/bmjopen-2017-015854
// De magenta omlijning geeft de netto maat aan en zal niet zichtbaar zijn in het eindproduct //
// Let op: Dit proef bestand is niet geschikt om correcties in te maken //
555031-L-sub01-bw-Hilderink




When monitoring patients over time, clinicians may struggle to distinguish ‘real changes’ 
in consecutive blood parameters from so-called natural fluctuations. In practice, 
they have to do so by relying on their clinical experience and intuition. We developed 
Labtracker, a medical app that calculates the probability that an increase or decrease 
over time in a specific blood parameter is real, given the time between measurements.
Design
We presented patient cases to 135 participants to examine whether there is a 
difference between medical students, residents and experienced clinicians 
when it comes to interpreting changes between consecutive laboratory results. 
Participants were asked to interpret if changes in consecutive laboratory values 
were likely to be ‘real or rather due to natural fluctuations. The answers of the study 
participants were compared to the calculated probabilities by the app Labtracker 
and the concordance rates were assessed.
Setting and participants
Medical students (n=92), medical residents from the department of internal 
medicine (n=19) and internists (n=24) at a Dutch University Medical Centre.
Primary and secondary outcome measures
Concordance rates between the study participants and the calculated probabilities 
by the app Labtracker were compared. Besides, we tested whether physicians with 
clinical experience scored better concordance rates with the app Labtracker than 
inexperienced clinicians.
Results
Medical residents and internists showed significantly better concordance rates with 
the calculated probabilities by the app Labtracker than medical students, regarding 
their interpretation of differences between consecutive laboratory results (p=0.009 
and p<0.001, respectively).
Conclusion
The app Labtracker could serve as a clinical decision tool in the interpretation of 
consecutive laboratory test results, and could contribute to rapid recognition of 
parameter changes by physicians.
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Background
Medical doctors frequently monitor the laboratory results of patients to determine 
whether their condition is stable, improving or deteriorating, and to decide whether 
treatment should be continued, initiated, or rather be postponed. Hence, an 
intuitive ‘reference frame’ of the patient can be formed by repeated assessment 
of laboratory parameters. An expertise-based reference frame is often lacking in 
less experienced clinicians, such as medical residents, or medical students. Hence, 
it can be difficult for less experienced clinicians to distinguish natural fluctuations 
in laboratory results from ‘real changes’ and vice versa.
According to a study of Jones et al., 1 in 5 medical graduates identified themselves 
as being ‘less than competent’ in using laboratory testing (1). Additionally, a 
study of Hickner et al. demonstrated that even experienced clinicians reported 
uncertainty in interpreting laboratory test results in approximately 10% of the 
ordered laboratory tests (2). 
To help (inexperienced) clinicians to make the distinction whether a change 
between measurements is real or not, we developed a medical app (Labtracker),that 
calculates the probability of a ‘real change’ between two consecutive laboratory 
results. It is simple to use in clinical practice and provides evidence-based 
decision support to complement intuitive interpretation of changes in consecutive 
laboratory results.
The current study tests the hypothesis that experienced clinicians show better 
concordance rates with Labtracker-based calculations than medical students and 
less experienced clinicians.
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Methods
This study was approved by the Dutch Association for Medical Education (NVMO). 
Study participants provided written informed consent.
Study participants
135 participants were included: 92 medical students, 19 medical residents, and 24 
medical specialists. We scheduled six days on which medical students participated 
in our study. All students were at the same stage of their internship and 92% of 
them were in their first medical internship (usually in their fourth year of the 
six years training to become a medical doctor in the Netherlands). The medical 
residents and medical specialists, all employed at the department of internal 
medicine at Maastricht University Medical Centre, were recruited during the daily 
morning briefing. The mean number of clinical experience years was 24 ± 9 for the 
internists and 3.5 ± 2 for the residents.
Exclusion criteria were: medical students in the bachelor phase of their studies and 
residents or specialists of a specialty other than internal medicine.
Study design
Ten fictive clinical cases were presented to the study participants. These cases were 
conceived and developed by the authors of this article. Central to each case was to 
interpret the likelihood of change between consecutive measurements of a certain 
laboratory parameter. The time interval between the measurements varied for all 
cases. The cases can be found in the supplemental material.
The participants were asked to categorize the presented changes in one of four 
likelihoods: ‘unlikely’ (<50%), ‘doubtful’ (50-80%), ‘probably’ (80-95%), and ‘very 
likely’ (> 95%). Participants answered these questions individually. The extent to 
which the responses of the participants were in accordance with the calculated 
probabilities by the app Labtracker was analyzed.
The laboratory parameters that were incorporated in the cases were: 
hemoglobin, leukocytes, thyroid stimulating hormone (TSH), vitamin B12, alanine 
aminotransferase (ALAT), glucose, glycosylated hemoglobin type A1c (HbA1c), 
creatinine, activated partial thromboplastin time (aPTT) and C-reactive protein 
(CRP).
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Statistical analysis
All answers given by the study participants were compared to the calculated 
probabilities by the app Labtracker. Two statistical analyses were performed. 
Firstly, differences among the study groups were calculated using one-way analysis 
of variance (ANOVA). P-values < 0.05 were considered statistically significant. 
Comparisons between pairs of groups were adjusted for multiple testing using 
the Bonferroni correction.
Secondly, two groups were compared; the medical students formed the 
‘inexperienced group’ and the medical residents and internists together formed 
the ‘experienced group’. The two groups were compared using the Fisher’s exact 
test. All statistical calculations were performed using SPSS version 23 (IBM SPSS 
Statistics. IBM Corporation, Armonk, New York).
Calculating the probability of change using the app Labtracker
For a change between consecutive measurements to become significant, the 
difference must be larger than the change that would reasonably be expected 
due to normal analytical- and biological variation. This is termed the reference 
change value (RCV) and was first described by Fraser et al (3). The RCV has become 
an established concept in laboratory medicine.
The RCV differs for each parameter and depends on the within-subject biological 
variation (CVI) and the analytical variation (CVA) and can be calculated as follows 
(4,5):
𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅 =  √2 ∗ 𝑍𝑍𝑍𝑍 ∗  �𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝐴𝐴𝐴𝐴2 + 𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝐼𝐼𝐼𝐼2 
In this formula, the Z-score represents the number of standard deviations and 
corresponds to the desired probability. Commonly used Z-scores are 1.96 and 2.56. 
These Z-scores calculate the percentage increase or decrease that is required to 
become statistically significant, with a false positive rate of 5%, (p <0.05) and 1% 
(p <0.01), respectively.
An important side note to calculate the RCV is that not all clinical decisions are made 
with statistical probabilities of >95%. In other words, some changes are strictly 
not statistically significant, but the probability may be high enough to lead to a 
treatment or clinical decision. For example, a hemoglobin concentration of 6.1 
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mmol/L was measured in a male patient. After a week, it dropped to 5.8 mmol/L. 
Although the likelihood probability of a ‘real’ decrease in hemoglobin level is less 
than 95% in this case - namely around 70% - the clinician may still decide to use 
additional diagnostic testing or to treat the patient.
For implementation in the smartphone app, we rearranged the RCV-formula so 
that the Z-score (and therefore the likelihood probability) is the unknown. The 
probability of a real change between consecutive measurements will then be 
calculated. The rearranged RCV-formula is:
Z-score = 
The calculations of the app Labtracker are based on the above formula. This makes 
it possible to compare two consecutive laboratory results and to calculate the 
probability of a real change.
Time-dependency of within-subject biological variation in some parameters
In a number of laboratory parameters, the within-subject biological variation 
(CVI) changes over time. We systematically reviewed published biological 
variation studies of 106 laboratory tests and found a time-dependent increase 
of the biological variation for 21 parameters. For the laboratory parameters with 
sufficient information about their biological variation in the scientific literature, the 
associations between biological variation data and the time interval to which they 
apply were modeled statistically and integrated into Labtracker. This enabled the 
calculation of probabilities of a change between measurements, while accounting 
for the time-span between consecutive measurements.
Practical functionality of the app Labtracker
In total, 106 parameters are available in Labtracker. When using the app, users can 
choose the desired parameter out of a list that is displayed in alphabetical order. 
Subsequently, they have to choose the ‘body liquid’ in which the measurements 
were performed and, if relevant, whether the blood sampling regards a male or a 
female person. However, this question is asked only to display an indication of the 
reference values, but it does not affect the final calculation of the probability. Then 
the user fills in the previous and the recent value, as well as the time interval in days 
between the measurements. Also the ‘a priori expectation’ of the change between 
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the measurements has to be chosen (‘rise’ for an expected increase, ‘fall’ for an 
expected decrease or ‘either’ when there is no prior expectation). Labtracker will 
then calculate the probability that the change between the two measured values 
is a ‘real change’. In figure 8.1, screenshots of the app were presented to visualize 
the functionality of the app.
Figure 8.2. Percentage concordant answers per group
Values are mean percentages ± SD.
Medical students vs. internists, p<0.001; 95%CI 6.96–22.59, medical students vs. medical residents, 
p=0.009; 95% CI 1.10-18.28, medical residents vs. internists, p=0.321; 95% CI -5.36–15.53.
p-values < 0.05 were considered statistically significant (*).
Results
Data collection was incomplete for two subjects (1.5%); it concerns two medical 
students who did not fill in all questions and therefore, they were excluded from 
all analyses.
Psychometric analysis
We performed the ‘Item Test Correlation (RIT)’ test, a psychometric analysis to 
check the distinctiveness of the case questions (6,7). Briefly, the RIT is a correlation 
coefficient, which can vary between -1 and 1; a question with a RIT score of 0 does 
not distinguish between good and poor performers. If the RIT score is negative 
then the question may not be valid and should be removed (6,7). The RIT score of 
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the aPTT-question had a negative value and therefore, this question was excluded 
from further analyses. The RIT score of the other questions were all considered 
sufficient.
Figure 8.3. Percentage concordant answers when also the probability adjacent to the 
designated category was considered correct.
Values are mean percentages ± SD.
Medical students vs. internists, p=0.007; 95% CI 4.72–19.00, medical students vs. medical residents, 
p=0.031; 95% CI 1.07-16.76, medical residents vs. internists, p=0.609; 95% CI -5.36–15.53.
p-values < 0.05 were considered statistically significant (*)
Comparison of the app Labtracker with the estimates of physicians
The correct answer was defined as the answer that matched exactly with the 
calculated probability by the app Labtracker i.e. the answer category containing 
the calculated probability percentage.
In figure 8.2, the estimates of the study groups were shown. Participants with 
extensive clinical experience showed higher concordance rates with Labtracker- 
calculations; with internists and the medical residents scoring significantly better 
than the medical students (p < 0.001 and p = 0.021, respectively). The percentage of 
questions answered correctly by the medical residents did not differ significantly 
from the internists (p = 0.719; 95% CI -5.4 – 15.5).
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A sensitivity analysis was conducted that allowed a broader range to define 
concordant answers. In this sensitivity analysis, not only the answer category 
that matched exactly with the calculated probability by Labtracker was considered 
correct, but also the answer category adjacent to that category. The results of this 
analysis are shown in figure 8.3. On average, the medical students answered 69% 
of the questions correctly, the medical residents 78% and the internists 81%. Similar 
to the primary analysis, concordance rates of answers from internists with the 
Labtracker-calculated probabilities were significantly better than medical students 
(p<0.001; 95% CI 4.7 – 19.0). Again, the difference between medical residents and 
medical students was statistically significant as well (p=0.020; 95% CI 1.1 – 16.8). 
And, like the first analysis, concordance rates between the medical residents and 
Labtracker did not differ significantly from the internists (p=1.000; 95% CI -12.5 – 6.6). 
Therefore, in subsequent analyses, internists and medical residents were pooled 
as one group (the experienced clinicians) and compared with medical students.
Analysis per parameter
The scores of the study participants for each parameter were assessed separately. 
Figure 8.4 depicts the percentage of correct answers from the study groups per 
parameter. The ‘experienced’ group (the residents and the internists) was compared 
with the medical students. In general, the experienced group demonstrated the 
most concordant answers, compared to the inexperienced medical students. The 
experienced clinicians scored best on the parameter hemoglobin (95%) and the 
parameter they scored the worst on was creatinine (28%). The medical students 
scored best on the hemoglobin parameter as well (82%). They scored worst on the 
TSH question (6%).
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Figure 8.4. Percentage concordant answers per parameter
TSH p<0.001, creatinine p=0.012, vitamin B12 p=0.024, HbA1c p=0.036, haemoglobin p=0.056, ALAT 
p=0.237, leukocytes p=0.307, glucose p=0.462, CRP p=0.574
In this figure, the medical residents and the internists were combined into the group ‘clinicians 
with experience’
In accordance with the previous analysis, we conducted a sensitivity analysis in 
which the category adjacent to the correct answer was also considered to be 
correct. These results are shown in figure 8.5. Again, the experienced clinician gave 
the most concordant answers. In this analysis, the experienced group (residents 
and internists) scored 88% correct answers on average. They scored the best on 
the vitamin B12, leukocytes, and hemoglobin questions (98%). The TSH question 
was the least well answered of all parameters (70%). The medical students scored 
90% correct answers on the hemoglobin question. The least concordant question 
by the students was TSH (44%).
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Figure 8.5. Percentage concordant answers per parameter when also the probability adjacent 
to the designated category was considered correct.
Vitamin B12 p=0.002, TSH p=0.006, leukocytes p=0.012, hemoglobin p=0.167, creatinine p=0.012, 
ALAT p=0.221, glucose p=0.329, HbA1c p=1.000, CRP p=1.000.
In this figure, the medical residents and the internists were combined into the group ‘clinicians 
with experience
Discussion
The current study demonstrated that experienced clinicians show better 
concordance rates with the calculated probabilities by the app Labtracker than 
less experienced medical students. Stratified analyses reveal that this pattern holds 
true for the majority of studied laboratory parameters. Concordance rates with the 
app demonstrate an incremental improvement from medical students, to residents 
and internists. The differences between clinicians with experience (internists and 
residents) and inexperienced medical students were statistically significant. This 
outcome illustrates the relevance and added value of the medical app Labtracker.
The clear association between the degree of clinical experience and improved 
concordance rates with the calculated probabilities by the app supports the validity 
of Labtracker calculations. Improved concordance rates with increasing clinical 
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experience suggest that Labtracker may well be of benefit for less experienced 
clinicians, such as medical students.
However, Labtracker is not only a useful tool for inexperienced clinicians. We 
believe the app can form a ‘bridge’ between laboratory science and clinical 
practice. Labtracker could be useful in reducing information overload and enabling 
rapid recognition of parameter changes by expert clinicians, especially in time 
constrained and rapidly changing environments (e.g., intensive care units). 
Clinicians do not have to make cumbersome calculations when estimating whether 
a change between consecutive measurements is a real change or not. By using the 
app, the quality of the laboratory information that often plays an important role 
in clinical decisions will improve. Labtracker enables clinicians to make efficient 
and standardized interpretations with minimal cognitive effort. Of course, the 
application will never replace clinical judgment, but it can serve as a supportive 
aid for diagnosis and treatment.
In addition, in current clinical practice, some clinical tasks that were always 
performed by physicians now more and more become the responsibility of 
physician assistants or nurse specialists. Such ‘shifts of tasks’ can be for instance, 
a diabetic nurse who monitors the routine diabetic check-ups. In 2014, Lenters-
Westra et al. demonstrated that there are significant differences in interpretation 
of changes in HbA1c results between physicians and nurses (8). Labtracker may 
serve as a useful support to standardize care in such a situation.
The benefit offered by the app may be parameter dependent. According to this 
external validation study, the concordance rates with the calculated probabilities 
varied from 6% for students for the TSH question to 98% for experienced clinicians 
for the hemoglobin question. This difference in concordance rates suggests that 
the ‘number intuition’ of a clinician differs per laboratory parameter and varies with 
clinical experience. It may be difficult for a clinician to estimate how a ‘normal value’ 
of a parameter fluctuates over time in an individual if the clinician has little actual 
experience with that parameter. In other words, a clinician with more experience in 
interpreting a specific parameter can better estimate its biological variation. Since 
the scores of the medical residents were not significantly different from those of 
the internists, it might be assumed that medical residents develop their ‘number 
intuition’ early in the residency training.
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The participants scored not all parameters equally concordant. A potential 
explanation for the ‘worse scored questions’ could be that not all laboratory 
parameters are widely used in clinical practice, and that clinicians therefore have 
little experience in interpreting those parameters. Another potential explanation 
could be that not all questions were of equal difficulty.
Some limitations in the current study merit attention. First, the groups of medical 
residents and specialists were relatively small (n = 19 and n = 24, respectively). 
Second, only nine parameters were tested, with one single interpretation per 
parameter. However, our estimation is that the study groups are a good reflection 
of the total population of people in these groups. In addition, the parameters we 
studied are commonly used in clinical practice and cover a broad range of clinical 
domains. Therefore, it can reasonably be expected that the results of this study 
can be generalized to all commonly used laboratory parameters. Third, the cases 
were not presented in random order to the subjects. It is possible that the subjects’ 
performances were partially influenced by the order of case presentation. However, 
if there were a learning curve, then this should be the same for all study groups.
Fourth, it remains unclear whether the use of the medical app Labtracker, would 
affect clinical decision-making. In that respect, a study that incorporated medical 
decision-making, based on hypothetical cases involving laboratory test result 
interpretation(s), would be an interesting addition. The hypothesis that could then 
be tested is whether inexperienced clinicians make the same decisions as more 
experienced clinicians when they use the app Labtracker.
In 2014, Abbot et al. demonstrated that the self-assessed knowledge about 
interpreting laboratory results of inexperienced medical residents significantly 
improved after receiving an educational program about ‘the basics of laboratory 
test ordering and interpretation (9). This finding endorses the importance of 
education for inexperienced clinicians. Elaborating on this, it would be interesting 
to investigate whether Labtracker, as an educative aid, could provide better medical 
decision-making.
In conclusion, the current study has provided insight into the intuition of medical 
students with hardly any clinical experience, clinicians with some experience 
(medical residents from the department of internal medicine), and experienced 
clinicians (internists), when interpreting a difference between consecutive 
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laboratory results The findings suggest the existence of a trend that the ‘number 
intuition’ of a clinician improves with more years of experience. The development 
of this intuition fosters a better interpretation of laboratory results and could 
possible improve clinical decision-making. In that sense, the use of the medical 
app Labtracker can be a useful tool, especially for inexperienced clinicians. Besides, 
Labtracker could be useful in reducing information overload and enabling rapid 
recognition of parameter changes by expert clinicians.
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Supplementary material: Case questions
Correct answers, calculated by the app Labtracker, are shown in bold.
Reference values are from Maastricht University Medical Center (MUMC).
1. Glucose
Reference values fasting glucose [4.0 – 7.0 mmol/L]
First measurement:  [7.3 mmol/L]
Second measurement (two weeks later) :  [6.9 mmol/L]
What is the probability likelihood that this is a real change?
 A: Unlikely (<50%)
 B: Doubtful (50-80%)
 C: Likely (80-95%)
 D: Very likely(>95%)
 
2. TSH
Reference values TSH [0.4-4.3 mU/L]
First measurement:  [6.5 mU/L]
Second measurement (three months later) : [7.1 mU/L]
What is the probability likelihood that this is a real change?
 A: Unlikely (<50%)
 B: Doubtful (50-80%)
 C: Likely (80-95%)
 D: Very likely (>95%)
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3. CRP
Reference values CRP: <10 mg/L
First measurement:  [79 mg/L]
Second measurement (two days later):  [106 mg/L]
What is the probability likelihood that this is a real change?
 A: Unlikely (<50%)
 B: Doubtful (50-80%)
 C: Likely (80-95%)
 D: Very likely (>95%)
4. Hemoglobin
Reference values hemoglobin for a woman (7.5-9.5 mmol/L)
First measurement:  [7.0 mmol/L]
Second measurement (six months later):  [7.2 mmol/L]
What is the probability likelihood that this is a real change?
 A: Unlikely (<50%)
 B: Doubtful (50-80%)
 C: Likely (80-95%)
 D: Very likely (>95%)
5. HbA1c
Target value HbA1c <58 mmol/mol
First measurement:  [55 mmol/mol] (= 7.2%)
Second measurement (6 months later):  [60 mmol/mol] (= 7.6%)
What is the probability likelihood that this is a real change?
 A: Unlikely (<50%)
 B: Doubtful (50-80%)
 C: Likely (80-95%)
 D: Very likely (>95%)
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6. Leukocytes
Reference values leukocytes [3.5-11.0*10⁹/L]
First measurement:  [12*10⁹/L]
Second measurement (14 days later):  [14*10⁹/L]
What is the probability likelihood that this is a real change?
 A: Unlikely (<50%)
 B: Doubtful (50-80%)
 C: Likely (80-95%)
 D: Very likely (>95%)
7. aPTT (this question was excluded from analyses)
Reference values aPTT [18-36 sec]
First measurement:  [30 sec]
Second measurement (a few hours later) :  [34 sec]
What is the probability likelihood that this is a real change?
 A: Unlikely (<50%)
 B: Doubtful (50-80%)
 C: Likely (80-95%)
 D: Very likely (>95%)
8. Vitamin B12
Reference values vitamin B12 [250-850 pmol/L]
First measurement:  [114 pmol/L]
Second measurement (3 months later):  [125 pmol/L]
What is the probability likelihood that this is a real change?
 A: Unlikely (<50%)
 B: Doubtful (50-80%)
 C: Likely (80-95%)
 D: Very likely (>95%)
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9. ALAT
Reference values ALAT < 45U/L
First measurement:  [44 U/L]
Second measurement (6 months later):  [55 U/L]
What is the probability likelihood that this is a real change?
 A: Unlikely (<50%)
 B: Doubtful (50-80%)
 C: Likely (80-95%)
 D: Very likely (>95%)
10.  Creatinine
Reference values creatinine for men [60-110 µmol/L]
First measurement:  [89 µmol/L]
Second measurement (one year later): [109 µmol/L]
What is the probability likelihood that this is a real change?
 A: Unlikely (<50%)
 B: Doubtful (50-80%)
 C: Likely (80-95%)
 D: Very likely (>95%)
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This thesis connects basic principles of laboratory medicine with daily clinical 
practice. Historically there is a strong intertwining between the hospital laboratory 
and various clinical departments (1-4). However, the theoretical concept of biological 
variation in relation to serial measurements, and especially its potential value in 
clinical decision-making, is relatively unknown to many physicians (5, 6). Monitoring 
patients over time and the repeated measurement of various biomarkers is 
common practice for almost all hospitalized patients, and frequently applied to 
ambulant patients with chronic diseases (7, 8). Changes between measurements 
can reflect clinical improvement or deterioration, and occur as a result of random 
fluctuation without clinical consequences. Clinicians rely on their intuition and 
experience to discriminate between these two possibilities. In this thesis biological 
variation data of biomarkers within subjects is used to develop an evidence-based 
approach for the monitoring of lab results over time. Within-subject biological 
variation is for most parameters the dominant source of variation, which defines 
whether observed changes between serial measurements should be ascribed to 
either “random fluctuation” or “real changes”(9-13). 
This thesis addresses 4 major topics.
Chapter 2 describes the development of a medical smartphone app Labtracker. 
Labtracker uses biological variation data from peer-reviewed literature and 
novel studies published in this thesis to provide evidence based support for the 
interpretation of serial laboratory results. Hence it can complement clinical intuition 
of physicians to make clinical decisions, and serve as an educational tool for medical 
students and residents. Chapter 3, 4, 5, 6 and 7 are biological variation studies that 
extend the availability of peer-reviewed literature of biological variation data, with 
a focus on within-day biological variation. Chapters 4-7 compare biological variation 
in healthy subjects to those with various chronic diseases. Finally, in chapter 8, a 
validation study of Labtracker is reported.
In this discussion we will elaborate on these 4 topics and provide directions for 
further research.
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Development of the medical smartphone app Labtracker
The backbone of this thesis is the development of the medical smartphone app 
Labtracker (chapter 2). The app Labtracker interprets the magnitude of change 
between two consecutive laboratory results, while taking into account the biological 
variation of the observed parameter, the time interval between the measurements, 
and the analytical variation. It calculates the probability (from 0%-100%) that the 
observed change is a real change. This output provides an individualized and 
objective assessment of the likelihood of a true change, and may benefit clinical 
decisions related to patient monitoring e.g. starting or changing a treatment.
Currently, physicians rely exclusively on their intuition and clinical experience 
when interpreting changes in consecutive laboratory results (14, 15). However, 
physicians often overestimated the analytical accuracy of biomarkers and presence 
of biological variation is not always appreciated (16-18). Especially for less trained 
or less experienced medical professionals, the lack of an easy reference for the 
interpretation of consecutive laboratory results can be challenging and may 
contribute to undesirable heterogeneity in clinical actions following biomarker 
measurements. Labtracker addresses this clinical problem by standardizing the 
interpretation of laboratory test results and hence contribute to more standardized 
care. Physicians, medical students, nurses and medical professionals may benefit 
from using this application, especially when their experience with the interpretation 
of changes between consecutive laboratory measurements is limited, or when 
using it for biomarkers they are less familiar with. A typical example of inconsistent 
interpretation among health care professionals is that of serially measured 
Hemoglobin A1c values. In a survey with various diabetes care professionals –104 
physicians, 177 diabetes specialist nurses, and 248 primary care nurses– 96% 
of physicians were aware of some inherent uncertainty when comparing serial 
Hba1C results, but only 56% of the nurses recognized some degree of random 
fluctuation between measurements as an intrinsic characteristic of biomarkers(19, 
20).  As a consequence, many nurses considered adjusting therapy based on very 
small, insignificant changes in HbA1c, whereas physicians adhered better to more 
clinically meaningful thresholds (20). This is just one of many clinical scenarios 
where Labtracker could contribute to better standardization, and prevent undue 
adjustments in the treatment of patients, based on incorrectly perceived biomarker 
changes.
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The term biological variation can either refer to between-subject biological variation 
(CVG) or to within-subject biological variation (CVI) (21, 22). Both are fundamentally 
different and have different clinical applications. CVG can be estimated from a 
single biomarker measurement in a large group of subjects (typically 100-1000), 
and it is based on population reference intervals. Reference intervals are a very 
familiar concept for most physicians (23). In contrast, CVI is derived from repeated 
measurements in a small set of subjects (typically 10-20), and the calculated 
variability within subjects can be used for monitoring patients, e.g by calculating 
reference change values or from estimations by Labtracker (24). The ratio between 
the within-subject biological variation and the between-subject biological variation 
is termed “index of individuality” (25-27). The low index of individuality has 
important consequences for the use of conventional reference values and the 
interpretation of laboratory values. When the index of individuality of a biomarker 
is low (usually <0.6), the dispersion of values of a person will span only a small 
part of the reference interval, and reference intervals will have limited utility (21, 
28, 29). Hence, for these biomarkers, calculation of reference change values is 
particularly useful (30, 31). Reliable CVI data are indispensable for this purpose, 
and chapters 3-6 provide a reference data set that extends our understanding of 
within-subject biological variation, to be used for RCV calculations, with emphasis 
on the variation within 24 hours. Within-day CVI is useful in hospitalized patients 
with short time intervals between biomarker measurements (32). Data from our 
laboratory information system show that at least 10% of hospitalized patients have 
multiple serial measurements within 24 hours, a time window that has conceivably 
different variability than intervals of multiple days, weeks or months.
Biological variation in healthy vs. non-healthy subjects
A largely unverified assumption for the validity of using reference change values 
(or Labtracker) in clinical practice is that within-subject biological variation does 
not change substantially in various chronic diseases, compared to healthy subjects 
(21, 33). In fact, consistent biological variation in health and chronic disease is an 
important prerequisite for the use of reference change values and derived medical 
devices such as Labtracker. An individual’s homeostatic set-point of a biomarker 
may increase or decrease in some chronic diseases, but variability around the set-
point is assumed to remain relatively constant. We tested this assumption for a 
number of biomarkers in by comparing CVI’s from CKD patients and aortic valve 
stenosis with healthy subjects (chapters 4, 5, 6 and 7, respectively), and did not 
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identify biological variation shifts of a magnitude that would invalidate the use of 
RCV’s, calculated with CVI data from healthy subjects, in these patients.
Clinical interpretation and medical practice and limitations
Fourth and final major topic of this thesis is the external validation of the 
smartphone app Labtracker (chapter 8). We evaluated concordance rates of 
Labtracker calculations with medical students, medical residents, and experienced 
physicians and showed progressively better concordance rates with Labtracker 
with increasing clinical experience. This confirms that especially less experienced 
medical professionals may benefit from using Labtracker. For this group, but likely 
also for nurses, physician assistants and other health care professionals, Labtracker 
could be useful in reducing information overload and allow more standardized 
recognition of parameter changes, and more aligned interpretation with the expert 
professional.
A limitation of Labtracker may be the conscious misinterpretation of 1-p, and 
translation of this value into a probability by Labtracker (34). Frequentist statistics 
is commonly misinterpreted in medicine, and also in the setting of Labtracker, 
we acknowledge that a true probability calculation would require a Bayesian 
approach, including the estimation of a prior probability of a change between 
serial measurements (35-37). Nevertheless, while being fully aware of this 
statistical nuance, we argue that the development of Labtracker, which can be 
easily understood and applied and provide clinical benefit to medical professionals, 
outweighs the limitation of statistical imperfection.
Concluding remarks and future perspectives
This thesis linked laboratory sciences to medical practice through the development 
of the medical smartphone app Labtracker and through extending the within-day 
biological variation database.
We propose a number of future directions. The first strategy would be to secure and 
extend the connection that Labtracker initiated, by incorporating the methodology 
and algorithms of Labtracker into the medical laboratory system of hospitals. 
Such infrastructure would also facilitate a particularly interesting future study: to 
evaluate whether Labtracker could not only harmonize interpretation, and clinical 
decision-making.
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The second future perspective relates to the use of more than one parameter at 
the same time, as well as calculations with three or more serial measurements. In 
clinical practice, most of the laboratory parameters are determined as a part of a 
set of laboratory parameters, and it is conceivable that combining these data will 
provide even more accurate estimations.
The third and final interesting future perspective is to extend the methodology 
behind Labtracker to commonly used non-laboratory measurements such as 
blood pressure, heart rate, oxygen saturation and temperature measurements. 
These measurements are performed multiple times per day in a large number of 
hospitalized patients. Provided that the analytical and within-subject biological 
variation of these determinations can be established, Labtracker could help 
harmonize their interpretation.
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Summary
Two major purposes for using laboratory results are: 1) diagnosing or ruling out 
a disease and 2) monitoring changes in the clinical condition of a patient. When 
using laboratory results for the latter purpose, physicians often have to determine 
whether an observed change between serial measurements is a ‘real change’ or 
a ‘random fluctuation’. Currently, physicians rely on their intuition and clinical 
experience, sometimes combined with using population based reference values. 
However, intuition and clinical experience are not the same across all physicians, 
and population based reference values based on between-subject biological 
variation are generally unsuitable for monitoring serial laboratory results within 
an individual.
To monitor changes in the clinical condition of a patient in a consistent and fact 
based way, the physician needs to apply principles of laboratory medicine in daily 
clinical practice. This thesis is about this intersection. It uses data on biomarkers to 
calculate within-subject biological variation estimates to facilitate evidence based 
approach for the monitoring of laboratory results over time. Further, it brings 
theoretical laboratory medicine findings to a user-friendly application that can 
help physicians to discriminate between ’real changes’ and ‘random fluctuations’ 
when interpreting serial laboratory results.
This thesis starts with a general introduction and addresses four major topics. The 
general introduction (chapter 1) describes the ‘clinical challenge’ that physicians 
face when it comes to interpreting laboratory results in further detail, and touches 
upon the (ir)relevance of population-based reference values when it comes to 
medical decision making.
The first major topic is the development of the medical smartphone app Labtracker. 
This app calculates the probability of change between two serial measurements 
and provides an individualized and objective assessment of the likelihood of a true 
change. With this, Labtracker interprets the magnitude of change between serial 
laboratory results, while taking into account the biological variation of the observed 
parameter, the time interval between the measurements and the analytical 
variation. In chapter 2, the background and underlying calculation algorithm of 
the medical smartphone app Labtracker is described.
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The second major topic concerns the provision of reliable data on within-day 
biological variation in healthy subjects that can extend the current datasets. 
Availability of data on within-subject biological variation is incomplete, which 
limits evidence-based interpretations of serial laboratory results in clinical practice. 
Chapters 3-7 provide a reference data set that extends the current knowledge of 
within-subject biological variation, to be used for calculations of Reference Change 
Values (RVC), with emphasis on the variation within 24 hours.
The third major topic concerns the comparison between within-subject biological 
variation in healthy and non-healthy subjects. A largely unverified assumption for 
the validity of using the RCV in clinical practice is that within-subject biological 
variation does not change substantially in various chronic diseases, compared to 
healthy subjects. It is assumed that the variability around a person’s homeostatic 
set-point is relatively constant in health and chronic diseases. In chapters 4-7, we 
tested this assumption by comparing the within-subject biological variation from 
patients with Chronic Kidney Disease (CKD) and aortic valve stenosis with healthy 
subjects and did not identify biological variation shifts of a magnitude that would 
invalidate the use of RCV’s, calculated with within-subject biological variation data 
from healthy subjects, in these patients.
Fourth, the external validation of the medical smartphone app Labtracker (chapter 
8). We evaluated concordance rates of Labtracker calculations with medical 
students, medical residents and experienced physicians and showed progressively 
better concordance rates with Labtracker with increasing clinical experience. With 
this Labtracker may benefit clinical decisions related to monitoring of a patient.
Lastly, chapter 9 contains a general discussion of the work presented in this thesis 
and provides directions for further research.
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Twee belangrijke doelen voor het gebruik van laboratoriumresultaten zijn: 1) het 
diagnosticeren of uitsluiten van een ziekte en 2) het volgen van veranderingen in 
de klinische toestand van een patiënt. Bij het gebruik van laboratoriumresultaten 
voor dit laatste doel moeten artsen vaak bepalen of een waargenomen verandering 
tussen opeenvolgende metingen een  ̔echte verandering  ̓ of een  ̔willekeurige 
fluctuatie  ̓ is. Momenteel vertrouwen artsen vaak op hun intuïtie en klinische 
ervaring, soms gecombineerd met het gebruik van op de bevolking gebaseerde 
referentiewaarden. Intuïtie en klinische ervaring zijn echter niet bij alle artsen 
hetzelfde, en op de populatie gebaseerde referentiewaarden op basis van 
biologische variatie tussen proefpersonen zijn over het algemeen niet geschikt 
voor het monitoren van seriële laboratoriumresultaten binnen een individu.
Om veranderingen in de klinische toestand van een patiënt op een 
consistente en op feiten gebaseerde manier te volgen, moet de arts de 
principes van laboratoriumgeneeskunde toepassen in de dagelijkse klinische 
praktijk. Dit proefschrift gaat over dit snijpunt. Het gebruikt gegevens over 
laboratoriumparameters om schattingen van biologische variaties binnen 
een proefpersoon te berekenen om een evidence-based benadering voor het 
monitoren van laboratoriumresultaten in de tijd te vergemakkelijken. Verder 
brengt het theoretische laboratoriumgeneeskundige bevindingen naar een 
gebruiksvriendelijke toepassing die artsen kan helpen onderscheid te maken 
tussen  ̔ echte veranderingen  ̓en  ̔  willekeurige fluctuaties  ̓bij het interpreteren van 
seriële laboratoriumresultaten.
Dit proefschrift begint met een algemene inleiding en behandelt vier 
hoofdonderwerpen. De algemene inleiding beschrijft de ‘klinische uitdaging’ 
waarmee artsen worden geconfronteerd als het gaat om het interpreteren van 
laboratoriumresultaten in meer detail, en gaat in op de (ir)relevantie van op de 
bevolking gebaseerde referentiewaarden als het gaat om medische besluitvorming.
Het eerste onderwerp is de ontwikkeling van de medische smartphone-app 
Labtracker. Deze app berekent de kans op verandering tussen twee opeenvolgende 
metingen en produceert een individuele en objectieve beoordeling van de kans 
op een echte verandering. Hiermee interpreteert Labtracker de omvang van de 
verandering tussen opeenvolgende laboratoriumresultaten, rekening houdend 
met de biologische variatie van de waargenomen parameter, het tijdsinterval 
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tussen de metingen en de analytische variatie. In hoofdstuk 2 wordt de achtergrond 
en het onderliggende rekenalgoritme van de medische smartphone-app Labtracker 
beschreven.
Het tweede onderwerp in dit proefschrift betreft het leveren van betrouwbare 
gegevens over biologische variatie binnen de dag bij gezonde proefpersonen die 
de huidige datasets kunnen uitbreiden. De beschikbaarheid van gegevens over 
biologische variatie binnen een proefpersoon is momenteel onvolledig, wat op 
bewijs gebaseerde interpretaties van opeenvolgende laboratoriumresultaten in 
de klinische praktijk beperkt. Hoofdstukken 3-7 bieden een set aan gegevens die de 
huidige kennis van binnen-persoons biologische variatie uitbreidt, om te worden 
gebruikt voor berekeningen van het ‘kritisch verschil’, ook wel de reference change 
value (RVC) genoemd, met de nadruk op de variatie binnen 24 uur.
Het derde onderwerp in dit proefschrift betreft de vergelijking tussen biologische 
variatie binnen individuen bij gezonde en niet-gezonde individuen. Een grotendeels 
niet-geverifieerde aanname voor de validiteit van het gebruik van het kritisch 
verschil in de klinische praktijk is dat de biologische variatie binnen de patiënt 
niet substantieel verandert bij verschillende chronische ziekten, vergeleken 
met gezonde proefpersonen. Aangenomen wordt dat de variabiliteit rond het 
homeostatische setpoint van een persoon relatief constant is bij gezondheid en 
chronische ziekten. In de hoofdstukken 4-7 hebben we deze aanname getest door de 
biologische variatie binnen patiënten van patiënten met chronische nierziekte (CKD) 
en aortaklepstenose met gezonde proefpersonen te vergelijken en identificeerden 
we geen biologische variatie schommelingen van een omvang die het gebruik van 
het kritisch verschil, berekend met binnen-persoons biologische variatiegegevens 
van gezonde proefpersonen, bij deze patiënten.
Het vierde onderwerp in dit proefschrift betreft de externe validatie van de 
medische smartphone-app Labtracker (hoofdstuk 8). We evalueerden concordantie 
percentages van Labtracker-berekeningen met coassistenten, arts-assistenten en 
ervaren internisten en toonden progressief betere concordantie percentages met 
Labtracker met toename van klinische ervaring. Hiermee kan Labtracker klinische 
beslissingen met betrekking tot de monitoring van een patiënt ten goede komen.
Tenslotte bevat hoofdstuk 9 een algemene bespreking van het werk dat in dit 
proefschrift wordt gepresenteerd en het geeft suggesties voor verder onderzoek.
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In this last chapter the valorization of this thesis will be further explored. Valorization 
is the social utilization of scientific knowledge. It is about the why behind the research 
and is intended to make knowledge usable other than for scientific purposes only.
The valorization of this thesis consists of two parts. The first part of the valorization 
in this thesis is the development of the medical smartphone app Labtracker. The 
development of the smartphone app Labtracker boosts the valorization of the 
results of this thesis. This app helps its users to compare two laboratory results 
with each other in a fact based and scientifically sound manner, and facilitates 
the assessment of whether the change between these two results is a clinically 
relevant change or not. Specifically, Labtracker calculates the probability that an 
increase or decrease over time in a specific blood parameter is real, given the time 
between measurements. It reduces the need for physicians to rely on their clinical 
experience and intuition when they have to interpret whether a change between 
serial laboratory measurements is a “real” change or a natural fluctuation.
Another important part of the valorization of this thesis is the enrichment of 
the database on within-subject biological variation along two dimensions. First, 
researching additional/new parameters has increased the breadth of the database; 
second, the depth of the database has been increased for specific parameters, by 
looking at the difference between healthy and chronically ill individuals, and by 
looking at the difference in biological variation within a day.
Both the development of the app and the enrichment of the biological variation database 
can have an impact on three important themes: health care, education, and prevention.
Healthcare
By using Labtracker based calculations to distinguish between a real change and a 
natural fluctuation, concerning a change between serial laboratory measurements, 
a physician can make a more scientifically based choice in the field of laboratory 
diagnosis and with this, he can make better decisions.
Besides, healthcare may improve by avoiding unnessacary treatments and/ or 
diagnostics when using Labtracker, such as prescribing a cholesterol inhibitor in a 
person with a cholesterol increase (that may be due to biological fluctuation instead 
of a real cholesterol increase).
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Concerning the enrichment of the biological variation database, healthcare may 
improve by facilitating physicians with an extensive dataset of biological variation 
of laboratory parameters, with which they can easily detect a ‘ real change’ in 
laboratory parameters that may be clinically relevant.
Possibly, in the future, the way of measuring laboratory parameters will change. 
Techniques such as body sensors or infrared methods are rapidly developing. When 
this data generation will be expanded, the biological variation database will be 
essential to deal with all these laboratory data.
Prevention
Through the broadening of the biological variation database and the development 
of Labtracker, physicians can make a better estimate of the variability of laboratory 
measurements over time and hereby, they can better predict and possibly prevent 
the development of a disease. With this, the results of this thesis open doors to ways 
of preventive healthcare. Also patient can use the app Labtracker for themselves, to 
monitor their laboratory values and compare them with each other. By detecting an 
abnormality in an early stage, prevention and early-stage treatments will become 
more important. And eventually, this may lead to less expensive treatments, and 
even more important, a more value based healthcare for the patient.
Education
Young or inexperienced doctors are quickly brought to a higher level of interpreting 
laboratory diagnostics and developing a clinical ‘sense’ or intuition whether a 
change between serial laboratory measurements is a real change.
This speeds up the growth and development of physicians. By using Labtracker 
(inexperienced) clinicians become more aware of the variation within laboratory 
results. This may lead to less incorrect interpretations of a change in serial 
laboratory results and to a decreasing amount of unneccesary treatments.
For example, this thesis shows the variablity of hemoglobin during the day. By having 
knowledge about the biological variation of such a parameter or using Labtracker 
(in which this kwowledge is incorporated), physicians can determine more easily 
whether or not it is necessary to give an iron supplement or a blood transfusion. The 
app Labtracker can serve as an educational tool to verify the clinical intuition and it 
can serve as a reference to check the (diurnal) biological variation of the parameter.
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List of abbreviations
RCV  reference change value
CVA  analytical coefficient of variation
CVI  intra-individual coefficient of variation
hsTnI  high sensitive troponin I
hsTnT  high sensitive troponin T
GP  general practicioner
FT4  free thyroxine 4
TSH  thyroid stimulating hormone
CI  confidence interval
II  index of individuality
CVG  group (inter-individual) coefficient of variation
MCV  mean corpuscular volume
MCH  mean corpuscular hemoglobin
MCHC  mean corpuscular hemoglobin concentration
MPV  mean platelet volume
IPF  immature platelet fraction
PCT  plateletcrit
PDW  platelet distribution width
BMI  body mass index
HbA1c  glycated hemoglobin A1c
HDL  high-density lipoprotein
LDL  low-density lipoproteine
eGFR  estimated glomerular filtration rate
EDTA  ethylenediaminetraacetic acid
ANOVA  analysis of variance
SEM  standard error of the mean
CV  coefficient of variation
CKD  chronic kidney disease
STFR  soluble transferrin receptor
LDH  lactate dehydrogenase
CK  creatine kinase
ASAT  asparate-aminotransferase
ALAT  alanine-aminotransferase
MDRD  modification of diet in renal disease
CKD-EPI chronic kidney disease epidemiology
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BNP  brain natriuretic peptide
NT-pro BNP  N-terminal pro natriuretic peptide
ST2  suppression of tumourigenicity 2
AVS  aortic valve stenosis
LVEF  left ventricular ejection fraction
SD  standard deviation
IQR  inter quartile range
RIT  item test correlation
aPTT  activated tromboplastin time
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Dit proefschrift was nooit tot stand gekomen zonder de hulp, inzet en steun van 
vele collega’s, vrienden en familie gedurende de afgelopen jaren. De volgende 
personen wil ik graag in het bijzonder bedanken.
Allereerst mijn twee promotores, prof. dr. Otto Bekers en prof. dr. Richard Koopmans. 
Beste Otto, dank voor je steun en vertrouwen tijdens mijn promotietraject. Met 
je dropjes wist je het altijd gezellig te maken tijdens de research meetings. Ik 
waardeer je pragmatische manier van aanpak; als jij iets moest regelen voor mijn 
proefschrift was het vaak dezelfde dag nog rond.
Richard, jouw enthousiasme en gedrevenheid zijn ongeëvenaard. Je bent altijd erg 
begaan geweest met mij en met mijn onderzoek. Als ik even niet goed wist hoe ik 
verder moest hoefde ik maar even bij je langs te gaan, plaats te nemen op je paarse 
bank en ik liep even later met een grote glimlach én vol nieuwe ideeën de deur uit.
Mijn co-promotor, dr. Meex, beste Steven, bij jou is het allemaal begonnen tijdens 
mijn geneeskunde studie met een les over zuur-base evenwichten. Vervolgens 
wees je me de weg in de wondere wereld van wetenschappelijk onderzoek. Dat die 
eerste stappen uiteindelijk zouden leiden tot een heus proefschrift had ik destijds 
nooit durven dromen. Ik ben ervan onder de indruk hoe je je drukke leven als 
klinisch chemicus hebt weten te combineren met het begeleiden van (destijds 5!) 
promovendi en een gezinsleven. Je hebt me de afgelopen jaren vrijwel onbegrensde 
vrijheid gegeven en ik heb ontzettend veel van je geleerd. Heel veel dank Steven!
Mijn paranimfen, Dorien en Evelyne. Dorien, lieve roomie, vanaf de eerste dag 
van mijn wetenschapsstage was jij mijn buddy (samen in de bezemkast, onder 
het genot van het foute uur). Ik heb zo veel aan je gehad en van je geleerd. Jouw 
eerlijke, respectvolle en integere houding, zowel als collega, als wetenschapper 
en als vriendin, vind ik enorm bewonderenswaardig. Het was fijn om altijd iemand 
te hebben om op terug te vallen en ben dan ook heel blij dat je me bij wilt staan 
als paranimf. We hebben in die 2,5 jaar dat we roomies waren heel wat successen 
gevierd (met foute drank). Ik had me geen betere roomie kunnen wensen. Wat ben 
ik blij dat ik jou heb leren kennen.
Lieve Evelyne, dankjewel dat jij mijn paranimf wilt zijn. Al sinds de bachelor van 
onze geneeskunde studie kan ik altijd op je terug vallen. Met heel veel plezier 
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kijk ik terug op al onze sportavonden en aansluitende etentjes (bij voorkeur een 
salade valdieu na het zwemmen ;-)). Na onze studies hebben we dit voortgezet 
en onze ervaringen als promovendi gedeeld. Gelukkig zien we elkaar nog steeds 
regelmatig. Ik bewonder je doorzettingsvermogen en positieve instelling. Ik hecht 
veel waarde aan onze vriendschap en kijk uit naar vele mooie jaren die nog komen 
gaan.
Prof. dr. Rennenberg, beste Roger, vanaf de eerste dag was je betrokken bij de 
brainstormsessies, en later de ontwikkeling van Labtracker. Jouw nuchtere kijk 
werkte voor mij vaak verhelderend.
Prof. dr. van Dieijen, beste Marja, ook al ben je officieel geen onderdeel van mijn 
promotieteam, maar ik heb (met name in het begin van mijn promotie onderzoek) 
erg veel aan je gehad. Jij hebt het unieke talent om na een periode van afwezigheid 
in een paar minuten en door de juiste vragen te stellen, volledig op de hoogte te 
zijn van de stand van zaken rondom mijn promotieonderzoek.
Leden van de beoordelingscommissie, Prof. dr. Walther van Mook, Prof. dr. Fred 
Sweep, Prof dr. Jan-Joost Rethans, Prof. dr. Eric Sijbrands en Prof. dr. Bram Kroon. 
Ik waardeer het zeer dat u allen plaats wilt nemen in de beoordelingscommisie. 
Dank voor de nauwkeurige beoordeling van mijn proefschrift.
Tevens wil ik de overige leden van de commissie bedanken voor de bereidheid om 
als opponent deel te nemen. Ik kijk er naar uit om met u van gedachten te wisselen 
tijdens de verdediging.
Dr. Bart de Wit, Dr. ir. Yvonne Henskens, Dr. Judith Bons, Dr. Alma Mingels, Dr. 
Jan Damoiseaux, Dr. Irene Korver-Keularts, Dr. Douwe de Boer, Dr. Will Wodzig, 
Dr. Joyce van Beers, Dr. ir. Sander Streng bedankt voor jullie interesse in mijn 
onderzoek en de kritische vragen tijdens de refereer sessies. Ik heb, mede dankzij 
jullie, een enorm leuke tijd gehad op het CDL.
Dat je onderzoek nooit alleen doet blijkt wel uit de vele co-auteurs die allen op 
hun eigen manier een bijdrage hebben geleverd aan de artikelen. Veel dank voor 
jullie hulp, commentaar en verbeteringen van onze research. Een aantal zou ik 
graag in het bijzonder willen bedanken. Dr. Kristin Aakre; early on in my PhD, we 
contacted you to brainstorm about the possibility of hour-to-hour calculations. You 
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have always been very helpful and you have made an essential contribution to the 
piece on hematological parameters.
Dr. Floris Vanmolkot, zonder aarzelen heb je de planning van de terugkomdagen 
van het co-schap interne geneeskunde aangepast zodat ik mijn ‘labtrackerquiz’ 
kon afnemen bij de coassistenten. Prof. Dr. Jeroen Kooman; ik geloof oprecht dat 
jouw kritische heldere commentaren op het manuscript over de nefrologische 
parameters het stuk naar een hoger niveau getild hebben
Vincent, ik, als kneusje op het lab keek in het begin mijn ogen uit (“Oh, is dat 
plasma? Ik dacht urine”) Als manusje van alles wist jij alle problemen en storingen 
(en die hebben we gehad!) altijd weer op te lossen. Je was onmisbaar tijdens de 
dagen op het lab, heel veel dank voor je hulp en gezelligheid
Petal, jij bracht altijd leven in de brouwerij en wist op jouw eigenzinnige manier 
kleur te geven aan de dagen op het lab. Dank voor je gezelligheid op het lab en 
op borrels.
Een zeer belangrijk aandeel in dit promotietraject is weggelegd voor mijn collega-
onderzoekers. Allereerst mijn ’voorgangers’ Lieke, Sander, Noreen en Linda. Jullie 
waren allen bezig met de afrondingen van jullie promotie onderzoeken toen ik 
begon als promovendus. Bedankt voor jullie goede voorbeelden en collegiale hulp. 
Heel veel succes in jullie verdere carrières.
Frederique, wat was je altijd een fijn gezelschap tijdens meetings, lunches en 
borrels. Jouw nauwkeurigheid en oog voor detail zijn voor mij een voorbeeld. 
Succes met jouw opleiding tot cardioloog!
Stephanie, bedankt voor de gezellige tijd. Heel veel succes met de laatste loodjes 
van jouw promotie onderzoek.
William (Willy), het was nooit saai met jou als collega. Altijd had je weer wat grappigs 
beleefd in het weekend en langzaam maar zeker werd je steeds volwassener. Ik 
bewonder je pragmatische aanpak en je ambitie. Ik kijk er naar uit om binnenkort 
weer naar Maastricht te rijden voor jouw verdediging!
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Wim, zelden heb ik zo een gedreven persoon als jij ontmoet. Dank voor de 
gezelligheid, de vele koffies en de fijne sfeer in onze werkkamer. Ik vond het 
inspirerend om te zien hoe jij tijdens jouw promotie onderzoek een heel helder 
doel voor ogen had en daar recht op af ging. Heel veel succes met het vervolg van 
je opleiding tot klinisch chemicus, en natuurlijk ook met je leven als kersverse papa.
Charlotte, Geneviève en Dorien, Lumière clubje, wat was het iedere keer weer 
gezellig om af te spreken en de ervaringen, belevenissen en frustraties van onze 
onderzoeken te kunnen delen. We hebben samen de nodige films gezien, colleges 
bijgewoond en koffies gedronken. Als laatste in ons groepje mag ik nu ook mijn 
proefschrift bij de verzameling voegen.
Dr. Emile De Bruijne, bedankt dat ik mijn opleiding tot internist in het IJsselland 
Ziekenhuis mocht starten. Ik heb onze samenwerking altijd als zeer prettig ervaren.
Dr. Adrienne Zandbergen en Prof. Dr. Stephanie Klein-Nagelvoort, bedankt dat 
jullie me zo fijn hebben ‘opgevangen’ in het EMC en dat jullie me direct lieten thuis 
voelen in zo’n grote organisatie.
Rianne en Nienke, ook al zijn we alle drie onze eigen weg gegaan na onze 
gezamenlijke turnjaren, we zijn elkaar nooit uit het oog verloren. Bedankt voor 
jullie fijne vriendschap.
Anne, wat ben ik blij dat we na onze jaren als Rowing Stones bij Saurus nog steeds 
contact hebben. Fijn dat ik altijd even kon uitstappen in Eindhoven voor een gezellig 
etentje ‘op de route’ als ik weer eens aan het pendelen was tussen Rotterdam en 
Maastricht. Ik prijs me gelukkig met jou als vriendin.
Veerle, je bent als familie voor me, maar vooral een hele waardevolle vriendin. 
Alles delen en bespreken we samen tijdens onze wekelijkse hardloop (en inmiddels 
wandel ;-)) rondjes. Dankjewel voor je luisterende oor en je goede adviezen. Jouw 
nuchtere kijk op het leven in combinatie met jouw heerlijke humor hebben mij vaak 
nieuwe inzichten gegeven.
Sophie, Eva, Saskia en Jessica, wat ben ik blij dat we na ons gezamenlijke jaar als 
ANIOS in het IJsselland nog steeds contact hebben, ook al zijn we allemaal een 
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andere kant op gegaan. Dank voor alle gezellige etentjes, escape rooms, (zoom-) 
bijklets sessies en nog veel meer.
Naomi, ook jij bent een hele fijne vriendin geworden. Altijd recht door zee, 
goudeerlijk en vol plannen. Fijn dat we elkaar nu in het EMC weer kunnen opzoeken.
Maarten en Cilia, vanuit het IJsselland gingen we met z’n drieën naar het EMC. 
Wat fijn dat we dit samen hebben kunnen doen en dat we elkaar nog geregeld 
opzoeken met koffies.
Susan, Ellen, Josje en Frida, sinds de middelbare school al mijn lieve vriendinnen 
waarmee ik alles kan delen. Van gezellige pauzes in de Kandeleer tot allemaal ons 
eigen leven in een andere stad; ik ben heel blij dat onze vriendschap er na al die 
jaren nog steeds is. Snel weer eens met de vijf op avontuur!
Ton en Ellen, al heel wat jaren kom ik bij jullie over de vloer en het voelt als een warm 
bad als ik bij jullie ben. Jullie zijn vanaf het eerste moment geïnteresseerd geweest 
in mijn promotie onderzoek. Bedankt voor het meedenken over toekomstplannen 
en voor al jullie wijze adviezen.
Caspar en Nina, wat fijn om jullie ook familie te mogen noemen. Jullie zijn een 
fantastisch duo!
Oma, dankjewel voor je oprechte interesse en belangstelling in ons leven. Ik vind 
het wonderbaarlijk dat je van al je (15!) kleinkinderen altijd precies kunt vertellen 
hoe het met iedereen gaat.
‘Zwagers’ Alexander, Martijn en Stein, wat een gezellige toevoeging zijn jullie aan 
onze familie. Fijn dat jullie mijn zussen zo gelukkig maken.
Anna, Olaf en Benjamin, de nieuwste generatie, jullie maken onze familie nog 
mooier, groter èn grappiger. Ontdek het leven en geniet!
Michelle, Lenny en Iris, liefste zussen, jullie kennen mij als geen ander. Alle vier 
zijn we zo verschillend, en toch delen we veel interesses. Ik bewonder jullie allemaal 
op jullie eigen manier en ik ben heel blij dat ik jullie heb.
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Papa en mama, bedankt voor jullie steun en vertrouwen. Jullie hebben mij 
altijd vrijgelaten in keuzes die ik wilde maken en me hierin laten inzien dat ik op 
mezelf kan vertrouwen. Jullie staan altijd voor mij klaar met (praktische) hulp en 
ondersteuning. Bij elke verhuizing kon ik weer op jullie rekenen. Bedankt voor al 
jullie zorgen en voor het bieden van de mogelijkheid om in Keijenborg altijd weer 
helemaal tot rust te komen.
En tot slot, lieve Rogier, de laatste woorden van dit dankwoord zijn vanzelfsprekend 
voor jou. Bedankt voor je onvoorwaardelijke liefde, begrip en vertrouwen. Al meer 
dan tien jaar ben je mijn steun en toeverlaat. Je gaf mij de tijd en ruimte die ik nodig 
had om naast een voltijd baan ook een promotie af te ronden. Je was altijd bereid 
om iets voor me na te lezen, samen te brainstormen, en vooral om me even te laten 
afschakelen van alles wat met werk- en PhD te maken had. Wat hebben we het fijn 
samen en wat ben ik blij dat we ons avontuur binnenkort met z’n drieën mogen 
voortzetten. Ik had het niet beter kunnen treffen!
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